Pharmacological and Molecular Characterisation of P2Y Receptors in Endothelial and Epithelial Cells by D’Souza, Vijay Kenneth
 
 
 
PHARMACOLOGICAL AND MOLECULAR 
CHARACTERISATION OF P2Y RECEPTORS IN ENDOTHELIAL 
AND EPITHELIAL CELLS 
 
 
 
VIJAY KENNETH D’SOUZA B.Pharm., MSc.  
 
 
 
A thesis submitted in partial fulfilment of the 
requirements of the University of Wolverhampton 
for the degree of Doctor of Philosophy 
 
 
 
2008 
 
 
 
This work or any part thereof has not previously been presented in any form to the 
University or to any other body whether for the purposes of assessment, publication or 
for any other purpose (unless otherwise indicated).  Save for any express 
acknowledgments, references and/or bibliographies cited in the work, I confirm that 
the intellectual content of the work is the result of my own efforts and of no other 
person. 
 
The right of Vijay Kenneth D’Souza to be identified as author of this work is asserted 
in accordance with ss.77 and 78 of the Copyright, Designs and Patents Act 1988.  At 
this date copyright is owned by the author. 
 
 
Signature: Vijay Kenneth D’Souza 
 
Date: 1st February 2008 
 
ABSTRACT 
 
In light of the significant modulation of receptor activity previously shown by a peptide 
(designated L247), designed to mimic the third extracellular loop of the human P2Y2 
receptor, the aim of this study was to use this peptide as an immunogen to generate and 
fully characterise polyclonal rabbit antibodies to the P2Y2 receptor. Other aims of this 
study were to characterise epithelial and endothelial cells for a thorough expression 
profile of P2Y receptor mRNA transcripts in order to provide a rapid screen for the 
molecular determinants of these receptors in these cells. These studies also aimed to 
confirm previously published pharmacology, thus, to set the basis for western blot 
studies using P2Y receptor antibodies. 
 
Bovine aortic endothelial cells that co-express P2Y1 and P2Y2 receptors; EAhy926, a 
human endothelial fusion cell line, that express P2Y2 receptors; and ECV304 human 
bladder cancer cell line, known to express P2Y2-like and P2Y11-like receptors were used 
in this study. The dose dependent accumulation of inositol phosphates and cAMP 
response to potent P2Y11 agonists and RT-PCR studies confirmed the functional 
expression of both P2Y2 and P2Y11 receptors in ECV304 cells. Likewise, the dose 
dependent accumulation of inositol phosphates in response to potent P2Y2 and P2Y6 
agonists and the presence of mRNA transcripts confirmed the expression of functional 
P2Y2/4- like and P2Y6- like receptors in EAhy926 cells.  
 
Polyclonal antiserum raised against L247 peptide was affinity purified and the purified 
fractions showed strong immunoreactivity with immobilised immunogenic antigen in 
ELISA. In western blot analysis L247 rabbit polyclonal anti-P2Y2 antibody detected 
strong bands in ECV304 and EAhy926 cells. On pre-absorption with the immunogenic 
peptide these responses were abolished suggesting that this antibody is antigen specific. 
Agonist induced P2Y2 receptor desentisation studies in ECV304 cells showed that 
prolonged agonist incubation caused the receptor sequestration. The loss of bands 
caused by P2Y2 receptor desensitisation and sequestration in membrane enriched 
fractions of agonist incubated ECV304 cells confirmed the specificity of L247 antibody. 
This antibody also showed no immunoreactivity in 1321N1 human brain astrocytoma 
cells devoid of any P2Y receptor subtypes cells. Deglycosylation studies revealed that 
the P2Y2 receptors are glycosylated in ECV304 cells.  
 i
 The polyclonal rabbit anti-P2Y2 receptor antibodies obtained from commercial sources 
produced completely different immunoreactive profiles with multiple bands even in 
1321N1 cells. Furthermore, in comparison to L247 anti-P2Y2 antibody the commercial 
antibody showed no difference between normal and agonist incubated cells suggesting 
that this antibody may not be recognising the P2Y2 receptors in ECV304 cells. Likewise 
polyclonal rabbit antibodies to other P2Y receptors either showed no response or 
showed strong immunoreactive profile with multiple bands even in 1321N1 cells 
suggesting that these antibodies may not have been extensively characterized. 
Furthermore, immunofluorescence studies with commercial anti-P2Y2 antibodies 
showed that they may be only recognising non-denatured receptors. These studies 
suggest that the L247 anti-P2Y2 antibody raised against peptide designed to mimic 
specific region in the third extracellular loop of human P2Y2 receptor is highly specific 
and sensitive and provides an important tool to study endogenously expressed P2Y2 
receptors in both non-denatured and denatured state. These studies indicate that this 
strategy of generating antibodies may be used to generate highly specific antibodies to 
other P2Y receptor subtypes. 
 
 ii
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CHAPTER 1 
 
 
GENERAL INTRODUCTION 
 
 
 1
1.1 Functional human P2Y receptor subtypes 
 
The role of purinergic receptors and the description of their pharmacology were 
originally proposed by Burnstock and colleagues (Burnstock et al., 1970) by way of 
describing responses that previously had been defined as nonadrenergic and 
noncholinergic. Adenosine triphosphate (ATP) was proposed as the natural ligand of 
these receptors. On further study, it was proposed that purinergic receptors should be 
subdivided into P1 receptors, which respond to adenosine and are coupled to adenylate 
cyclase, and P2 receptors, which respond to ATP and adenosine diphosphate (ADP). 
The P2 class has subsequently been divided further into P2X and P2Y receptors. P2X 
receptors are ligand gated receptors containing an intrinsic ion channel whereas 
metabotropic P2Y receptors belong to the super family of G protein coupled receptors.  
 
To date, eight functional human P2Y receptor subtypes have been identified (P2Y1, 
P2Y2, P2Y4, P2Y6, P2Y11 P2Y12, P2Y13 and P2Y14) that cannot be distinguished by their 
specific pharmacological selectivity for different nucleotides. The P2Y1 receptor is 
highly responsive to both ADP and ATP (Ayyanathan et al., 1996; Leon et al., 1996; 
Schachter et al., 1996; Palmer et al., 1998). The triphosphate-preferring P2Y2 receptor 
is activated equipotently by  ATP and UTP (Parr et al., 1994; Nicholas et al., 1996). 
The P2Y4 receptor is activated preferentially by UTP, while both UDP and ADP have 
little or no effect (Nguyen et al., 1995; Communi et al., 1996a; Nicholas et al., 1996). 
UDP potently activates the pyrimidine-preferring P2Y6 receptor, while UTP and ADP 
are low potency agonists (Communi et al., 1996b; Nicholas et al., 1996). 
 
The P2Y11 receptor is potently activated by ATP and certain ATP analogues e.g. 
BzATP and ATPγS  and this receptor couples to both phospholipase C and adenylyl 
cyclase stimulation (Communi et al., 1997; Communi et al., 1999a). Some of the 
functional P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, and P2Y11) are coupled to 
phospholipase C. Agonist stimulation of these receptor subtypes results in mobilisation 
of intracellular Ca2+ ions from internal stores via Gq/11-mediated phospholipase C 
activation but some may couple also to adenylyl cyclase either through Gi (P2Y2, P2Y4) 
or Gs (P2Y11) (Morse et al., 2001). Upon activation, phosphatidyl inositol bisphosphate 
 2
(PIP2) is hydrolysed leading to the generation of inositol triphosphate (Ins 1,4,5), which 
in turn releases calcium from intracellular stores (Lytton et al., 1991). 
 
ADP is a potent agonist at the P2Y12 receptor (Hollopeter et al., 2001; Zhang et al., 
2001). The P2Y12 receptor which was formerly called P2Y (ADP), P2Y (AC), P2Ycyc 
or P2T (AC) is activated by 2MeSADP and ADP and coupled to the inhibition of 
adenylyl cyclase through Gi (Hollopeter et al., 2001). The P2Y13 receptor shares high 
affinity for ADP and is coupled to inhibition of adenylyl cyclase and the stimulation of 
MAP kinases (ERK1 and ERK2) and is linked to the Gαi class of G proteins (Communi 
et al., 2001a; Zhang et al., 2002). The P2Y14 receptor is potently activated by UDP-
glucose and related sugar nucleotides such as UDP-galactose, UDP-glucuronic acid and 
UDP-N-acetylglucosamine and is coupled to G proteins of the Gi/o class (Chambers et 
al., 2000a; Abbracchio et al., 2003).  
 
The activation of a receptor by different nucleotides and the ability of a single 
nucleotide to activate more than one receptor makes it difficult to determine the identity 
of functionally expressed receptors. Therefore, there is a need for selective agents which 
are able to bind in an agonistic or antagonistic manner. The development of such agents 
would be beneficial to not only determine the functional expression but also to study the 
pharmacology of P2Y receptor subtypes. 
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1.2 Ligands for P2Y receptors 
 
Table 1.1 Human P2Y receptor agonists 
P2Y subtypes 
expressed in 
human tissues 
Agonists References 
P2Y1 2_MeSADP> ADP> 
2_MeSATP> ATP 
(Ayyanathan et al., 1996; Janssens et al., 
1996; Leon et al., 1996; Leon et al., 1997; Jin 
et al., 1998a; Palmer et al., 1998) 
P2Y2 UTP = ATP > Ap4A 
> ATP 
(Parr et al., 1994; Lazarowski et al., 1995; 
Nicholas et al., 1996) 
P2Y4 UTP > UTPγS >> 
ATP, UDP 
(Communi et al., 1995; Nguyen et al., 1995; 
Communi et al., 1996a; Nicholas et al., 1996) 
P2Y6 UDP = 5-Br-UDP 
>> UTP > 
2_MeSADP 
(Communi et al., 1996b; Southey et al., 1996; 
Maier et al., 1997) 
P2Y11 ATPγS = BzATP > 
ATP > 2_MeSATP 
(Communi et al., 1997; Communi et al., 
1999b) 
P2Y12 2_MeSADP > ADP (Hollopeter et al., 2001; Takasaki et al., 2001; 
Zhang et al., 2001) 
P2Y13 2_MeSADP = ADP 
> ADPβS > IDP 
(Communi et al., 2001a; Zhang et al., 2002) 
P2Y14 UDP-Glucose (Chambers et al., 2000a; Abbracchio et al., 
2003) 
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All the available agonists have been shown to activate more than one P2Y receptor. 
However, the main discriminating features in the profiles of agonist activating receptors 
are that P2Y1 and P2Y11 are selective for adenine nucleotides and all other P2Y 
receptors can be activated also by uracil nucleotides though some of these receptors 
show weak selectivity between uracil or adenine nucleotides (e.g. P2Y2, P2Y4). Also 
there is no preference between nucleotide diphosphate or nucleotide triphosphate as 
agonists (e.g. P2Y1, P2Y6). The agonist of P2Y1 receptor 2-methylthio adenosine 
trisphosphate (2MeSATP) can  also activate P2Y11, and uridine 5′-triphosphate (UTP) 
can activate P2Y2, P2Y4 and P2Y6 receptors (Lazarowski et al., 1995; Communi et al., 
1996a; Communi et al., 1996b). 
 
In addition, in the case of antagonists, the inhibition of agonist activity is not subtype 
selective for P2Y receptors (Charlton et al., 1996a). However in recent years a few 
agents have been reported to be selective antagonists like MRS2279 specific for the 
P2Y1 receptor with  no effect on activation of the human P2Y2, P2Y4, P2Y6, or P2Y11 
receptors by their cognate agonists (Boyer et al., 2002). MRS2567 and MRS2578 have 
been shown to block agonist effects at both human and rat P2Y6 receptors and 
MRS2575 was shown to selectively block human P2Y6 but not rat P2Y6 receptors 
(Mamedova et al., 2004). AR-C67085 is also reported as the selective antagonist at the 
platelet ADP receptor, P2Y12 (Ingall et al., 1999). There are at present, no commercially 
available selective antagonists for P2Y2, P2Y4, P2Y11, P2Y13, P2Y14 receptors (see 
Table 2).  
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 Table 1.2 Human P2Y receptor antagonists 
 
P2Y subtypes 
expressed in 
human tissues 
Antagonists 
(pA2 or pKB values or 
antagonistic effect at highest 
concentration 
References 
P2Y1 MRS2279 
MRS2179 (6.75) 
 Reactive blue 2 (6.1) 
Suramin (5.5) PPADS 
(5.4-4.9) 
(O'Grady et al., 1996; Schachter et al., 
1996; Moro et al., 1998; Boyer et al., 
2002) 
P2Y2 Suramin (4.3) (Charlton et al., 1996a; 1996b) 
P2Y4 PPADS (decrease by 30-
73 % at 100 µM)  
Reactive blue 2 (decrease 
by 33 % at 100 µM) 
(Charlton et al., 1996b; Communi et al., 
1996a) 
P2Y6 MRS2575, MRS2567, 
MRS2578 
Reactive blue 2 (6.0)  
PPADS (decrease by 69 
% at 100 µM) 
(Robaye et al., 1997; Mamedova et al., 
2004) 
P2Y11 Suramin (6.09)  
Reactive blue 2 (decrease 
by 80 % at 100 µM) 
(Communi et al., 1999b) 
P2Y12 AR-C69931MX >> 
2_MeSAMP 
(Hollopeter et al., 2001; Takasaki et al., 
2001; Zhang et al., 2001) 
P2Y13 No blockade by 
MRS2179 at 3µM 
(Zhang et al., 2002) 
P2Y14 No data  
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1.3 Molecular biology of P2Y receptors 
 
Table 1.3 Chromosomal locations of the genes encoding for the P2Y-receptors 
Receptor Type Species GenBank Access. No. Chromosomal Location
Human U42029, U42030, S81950 3q25.2 
Bovine X87628  
Rat U22830 2q31 
P2Y1 
Mouse U22829 3E1 
Human NM_002564 11q13.5 
Canine XM_542321 21 
Porcine AY620400  
Rat L46865, U09402 1q32 
P2Y2 
Mouse L14751 7F1 
Human U40223, X91852, 
X96597 
Xq13 
Rat Y11433, Y14705 Xq31 
P2Y4 
Mouse AJ277752 XC2 
Human U52464, AF007891 11q13.5 
Rat D63665 1q32 P2Y6 
Mouse NM_183168 7E1 
Human NM_002566 19p13.2 
P2Y11 
Canine   
Human AF313449, AF321815, 
AB052684 
3q25.1 
Bovine AJ623293  
Rat AF313450 2q31 
P2Y12 
Mouse AJ312130, NM_027571 3D 
Human NM_023914, NM_176894 3q24 
Rat AY639875 2q31 P2Y13 
Mouse NM_028808 3D 
Human NM_014879 3q21-25 
Rat U76206 2q31 P2Y14 
Mouse NM_133200 3D 
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P2Y receptors are highly diverse in their amino acid sequence as shown by P2Y1 and 
P2Y11 receptors, which share only 33% of amino acid sequence despite similarity in 
their agonist profiles (von Kügelgen and Wetter, 2000). Similarly P2Y1 and P2Y12 
receptor share only 18% similarity in amino acid sequence (von Kugelgen, 2006). 
However, the highly conserved amino acid residues in the predicted TM3 
(transmembrane 3), TM6 and TM7 regions of P2Y receptors close to the intracellular 
loop, is thought be responsible for their ligand specificity (von Kügelgen and Wetter, 
2000). All P2Y receptors pocess 4 cysteine residues at their extracellular domain and 
these residues form 2 disulfide bridges. The first one between the N-terminal domain 
and ECIV (extracellular region IV)  and the second bridge between ECII and ECIII 
(Hoffmann et al., 1999; Ding et al., 2003). P2Y2 and P2Y12 receptors expressed at the 
level of the cell membrane are shown to be modified by N-linked glycosylation (Erb et 
al., 1993; Zhong et al., 2004). Furthermore, N-linked glycosylation has been shown to 
be essential for signal transduction, but not for ligand binding or cell surface expression 
of P2Y12 refeptors (Zhong et al., 2004). 
 
Many orphan G-protein coupled receptors have a structural similarity with P2Y 
receptors e.g. the sequence similarity of pseudogene, psi GPR79 with the P2Y2 gene 
and GPR80 with the P2Y1 gene (Lee et al., 2001). Identification of closely related 
orphan G-protein coupled receptors (no identified natural ligand) at chromosomal 
location 3q24-3q25 along with P2Y1 and uridine 5'-diphosphoglucose receptor 
KIAA0001, suggest that these receptors may have evolved from a common ancestor and 
may be activated by related ligands (Wittenberger et al., 2001). Phylogenetic analysis of 
human G-protein-coupled receptors found that the orphan receptor GPR87 is closely 
related to the receptor for UDP-glucose KI01 and to the ADP-binding receptors P2Y12 
and GPR86 (Joost and Methner, 2002).  
 
With the help of phylogenetic analyses and sequence comparisons of GPCRs it is 
possible to group receptors based on their ligand preference, in so doing, able to predict 
ligand types for orphan receptors. Furthermore, GPCRs activated by the signals from 
endogenous sources such as peptides, lipids, neurotransmitters, or nucleotides are well 
conserved between human and mouse; and the genetic polymorphism and loss of such 
an GPCR may only cause a selective defect in particular physiological function it is 
involved in (Vassilatis et al., 2003). Orphan G-protein-coupled receptor 34 (GPR34) 
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which showed evidence for common evolutionary origin to ADP-like receptors (P2Y12 
and P2Y13) did not show any response to ADP and has been reported as the functional 
mast cell lysoPS receptor activated by Lysophosphatidyl-L-serine (lysoPS) (Schoneberg 
et al., 1999; Schulz and Schoneberg, 2003; Sugo et al., 2006). 
 
Diadenosine-polyphosphates which are known to activate P2Y1, P2Y2 and P2Y13 have 
also been reported to activate yet unidentified receptors in rat midbrain cholinergic 
synaptic terminals (Diaz-Hernandez et al., 2001; Patel et al., 2001; Marteau et al., 2003; 
Diaz-Hernandez et al., 2004). Diadenosine polyphosphates have also been shown to 
selectively activate an unidentified P2Y-like receptor in lung epithelial cells (Laubinger 
et al., 2003; Miras-Portugal et al., 2003). 
 
However, sequence similarity to P2Y receptor does not predict a P2Y receptor related 
response. Orphan receptor GPR80/GPR99, previously named the P2Y15 receptor, is 
responsive to AMP and adenosine and thought to resemble P2Y nucleotide receptors 
more than P1 adenosine receptors and is also thought to be coupled to Gq and Gs   (Inbe 
et al., 2004). However, this receptor responds predominantly to citric acid cycle 
intermediate α-ketoglutarate and therefore is not a P2Y receptor (He et al., 2004; 
Abbracchio et al., 2005). 
 
Genetic variations such as gene polymorphism of the P2Y gene family is thought to 
cause variability in P2Y receptor mediated responses. Interindividual variation of 
functional effects in terms of platelet response to ADP has been attributed partly to gene 
polymorphisms. Carriers of more than one G allele (frequency 0.15) at 1622 position of 
P2Y1 receptor was found to be associated with increased platelet response to ADP. 
However, this A〉G polymorphism at position 1622 in the coding sequence of the P2Y1 
gene was silent without affecting the amino acid structure of P2Y1 receptor 
(Hetherington et al., 2005). A recent study also has reported no association between 
response to aspirin or clopidogrel in cardiac patients and PlA2 gene polymorphism of 
glycoprotein IIIa, T744C polymorphism of the P2Y12 gene and the 1622A〉G 
polymorphism of the P2Y1 gene, indicating that the variability in anti-platelet drug 
response may not be only caused by single gene mutations but also could be due to 
other factors (Lev et al., 2007). 
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Chromosomal clustering and phylogenetic analysis has provided insights into diverse 
evolutionary arrangements of P2Y receptor gene family. The close arrangements of the 
chromosomal location of the genes encoding for P2Y2 and P2Y6 (11q13.5) has been 
explained on the premise that gene development occurred with local gene duplication 
before chromosomal duplication (Somers et al., 1997; Fredriksson et al., 2003). For 
human P2Y2 receptors gene polymorphism has been reported from European 
populations characterized by an Arg334 - Cys334 transition (arginine 334 to cysteine 
334) with frequency distribution of R (Arg) allele 0.8 versus 0.2 for the C (Cys) allele 
(66% of the tested persons were homozygotes R/R (Arg/Arg), 29% were heterozygotes 
R/C (Arg/Cys) and 5% were homozygotes C/C (Cys/Cys) (Janssens et al., 1999). This 
polymorphism, however, did not affect the agonist affinity but the stimulation of P2Y2 
receptor with Cys variant resulted in a slower time course (Janssens et al., 1999). 
 
Analysis of the coding region of P2Y2 gene in CF (Cystic Fibrosis) patients revealed 
three frequent nonsynonymous P2Y2 receptor polymorphisms (Leu46Pro; Arg312Ser 
and Arg334Cys). The intracellular Ca2+- release was significantly increased in cells 
expressing the homozygous Cys334 variant compared to wild type and this effect was 
more pronounced in cells carrying the homozygous Ser312 variant. These studies 
indicate that the P2Y2 receptor gene haplotypes resulted from gene polymorphism 
influence intracellular Ca2+- release (Buscher et al., 2006).  
 
The extremely rare case of intergenic splicing seen in mammalians has been found 
between the P2Y11 and SSF1 gene (Saccharomyces cerevisiae nuclear protein, which 
plays an important role in mating) in cDNA libraries. The gene encoding P2Y11 and the 
human orthologue of SSF1 are located on chromosome 19. The chimeric SSF1-P2Y11 
receptor fusion protein, when stably expressed in CHO-K1 cells generated a cAMP 
response to a P2Y11 agonist which was qualitatively similar to that observed for P2Y11 
receptor (Communi et al., 2001b). The common P2Y11 gene polyorphism of Ala87Thr 
has been reported to be associated with acute myocardial infarction (AMI) with patients 
carrying homozygous Thr87 posing greater risk with increased levels of C-reactive 
protein (Amisten et al., 2007).  
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 The polymorphism of P2Y12 receptor gene expressed in platelets from a person with 
congenital bleeding disorder was characterized by a G-to-A transition in one allele 
(changing the codon for 256Arg-256Gln in the sixth transmembrane domain) and a C-
to-T transition in the other allele (changing the codon for Arg265- 256Trp in the 
beginning of the third extracellular loop) (Cattaneo et al., 2003). These mutations did 
not interfere with ADP analogue binding to the receptor but altered the function of the 
receptor thought to be caused by defective signalling. The binding of the receptor with 
nucleotides was previously proposed to be caused by the interaction of positive charged 
residue on the external domain with the phosphate groups of nucleotides. However, this 
positive charge was lost in this case by the mutation to Trp  (Moro et al., 1999; Cattaneo 
et al., 2003). These reports underscore the role of molecular characterisation of P2Y 
receptors in designing receptor subtype selective ligands, identifying novel targets and 
analysing the altered response caused by genetic variation in receptor mediated therapy.  
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1.4 P2Y Receptors and binding domains 
 
Since the fully ionized form of nucleotides have been shown to be an activating ligand 
for both P2Y1 and P2Y2 receptors the positively charged amino acids conserved in 
TM3, TM6, TM7 are involved in binding of the negatively charged phosphate groups of 
nucleotides. Mutational analysis of the P2Y1 receptor suggested that positively charged 
residues on the exofacial side of TM3 and TM7 are critical determinants of the ATP 
binding pocket (Jiang et al., 1997). Site-directed mutagenesis of His132 and Tyr136 in 
TM3, Thr222 and Phe226 in TM5, Lys280 in TM6 and Gln307 and Ser314 in TM7 of the 
human P2Y1 receptor decreased agonist induced reponses and antagonistic potency of 
MRS 2179 sugesting their role in nuleotide binding (Guo et al., 2002). The basic amino 
acid lysine appeared to be more important in P2Y1. Other than its critical role for the 
activation of the receptor, it has been shown to be important in the binding of P2 
receptor antagonists. The antagonistic potencies and affinities of chemically unrelated 
agents such as PPADS, NF023 and reactive blue 2 were affected by the mutation of 
Lys280 on TM6 of the human P2Y1 receptor (Guo et al., 2002). 
  
Site-directed mutagenesis of the P2Y2 receptor suggested that positively charged amino 
acids on TM6 and TM7 are involved in ligand binding. The mutation of histidine262 and 
arginine265 to leucine decreased the potency of ATP and UTP with no affect on the 
ability to select between tri- and diphosphates (Erb et al., 1995). Recent studies have 
revealed in formation about the conserved residues in the transmembrane regions of the 
human P2Y receptor subtypes. The P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and 
P2Y14 receptors have an H-X-X-R/K motif in TM6.  P2Y1, P2Y2, P2Y4, P2Y6 and 
P2Y11 receptors have a conserved Y-Q/K-X-X-R motif in TM7 whereas P2Y12, P2Y13 
and P2Y14 have K-E-X-X-L motif in TM7 (Abbracchio et al., 2003). 
 
The diphosphates selectivity of canine P2Y11 receptor unlike the triphospahte selectivity 
of human P2Y11 receptor was attributed partly to the mutation of arginine265 in human 
P2Y11 receptor to glutamine in the canine P2Y11 receptor. The positively charged 
arginine residue appear to be crucial to the recognition of extracellular nucleotides by 
the P2Y11 receptor (Qi et al., 2001). In platelet P2Y12 receptors from a patient with a 
congenital bleeding, the polymorphism of Arg-256-Gln at one allele in the sixth 
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transmembrane domain, and an Arg-265-Trp at the other allele in the third extracellular 
loop has been reported (Cattaneo et al., 2003). 
 
In the P2Y1 receptor the presence of two critical disulfide bridges and involvement of 
charged residues in ligand recognition has indicated the involvement of second and third 
extracellular loops and transmembrane regions (Hoffmann et al., 1999). In addition, low 
affinity binding sites termed “meta-binding sites” have been suggested for the 
nucleotide binding of the P2Y1 receptor in the second and third extracellular loop (Moro 
et al., 1999). In a study involving the P2Y1/6 chimeric receptor (chimera of human P2Y1 
with rat P2Y6 receptor), Tyr110 residue was identified to play an important role in the 
recognition of the nucleobase in the P2Y1 and P2Y6 receptors. Furthermore this study 
ruled out the possibility of recognition of uracil nucleotides exclusively by extracellular 
regions, but indicated that ligand recognition must involve a combination of 
extracellular and transmembrane domains. Thus it was believed that the initial binding 
of the ligand takes place to the exofacial region and the subsequent movement of it to a 
deeper binding site in the transmembrane regions (Hoffmann et al., 2004). Analysis of 
receptor-ligand complexes of the human P2Y1 receptor with its ligand ATP in a 
homology modeling using the 2.6 A crystal structure of bovine rhodopsin suggests that 
the triphosphate moiety is tightly bound by a multitude of interactions (Major and 
Fischer, 2004). 
 
Studies involving human/rat P2Y4 receptor chimeras revealed that the second 
extracellular loop and the N-terminus play a key role in determining agonistic activity 
of ATP at mammalian P2Y4 receptors. According to the mutational analysis, Asn177, 
Ile183, and Leu190 were crucial residues within the EL2 (extracellular loop 2) which 
impart ATP agonism (Herold et al., 2004). The disulphide bridge between the second 
extracellular loop (EL2) and third transmembrane region (TM3) and the residues within 
EL2 are considered to be essential for activation for most GPCR (Klco et al., 2005).  
 
The P2Y2 nucleotide receptor contains the integrin-binding domain arginine-glycine-
aspartic acid (RGD) in its first extracellular loop which interacts with integrins and the 
integrin-associated thrombospondin receptor, CD47. The RGD sequence associated 
interaction of P2Y2 receptor with integrins and CD47 was considered necessary for 
coupling the P2Y2 with Go protein (Erb et al., 2001).  SH3 binding sites (PXXP motifs) 
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serve important functional roles including protein interaction in many GPCRs   (Mayer, 
2001). The human P2Y2 nucleotide receptor has two proline-rich, SH3 binding sites 
(PXXP) in the carboxyl-terminal tail and these SH3 domains directly associate with the 
tyrosine kinase Src and activate Src (Liu et al., 2004b). 
 
The dimer formation of P2Y1 with A1 receptor has given new insights into purine 
signalling and P2Y receptor interaction with other GPCRs (Yoshioka et al., 2001). 
These studies suggested that A1 and P2Y1 receptors can form constitutive hetero-
oligomers caused by simultaneous agonist promoted activation in living cells (Yoshioka 
et al., 2002b). The composition of ligand binding domains of P2Y receptors, therefore, 
is valuable in understanding the mechanism of ligand recognition and receptor 
activation. It also facilitates the analysis and regulation of the multiple signalling 
pathways that are then activated by receptor complex formation with growth factors, 
receptors and other proteins. Comparison of the binding domains and their structual 
homologues in other P2Y receptors will help in understanding their allosteric regulation 
and also in designing selective ligands to alter their function. 
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1.5 Antibodies to P2Y receptors 
 
Antibodies, which are raised against the receptor protein or against peptide sequences, 
are commonly used to localize receptor proteins at the microscopic levels and they 
present a potential tool to study the target protein (Mijares et al., 2000). Polyclonal 
antibodies are directed against different epitopes on the target protein and interact with 
different affinities. Therefore they detect multiple epitopes and recognise the antigen 
from different orientations.  Monoclonal antibodies, on the other hand, are monospecific 
as they are specific for a single epitope. Moreover, polyclonal antibodies are less time 
consumng simple and cheaper to produce than monoclonal antibodies. However, 
polyclonal antibodies are susceptible to differences in reactivity and titre that might be 
caused by batch to batch variation. The continuous production of monoclonal antibodies 
in culture with B cell hybridomas can produce unlimited supply of antibodies of unique 
specificity but their production is time consuming (Nelson et al., 2000). 
 
The lack of sensitive and selective antibodies to P2Y receptors, which belong to the 
rhodopsin-like/beta adrenergic receptor family, has hindered the task of studying the 
biochemical and cell biological properties of endogenous P2Y receptors. To date, the 
study of biochemical properties of GPCRs has mainly resorted to the use of receptor 
cDNAs to introduce an epitope tag at the N-terminus. Antibodies directed against this 
tag are then used to investigate epitope-tagged receptors expressed in heterologous cells. 
On the other hand, generation of antibodies to closely related receptors advocates the 
use of peptides derived from the N-terminal region as this region is comparatively 
diverse between closely related receptors (Gupta and Devi, 2006). 
 
However, suitable antibodies have been generated - using sequences taken from other 
regions- which have shown specific interaction with the native receptor belonging to 
GPCR superfamily. Antibodies directed against the second extracellular loop of the 
human β1-adrenoceptor reacted strongly with non-denatured receptors and decreased the 
affinity of the radiolabelled antagonist ([3H]CGP 12 177). However, antibodies directed 
against carboxy- and amino-terminal receptor domains reacted strongly with denatured 
and non-denatured receptors but did not interfere with binding of antagonist (Jahns et 
al., 1996). 
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These subtype-specific antibodies to β1 and β2-adrenoceptors (AR) have been used to 
map the distribution of subtypes in the rat nephron using immunofluorescence 
techniques (Boivin et al., 2001). Peptides derived from N-terminal region have been 
successfully used to raise antibodies to μ, δ and κ subtypes of opioid receptors which 
recognize recombinant as well as endogenous receptors (Gupta and Devi, 2006). 
A recent study has reported the successful generation of antibodies to GPCR that could 
detect conformational changes in N-terminal region following receptor activation. These 
antibodies differentially recognized inactive and agonist-activated μ opioid receptors. 
Furthermore, antibodies generated to the mid-portion of the N-terminal tail exhibited 
enhanced recognition of activated receptors whereas those to the distal regions did not. 
Targeting the N-terminal region to generate receptor conformation specific antisera has 
been successfully applied to other Gαi-coupled (δ opioid, CB1 cannabinoid, α2A 
adrenergic) as well as Gαs- (β2 adrenergic) and Gαq-coupled (AT1 angiotensin) 
receptors (Gupta et al., 2007). Receptor confirmation change affecting the ligand 
binding has also been seen in antibodies raised against synthetic peptides of 
extracellular domain of human follicle-stimulating hormone receptor (hFSHR) (Schmidt 
et al., 2001). 
 
Monoclonal antibodies produced against a peptide corresponding to the second 
extracellular loop of the human β2-adrenoceptor exerted a dose-dependent “agonist-
like” effect on the spontaneous beating rate of neonatal rat cardiomyocytes. This agonist 
effect was blocked by preincubation with the target peptide and with the β2-antagonist 
indicating the receptor specificity of the antibody. However, this antibody which 
recognised the receptor in its native form failed to recognise denatured receptor on 
western blot analysis (Lebesgue et al., 1998). The monomeric Fab fragments of this 
monoclonal antibody to human β2-adrenoceptor, however, inhibited the agonist induced 
receptor activation. Furthermore, the cross-linking of Fab fragment with rabbit anti-
mouse IgG restored the agonist-like effect to Fab fragments thought to be caused by 
dimerization of receptor conformation. Therefore these studies suggested that anti-
receptor antibodies can thus act both as agonist in the dimeric state and as antagonist in 
the monomeric state (Mijares et al., 2000). Monoclonal antibody directed against the 
second extracellular loop of the human 5-HT4 receptor showed an antagonist like 
activity at higher concentration of 50 and 500 pM; and facilitated the agonist action at 
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lower concentration range of 5 pM. This study suggested that the high affinity antibody 
at higher concentrations favours monovalent binding resulting in antagonist like activity 
and which at lower concentration results in agonist action because of bivalent 
recognition of the receptor (Kamel et al., 2005). 
 
Polyclonal antibodies raised against synthetic peptide corresponding to the second 
extracellular loop of human cardiac 5-HT4 receptor, a GPCR has been shown to exert 
"inverse agonist-like" (ligands with higher affinity favouring the resting conformation 
than the active conformation of the receptor) activities. This antibody was found to 
allosterically inhibit receptor activation by blocking the induction of an active 
conformation by the agonist. Furthermore, the antibody also recognized the denatured 
5-HT4 receptor in immunoblots (Salle et al., 2001). The same antibody when analysed 
in cell systems expressing a larger amount of human 5-HT4 receptors has shown 
"agonist-like" effects indicating that the activity of the antibody may also depend on the 
molecular density and/or the cellular environment of the target receptors in addition to 
epitopic region recognised by the antibody (Bozon et al., 2002).  
 
A monoclonal antibody mapping distinct epitopes of the CCR5 receptor have shown 
existence of multiple active conformation states of receptors. Amongst them, a 
monoclonal antibody mapping epitopes of second extracellular loop has been shown to 
compete for gp120 binding and promote efficient internalization of the receptor without 
triggering intracellular signaling (Blanpain et al., 2002). A scFv fragment (single chain 
variable fragment), of a monoclonal antibody directed against the second extracellular 
loop of the β2 adrenergic receptor recognised the receptor having shown inverse agonist 
like properties both in vitro and in vivo. Inverse agonism is observed when molecules 
specifically recognize the resting conformation of the receptor and shift the active 
resting conformational equilibrium to the right (Peter et al., 2003).  
 
On the basis of these published studies, the idea of generating antibodies to P2Y 
receptors (family A GPCRs), directed not only to the N-terminal region but also to 
transmembrane and extracellular domains involved in ligand recognition and receptor 
activation seems realistic. Antibodies so generated could be used to examine the 
localization of active receptors as well as the extent of modulation of receptor activity 
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by cross-talk between receptors. Therefore, antibodies to P2Y receptors could provide 
powerful tools to examine the duration and extent of activation of endogenous receptors 
as well as to screen for drugs of potential therapeutic value that act as allosteric 
modulators. 
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1.6 P2Y receptors and intracellular signaling transduction pathways  
 
The P2Y receptor subtypes can be classified in two principal signaling transduction 
pathways. The receptors subtypes belonging to the first group (P2Y1, P2Y2, P2Y4, 
P2Y6, and P2Y11) are coupled to phospholipase C (PLC) via Gq- proteins. Agonist 
stimulation of these receptor subtypes results in mobilisation of intracellular Ca2+ ions 
from internal stores via Gq/11-mediated phospholipase C. Upon activation, phosphatidyl 
inositol bisphosphate (PIP2) is hydrolysed leading to the generation of inositol 
triphosphate (Ins 1,4,5), which in turn releases calcium from intracellular stores (Lytton 
et al., 1991). In addition, P2Y11 is also coupled to adenylyl cyclase via Go through UTP 
stimulation and via Gq and Gs through ATP stimulation (Morse et al., 2001; White et 
al., 2003). Upon activation, phosphatidyl inositol bisphosphate (PIP2) is hydrolysed 
leading to the generation of inositol triphosphate (Ins 1,4,5), which in turn releases 
calcium from intracellular stores (Lytton et al., 1991). The second group which consists 
of P2Y12, P2Y13 and P2Y14 all couple to the inhibition of adenylyl cyclase through Gi- 
proteins which results in a decrease in intracellular cAMP (Chambers et al., 2000a; 
Communi et al., 2001a; Hollopeter et al., 2001; Abbracchio et al., 2003).  
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Figure 1.1 IP3 signal transduction pathway: Agonist stimulation of 
P2Y receptors leads to activation of heterotrimeric G proteins and 
their dissociation into α and βγ subunits. The activation of P2Y1, 
P2Y2, P2Y4, P2Y6 and P2Y11 receptors coupled to Gq/11-mediated 
phospholipase C cause the hydrolysis of the phosphatidyl inositol 
bisphosphate (PIP2) leading to the generation of inositol triphosphate 
(IP3) and DAG (Diacylglycerol) to cause the mobilization of 
intracellular Ca2+. 
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 Figure 1.2 cAMP signal transduction pathway: Agonist stimulation of 
P2Y receptors leads to activation of heterotrimeric G proteins and their 
dissociation into α and βγ subunits. The P2Y11 receptor activates both 
phospholipase C and adenylyl cyclase. The avtivation of the P2Y11 
receptors coupled to Gs stimulate adenylyl cyclase leading to a rise in 
cAMP whereas P2Y12 and P2Y13 receptors are coupled solely to Gi and 
inhibition of adenylyl cyclase. 
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 Figure 1.3 Other signal transduction pathways coupled to P2Y receptors. 
Concomitant activation of P2Y1 (causes platelet shape change) and P2Y12 
receptor initiates signaling pathways that trigger the activation of 
Glycoprotein-IIB/IIIA, which then promote high-affinity binding to fibrinogen 
and platelet aggregation. P2Y-regulated activation of RTKs (Receptor Tyrosine 
Kinases) coupled to PLC activate the Ras-MEK cascade whereas P2Y receptor 
activation mediated dissociated G-Protein βγ subunits initiate PI3K 
(Phosphatidylinositol- 3-Kinase) and activate NF-KappaB (Nuclear Factor-
KappaB) pathway. 
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The selectivity of signaling pathways between these two groups of P2Y receptors has 
been confirmed by various studies. The purified P2Y1 receptor showed receptor activity 
when reconstituted with Gαq/β1γ2 or Gα11/β1γ2 proteins (its protein-signaling cohorts) 
(Waldo and Harden, 2004). Similarly, the purified P2Y12 receptor protein coupled more 
effectively with Gαi2/β1γ2 than Gαi1 and Gαi3 and did not couple with Gαo or Gαq/β1γ2 
proteins when reconstituted with β1γ2 and Gα- subunits in lipid vesicles (Bodor et al., 
2003). Later studies reported that two arginine residues (R333 and R334) in the 
conserved BBXXB (B for basic and X for non-basic residue) region of the carboxyl 
(COOH) terminus of the human P2Y1 receptor are essential for the coupling of Gq- 
protein (Ding et al., 2005). Gi-coupled P2Y12 and P2Y13 receptors have been shown to 
cause an inhibition of voltage dependent N-type calcium channels in neuronal cells 
mediated by βγ- subunit release from a heterotrimeric G-protein(Kulick and von 
Kugelgen, 2002; Simon et al., 2002; Wirkner et al., 2003). An inhibition of N-type 
calcium channels has also been demonstrated for the P2Y1 receptor suggesting that this 
may interfere in the regulation of neurotransmitter release or neuronal excitability 
(Filippov et al., 2000; Gerevich et al., 2004).  
 
Evidence for the activation of two distinct signaling pathways by P2Y receptors 
diverging at the G protein level has been provided by human erythroleukemia (HEL) 
cells. In these cells the activation of phospholipase C (PLC) by the P2Y2 receptor was 
inhibited completely by Gα16 antisense RNA and partially by pertussis toxin (PTX) 
(Baltensperger and Porzig, 1997). Furthermore, studies have suggested that P2Y2 
receptors in visceral smooth muscle and vascular smooth muscle are coupled to PLC-β1 
via Gαq/11 and to PLC-β3 via Gαi3/β1γ2 derived βγ subunits (Murthy and Makhlouf, 
1998). RGD-dependent interaction between the P2Y2 and αv integrins has been shown 
to be vital for the receptor to initiate Go-mediated signaling events leading to 
chemotaxis (cell migration) (Bagchi et al., 2005). 
 
P2Y12 receptors that regulate platelet activation, couple to inhibition of adenylate 
cyclase (Hollopeter et al., 2001). However, the involvement of other signaling 
transduction pathways including the activation of phosphotidylinositol 3-kinase (PI3-
kinase) via Gαi and RhoA and Rho- kinase may also play a major role in platelet 
aggregation (Resendiz et al., 2003; Soulet et al., 2004). In addition, Gα13 but not Gα12 
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deficiency in platelets reduces activation of RhoA and Gα13 mediated signaling 
processes are required for normal hemostasis and thrombosis (Moers et al., 2003).  
In heterologously-expressed human P2Y11 receptors, UTP was found to be a Ca2+-
mobilizing agonist without inositol triphosphate (IP3) or cAMP increase and stimulation 
with ATP resulted in elevated IP3, cAMP and cytosolic calcium. Thus, ATP and UTP 
acting at the same receptor work through distinct signaling pathways suggesting the 
possibility of agonist-specific signaling (White et al., 2003). Multiple active (ligand-
specific) conformations have been proposed for the P2Y13 receptor depending on 
variation in the concentration ratio of ADP/2MeSADP which affects its coupling to G
16, Gi and Gs (at high concentration of ADP) coupled pathways, thus resulting in distinct 
receptor conformations based on structure and concentration of the receptor ligand 
(Marteau et al., 2003). 
 
Activation of P2Y receptor subtypes is associated with stimulation of mitogen-activated 
protein (MAP) kinase, in particular extracellular signal related protein kinase (ERK) 
1/2.  However, other classes of MAP kinases (MKK3/6- p38-MAPK cascade), related 
adhesion focal tyrosine kinase (RAFTK), protein kinase C (PKC), calcium and 
phosphatidylinositol 3-kinase (PI3-K) are also involved (Soltoff, 1998; Huwiler et al., 
2000; Communi et al., 2001a; Santiago-Perez et al., 2001). 
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1.7 Tissue distribution of P2Y receptor subtypes 
 
P2Y receptors are a major class of receptors ubiquitously expressed throughout the 
tissues of the body. The P2Y1 receptor is expressed in placenta, prostate and brain tissue 
(Ayyanathan et al., 1996; Moore et al., 2001). P2Y2 receptors have been detected in 
skeletal muscle and heart and they were present in spleen, lymphocytes, macrophages, 
bone marrow and lung (Parr et al., 1994; Moore et al., 2001). Intestine, pituitary, 
placenta and brain were reported to have P2Y4  receptors (Communi et al., 1995; Moore 
et al., 2001). P2Y6 mRNA has been detected in spleen, placenta and kidney, lung, 
intestine, adipose, bone and heart (Maier et al., 1997; Moore et al., 2001). P2Y11 
receptors have been detected in brain, pituitary, lymphocytes as well as spleen 
(Communi et al., 1997; Moore et al., 2001). P2Y12 receptor mRNA has been shown to 
be expressed in spinal cord and brain (Hollopeter et al., 2001; Zhang et al., 2001). In 
situ hybridisation data had suggested that P2Y12 is expressed in astrocytes and not 
neurons (Hollopeter et al., 2001) and expression of this receptor has been located in 
substantia nigra, caudate-putamen, thalamus, and temporal cortex (Hollopeter et al., 
2001; Zhang et al., 2001). Analysis of P2Y13 distribution revealed that these receptors 
are expressed in brain tissue and the immune system (Zhang et al., 2002).  Cells of the 
placenta, adipose tissue, stomach and intestine express the P2Y14 (UDP- glucose) 
receptor (Chambers et al., 2000a) (See Table 1.4).  
 
Studies have reported the location of P2Y receptor expression particularly in the 
epithelial cells. The polarised expression of human P2Y receptor subtypes (P2Y1, 
P2Y11, P2Y12, and P2Y14 receptors at the basolateral membrane and P2Y2, P2Y4, and 
P2Y6 receptors at the apical membrane) has been reported in epithelial cells (Wolff et 
al., 2005). Furthermore, the Gq-coupled P2Y receptors (P2Y1, P2Y2, P2Y4, P2Y6, and 
P2Y11 receptors) were targeted in identical manner in MDCK(II), 16HBE14o (derived 
from bronchial epithelial cells transformed with the SV40 virus) and Caco-2 (derived 
from a colonic adenocarcinoma), the three epithelial cells suggesting that polarized 
expression of these P2Y receptor subtypes does not depend on the type of epithelial cell 
in which they are expressed (Wolff et al., 2005). Further studies showed that the apical 
targeting signal in the P2Y2 receptor located in its first extracellular loop and that four 
amino acids (Arg95, Gly96, Asp97, and Leu108) within this loop play a major role in 
directing apical targeting (Qi et al., 2005).  
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Table 1.4 Tissue distribution of P2Y receptor subtypes 
 
P2Y 
Receptor 
Tissue distribution 
P2Y1 Placenta, prostate and brain tissue 
P2Y2 Skeletal muscle, heart, spleen, lymphocytes, macrophages, bone 
marrow and lung 
P2Y4 Intestine, pituitary, placenta and brain 
P2Y6 Spleen, placenta, kidney, lung, intestine, adipose, bone and heart 
P2Y11 Brain, pituitary, lymphocytes and spleen 
P2Y12 Astrocyte cell line,  substantia nigra, caudate-putamen, thalamus, and 
temporal cortex 
P2Y13 Brain tissue and the immune system 
P2Y14 Placenta, adipose tissue, stomach and intestine  
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1.8 Diagnostic and therapeutic potential for P2Y receptors 
 
1.8.1 Cystic fibrosis and chronic obstructive lung diseases 
 
P2Y receptors mediate a broad spectrum of signaling events, such as sensory perception, 
cell growth, allergic responses in asthma, regulation of insulin secretion  and 
microvascular tone (Erlinge, 1998; Hazama et al., 1998; Forsythe and Ennis, 1999; 
Burnstock, 2000; Lewis et al., 2000). Cystic fibrosis (CF) is characterized by abnormal 
electrolyte transport across the epithelia of the airways. In particular, there is excessive 
sodium absorption and deficient chloride secretion. In this condition and in chronic 
bronchitis the mucociliary clearance is impaired. P2Y receptors, which are found on the 
apical surface of airway epithelia, which are thought to contribute to the mucociliary 
clearance mechanism in the lung have been extensively studied (Yerxa, 1999). The 
natural ligand of P2Y2 receptors, uridine triphosphate (UTP), stimulates serosal-to-
mucosal chloride transport and fluid transport via a non- Cystic Fibrosis (CF) 
transmembrane regulator (CFTR) mechanism in isolated normal and CF epithelial cells 
and may be useful in the hydration of mucus and respiratory mucosa (Knowles et al., 
1991; Mason et al., 1991; Benali et al., 1994). Subsequently, it was found that UTP 
stimulates mucin secretion from goblet cells, increased surfactant release from type II 
alveolar cells, and increased the beat frequency of cilia in isolated normal and CF 
epithelial cells (Gobran et al., 1994; Kim et al., 1996; Morse et al., 2001). This provides 
evidence for the presence of P2Y2 receptors that can stimulate the major components of 
the mucociliary clearance system. 
 
Chloride and fluid transport and mucin secretion in the airways have been shown to be 
regulated in fundamentally important ways by ATP and UTP acting from the lumen via 
apical membrane P2Y2 purinoceptors (Boucher, 1994; Knowles et al., 1995; Kim et al., 
1997; Ralevic and Burnstock, 1998). UTP has been shown to stimulate mucociliary 
clearance whereas  ATP has been shown to stimulate ciliary activity directly (Wong and 
Yeates, 1992; Geary et al., 1995; Bennett et al., 1996; Sabater et al., 1999). A 
concentration-dependent relationship between ATP and ciliary beat frequency (CBF) 
and a positive correlation between the ATP-induced responses in intercellular Ca2+ and 
CBF has been reported in rabbit trachea epithelial cells (Korngreen and Priel, 1996). 
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 ATP and UTP are equipotent in their stimulatory effects on chloride and, fluid secretion 
and the agonists are equipotent and cross-desensitize in their activation of phospholipase 
C (PLC) (Brown et al., 1991; Mason et al., 1991; Parr et al., 1994; Cressman et al., 
1999). ATP and UTP effect these responses selectively through P2Y2 receptors. This 
was indicated in a study showing >85% of the chloride secretory response to each 
agonist was lost in the trachea of the P2Y2-R (-/-) mouse (Cressman et al., 1999). In 
addition to its actions at P2Y receptors, ATP also acts to effect responses through a 
family of ligand-gated P2X purinoceptors (Ralevic and Burnstock, 1998). Adenosine 
also stimulates chloride secretion in airways a response mediated by the P1 purinoceptor 
A2BAR (Pratt et al., 1986; Lazarowski et al., 1992; Stutts et al., 1994; Ralevic and 
Burnstock, 1998). 
 
Northern blotting studies in cell lines derived from the human lung revealed the co-
expression of P2Y2, and P2Y6 mRNA in the epithelial cell lines derived from the airway 
epithelium and type II alveolar epithelial cells (Communi et al., 1999a). mRNA for 
P2Y4 receptors was detected in epithelial cell lines derived from the airway epithelium, 
submucosal cells and airway smooth muscle cells and P2Y1 mRNA was detected in 
serous cells (Communi et al., 1999a). Furthermore, the inositol trisphosphates assays 
have identified responses typical of the P2Y2 receptors in the airway epithelial cell lines 
and P2Y4 receptors in submucosal cells (Communi et al., 1999a).  
The Ca2+-activated chloride (Cl-) channels (CaCC) expressed in human airway epithelia 
are activated by extracellular nucleotides (ATP and UTP). These Cl- channels are up-
regulated in the airways of cystic fibrosis (CF) patients. Activation of the cAMP 
pathway has been shown to increase CaCC-mediated secretion in CF. Moreover, the 
activation of Ca2+-dependent basolateral K+ channels has also been shown to improve 
CaCC mediated Cl- secretion. The same study showed that the co-activation of cAMP- 
and Ca2+-dependent basolateral K+ channels (hKvLQT1 and hSK4) participate in 
CaCC-mediated Cl- secretion and cystic fibrosis transmembrane conductance regulator 
(CFTR) in human airway epithelia. Therefore, both K+ channels form novel targets to 
improve mucociliary clearance in the CF airway disease (Mall et al., 2003). 
Furthermore, P2Y2 receptor agonists have shown to mediate Cl- secretory response 
through Ca2+-dependent stimulation of CaCC, and PKC-dependent stimulation of CFTR 
(Paradiso et al., 2000). Therefore, the impaired chloride transport in airway disease 
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caused by dysfunctional CFTR can be overcome by activating alternative (CaCC 
activated) chloride channels.  
Recent studies have attempted to identify the cause responsible for the termination of 
aerosolized nucleotide-mediated mucociliary clearance (MCC). The rapid elimination of 
P2 receptor agonists from human airway epithelial surfaces by epithelial 
ectonucleotidases with an enhanced efficiency in chronic inflammatory lung diseases, 
including CF, limits the nucleotide-mediated mucociliary clearance (MCC) capacity of 
these agents. The nucleotides are not cleared by permeation through the epithelial layer 
as human bronchial epithelial cells seem impermeable to extracellular nucleotides. 
Rather, the nucleotides are cleared by extracellular metabolism by cell-associated 
ectonucleotidases. These enzymes have been reported to show higher activities on 
mucosal epithelial surfaces and act with increasing efficiency in areas most susceptible 
to airway obstruction. The enzyme, non-specific alkaline phosphatase, is the major 
ectonucleotidase responsible for the termination of aerosolized nucleotide-mediated 
MCC in the lungs of CF patients (Picher et al., 2004). 
 
Metabolically stable dinucleotides present a promising therapeutical approach to the 
treatment of CF. P2Y2 receptor agonist, Denufosol tetrasodium (INS37217) is a 
deoxycytidine-uridine dinucleotide, which resists metabolism by airway cells and 
sputum enzymes. This compound lead to an increased chloride and water secretion, 
increased cilia beat frequency, and increased mucin release. At micromolar 
concentrations in an animal model this compound produced greater peak increases in 
tracheal mucus velocity (TMV) with a single administration significantly enhancing 
mucus transport for at least 8 hours. This type of P2Y2 agonist attempts to enhance 
mucociliary clearance components by activating alternative chloride channels not 
dependent on CFTR to provide effective treatment for CF lung disease (Yerxa et al., 
2002). Phase 1 and Phase 2 clinical trials for this compound have been completed where 
doses up to 60 mg of denufosol inhalation solution were well-tolerated in most subjects 
with CF (Deterding et al., 2005). 
 
UTP and ATP induced chloride secretory response was abolished in the jejunal 
epithelium of P2Y4-null mice. An oral P2Y4 receptor agonist has been suggested to 
stimulate the jejunal secretion of electrolytes and water as a therapeutic strategy to treat 
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gastrointestinal abnormalities associated with CF including meconium ileus and chronic 
malabsorption in newborns (Robaye et al., 2003). Treatment with topical application of 
P2Y2 receptor agonist has been shown to acutely stimulate MCC and enhance sputum 
expectoration in mild chronic bronchitics (Bennett et al., 2001; Donnelly and Rogers, 
2003). The involvement of P2Y receptor in cystic fibrosis and chronic obstructive lung 
disease make them the ideal targets to devise novel therapies not only to improve the 
health status but also to modify the natural course of the disease. 
 
1.8.2 P2Y receptors and cancer 
 
The growth inhibition and programmed cell death (apoptosis) observed in various 
tumour models induced by ATP was thought to be mediated by ionotropic P2- receptors 
alone. Evidence for this was shown by the requirement of extracellular ATP for efficient 
interleukin 2-activated peripheral blood lymphoid cells (LAK) cell-mediated killing of 
tumour cells through the activation of P2X receptors (Correale et al., 1997). However, 
growing evidence suggests that by altering intracellular calcium concentrations, 
metabotropic P2Y-receptors may be involved in both growth inhibition and apoptosis. 
Earlier reports show that ATP and hydrolysis-resistant ATP analogues induced greater 
than 90% inhibition of the growth of human androgen-independent prostate carcinoma 
cell lines (Fang et al., 1992). However, later studies involving prostate carcinoma cells 
showed variability in the activity of nucleotides in the mediation of the P2Y2 receptor in 
inducing inhibition of cell growth and apoptosis. Janssens and Boeynaems (2001), 
reported that ATP caused the inhibition of cell growth and caused cell death either by 
apoptosis or by necrosis; whereas UTP failed to produce any effect on growth 
eventhough it was equipotent to ATP in accumulation of Ins(1, 4, 5)P3. Furthermore, the 
Ins(1, 4, 5)P3 accumulation in response to nucleotides involved the P2Y2 receptor but 
the growth inhibitory effect was shown to be unrelated to Ins(1, 4, 5)P3 or cyclic AMP 
(cAMP) accumulation suggesting the possible involvement of P2X receptors in 
inhibition of cell growth and cell death (Janssens and Boeynaems, 2001). 
 
In studies employing a rabbit lens cell line, agonists that mobilise calcium also 
modulated lens cell growth, and the inactivation of the same calcium stores by agents 
such as thapsigargin and caffeine, inhibited growth (Duncan et al., 1996). In another 
study, P2Y2 receptor agonists induced a time-dependent increase in apoptosis and dose-
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dependent inhibition of cell proliferation in two colorectal carcinoma cell lines (Hopfner 
et al., 2001). Reports have suggested that ATP is released from malignant cells in 
response to chemo or radiotherapy. Extracellular ATP is known to inhibit growth of 
Ehrlich ascites tumour cells, colon cancer, ovarian cancer, endometrial cancer, breast 
cancer and fibroblast cell lines (Estrela et al., 1995; Correale et al., 1997; Hopfner et al., 
1998; Katzur et al., 1999; Li et al., 2000; Schultze-Mosgau et al., 2000). ATP is thought 
to inhibit proliferation and induce anti-apoptotic effects by emptying the calcium pool 
in human breast tumor cell lines, which in turn causes cell growth inhibition and 
induction of apoptosis (Vandewalle et al., 1994). It has also been shown that the ovarian 
epithelial cell lines which express functional P2Y2 receptors inhibit cell proliferation 
when activated by extracellular ATP (Schultze-Mosgau et al., 2000). 
 
In endometrial carcinoma cell lines, activation of P2Y2 receptors by a slowly degradable 
ATP analogue, ATPγS, was associated with a significant suppression of cell 
proliferation without affecting cellular apoptosis (Katzur et al., 1999). The 
antiproliferative and apoptotic effects of P2Y2 receptor stimulation by nucleotides have 
also been reported in the human colorectal cancer cell line (Hopfner et al., 1998). 
However, the combined antiproliferative effects of P2Y2 receptors and the apoptosis 
inducing effects of nucleotides through P2Y receptors has been shown in relatively few 
cell lines (Vandewalle et al., 1994; Hopfner et al., 2001; Maaser et al., 2002). The 
stimulation of P2Y2 receptors by ATP in oesophageal cancer cells leads to cell cycle 
arrest and apoptosis (Vandewalle et al., 1994; Hopfner et al., 2001; Maaser et al., 
2002). These cells responded to both purine and pyrimidine nucleotides and the increase 
of [Ca2+]i was shown to be PLC-dependent, indicating that the induction of [Ca2+]i was 
mediated by Gq/11-coupled and PLC-linked metabotropic P2Y2 receptors (Maaser et al., 
2002). The ionotropic P2X receptor subtypes P2X1, and P2Z/P2X7  implicated in 
apoptosis induced by extracellular ATP were, however, not found to be functionally 
expressed in both primary oesophageal  cancer cells and oesophageal cancer cell lines 
(Chvatchko et al., 1996; Ferrari et al., 1999; Maaser et al., 2002).  
 
ATP has also been studied as an anti-cachexia and antiproliferative agent in advanced 
lung cancer. ATP was shown to inhibit loss of skeletal muscle mass, muscle strength 
and a temporary dose-dependent increase in whole-body glucose turnover during high 
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doses of ATP infusion in patients with advanced lung cancer (Agteresch et al., 1999; 
Agteresch et al., 2000a; Agteresch et al., 2000b). However, glucose turnover is 
inhibited with long term exposure to ATP (Agteresch et al., 2000b). It is proposed that 
the cytotoxic cell lysis effect of CTL (Cytotoxic T lymphocytes) and LAK 
(Lymphokine-activated killer cells) in immune defence against tumour cells and virus 
infected cells could be mediated by ATP and that LAK and CTL cells themselves act as 
a putative source of ATP (Di Virgilio et al., 1990). Surprisingly these cells themselves 
were resistant to the lytic effects of ATP (Di Virgilio et al., 1989; Zanovello et al., 
1990). This was attributed to the possibility of the absence of purinergic receptors and 
presence of ectonucleotidases in these cells (Correale et al., 1995). 
 
In contrast to these inhibitory effects, ATP has also been implicated in proliferation of a 
breast cancer cell line through elevation of intracellular calcium [Ca2+]i (Dixon et al., 
1997). At micromolar concentrations ATP promoted a biphasic rise in [Ca2+]i and 
stimulated growth of the human ovarian cancer cell line (Popper and Batra, 1993). A 
similar pattern of biphasic increase in [Ca2+]i  was also observed following stimulation 
with micromolar concentrations of ATP in another human ovarian cancer cell line. Here 
the pattern was a rapid rise to a peak level followed by a smaller but more sustained 
phase. ATP induced a stimulatory effect on cell proliferation at micromolar 
concentration and at higher concentration (100μM-1mM) significantly decreased 
cellular proliferation (Batra and Fadeel, 1994).  
 
Cell proliferation of many other tissues stimulated by nucleotides through the activation 
of P2Y receptors-mainly P2Y2- has been reported. Recent studies have reported that 
agonist-induced binding of Src to two Src homology 3 (SH3) binding sites (PXXP 
motifs) in carboxyl-terminal tail of the human P2Y2 nucleotide receptors transactivate 
epidermal growth factor receptor (EGFR), and platelet-derived growth factor receptor in 
1321N1 astrocytoma cells (Liu et al., 2004b). Agonist induced P2Y2 receptor activation 
through the mediation of PKC, rise of intracellular Ca2+ and tyrosine kinase pathway 
has been associated with cell proliferation. Here, P2Y2 receptor agonist increased 
mitogen-activated protein kinase (MAPK) activation through the activation of 
Ras/Raf/MEK/MAPK pathway in the proliferation of C(6) glioma cells (Tu et al., 
2000). P2Y1 receptors were found in keratinocytes of human foetal epidermis positive 
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for PCNA (proliferating cell nuclear antigen) and Ki-67, suggesting a role in 
proliferation (Greig et al., 2003). 
 
ATPγS (ATP gamma S) and UTP treatment of MCF-7 cells activated transcription of 
the immediate early gene c-fos leading to elevated intracellular calcium levels and 
increased proliferation (See Figure 1.3) (Wagstaff et al., 2000). Furthermore, ATP S 
and epidermal growth factor (EGF) together synergistically activated c-fos involving the 
ERK cascade with notably increased levels of ERK, CREB and EGF receptor 
phosphorylation, as well as hyperphosphorylation of ternary complex factor (Wagstaff 
et al., 2000). The studies also reported that the activation of P2Y2 receptor by 
extracellular ATP and UTP brings about PI3K (phosphoinositide 3-kinases) and 
downstream PKC- epsilon and ERK1/2 activation to induce transcription of c-Fos 
protein and cell proliferation in HeLa cells (Muscella et al., 2003).  
 
However, this is not an exclusive signaling transduction pathway associated with P2Y 
receptor regulated proliferation. Proliferative activity of extracellular nucleotides 
(ATP/UTP/UDP) on human lung epithelial cell line, A549, has been attributed to the 
activation of the P2Y2 and P2Y6 receptors (Schafer et al., 2003). Moreover, the P2Y2 
receptor mediated proliferative activity downstream of phospholipase C has been shown 
to be dependent on Ca2+/calmodulin-dependent protein kinase II (CaMKII) and nuclear 
factor-kappaB (NF- B). Furthermore, inflammatory cytokines IL-1β (interleukin-1beta) 
and IL-6 (interleukin-6) attenuated UTP but not ATP stimulated cell proliferation 
(Schafer et al., 2003). The P2Y6 agonist induced cell proliferation in HeLa cells 
activated multiple signalling pathways where conventional and atypical PKCs were 
responsible for the induction of c-Fos and ERK was responsible for cell proliferation 
which was dependent on both novel and atypical PKCs and PI3K activities (Muscella et 
al., 2004). 
 
In addition to acting like proliferative agents, P2Y receptor agonists have promoted 
tumour aggression by cell invasion. P2Y receptors and their down-stream ERK1/2 and 
p38 protein kinases have been shown to enhance prostate cancer cell invasion in two 
human prostate carcinoma cell lines (Chen et al., 2004). Furthermore, extracellular 
nucleotides have been reported to exert differential effects on anticancer drugs. A study 
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reported that ATP antagonized the antiproliferative effect of paclitaxel and etoposide, 
the cytostatic drugs which inhibit cell cycle progression and are used in 
chemotherapeutic regimens in lung cancer treatment. Whereas ATP enhanced the 
activity of cisplatin, also a cytostatic drug, thus suggesting the differential control of 
proliferation of lung epithelial tumor cells by extracellular nucleotides (Schafer et al., 
2003). Extracellular nucleotides acting on P2Y receptors play a complex role in 
regulating cell growth, they aid growth inhibition and apoptosis and conversely they act 
as proliferative agents to promote tumour progression. A comprehensive understanding 
of distinct signaling pathways employed by the P2Y receptors in promoting apoptosis 
and cell proliferation in different tissue types would make them ideal targets for 
therapeutic intervention.   
 
1.8.3 P2Y receptors and the vascular system 
 
Vascular endothelial cells have been shown to release ATP, an endogenous P2Y 
receptor agonist not only in response to numerous stimuli, such as shear stress and 
vasoactive agonists but also in response purine nucleotide analogues (Yang et al., 
1994). The P2Y receptor mediated actions of ATP on the endothelium in coronary 
vessels of guinea pigs resulted in the Nucleotide Axis Hypothesis (Buxton et al., 2001).  
According to this hypothesis, ATP stimulates the release of vasoactive mediators from 
endothelium, including ATP which in turn propagates the actions of ATP in blood 
vessels (Buxton et al., 2001). P2Y receptors in endothelial cells are the mediators to act 
on contraction and relaxation of the glomeruli (Jankowski et al., 2001a). The receptor 
ligand, in the form of extracellular ATP was stated to be involved in the activation of 
P2Y-receptors in regulating the volume of renal glomeruli and influencing glomerular 
filtration rate of rats. ATP-dependent glomerular relaxation in the initial phase and 
glomerular contraction caused by either ATP itself or adenosine formed from ATP 
hydrolysis in the maintenance phase was the likely mechanisms of this action 
(Jankowski et al., 2001b).  P2Y1, P2Y2, P2Y4, P2Y6 and P2Y11 receptors have been 
shown to be expressed in human umbilical vein endothelial cells (Jin et al., 1998b; 
Wang et al., 2002).  
 
Stimulation of endothelial P2Y2 receptors in rat-isolated mesenteric artery by P2Y2 
agonist ATPgammaS (ATPγS) showed potentiation of relaxation and hyperpolarization 
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(Mistry et al., 2003). The relaxation of mesenteries by ATP and analogues was 
mediated by endothelial P2Y1 and P2Y2 receptors coupled to the NO/cGMP (nitric 
oxide and guanosine 3',5' cyclic monophosphate) pathway (Buvinic et al., 2002). Only 
the presence of ATP and UTP facilitated a prolonged and stable flow-induced 
vasodilatation in rat small mesenteric arteries suggesting the physiological importance 
of nucleotides released by endothelial cells during intraluminal flow in blood vessels 
(Liu et al., 2004a) . The activation of endothelial P2 receptors in the cerebral circulation 
are known to dilate the vessel through releasing NO, prostanoid, and/or EDHF in the 
vasculature with the variation of these relaxing factors  depending on species, size, and 
location of vessels (Ralevic and Burnstock, 1998). The vasodilation induced by P2Y1 
agonist was nitric oxide (NO) dependent and that produced by P2Y2 agonist was 
endothelium-derived hyperpolarizing factor (EDHF) and NO-dependent in rat middle 
cerebral arteries (Marrelli, 2001; Wang et al., 2002). However, in rat intracerebral 
arterioles the P2Y1 receptor activation caused the dilation via both NO and potassium 
channels (probably EDHF), whereas the P2Y2 receptor activation dilated the cerebral 
arteriole via potassium channel activation independently of NO (Horiuchi et al., 2003). 
 
In humans, the P2Y1 receptor selective agonist 2-MeSADP reported to induce potent 
dilation of left internal mammary artery (LIMA) obtained from patients undergoing 
coronary artery bypass surgery. The vasodilatation was higher than that observed for the 
P2Y2 and P2Y4 agonist UTPγS and selective P2Y6 agonist UDPγS and mediated through  
release of EDHF, NO and prostaglandins (Wihlborg et al., 2003). The pathological 
condition of ischemia-reperfusion (I/R) – worsening of a hypoxic injury after 
reperfusion of ischemic tissues- attenuated the dilation induced by P2Y1-selective 
agonist 2MeS-ATP in the rat middle cerebral arteries (MCAs). However, the dilations 
to the P2Y2-selective agonist UTP were potentiated due to the upregulation of the 
EDHF mechanism which relaxes the vessel by hyperpolarizing the vascular smooth 
muscle (Marrelli et al., 1999). In guinea-pig thoracic aorta (endothelial cells) UTP 
stimulated a robust P2Y4 mediated vasodilation (Kaiser and Buxton, 2002).  
 
P2Y receptor stimulation on smooth muscle cells has been shown to cause 
vasoconstriction. ADP acting on P2Y12 receptors has been reported not only important 
for platelet activation but also found to stimulate vasoconstriction in internal mammary 
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artery. Drugs with P2Y12 receptor antagonistic effects affecting both platelets and 
vascular smooth muscle cells could be beneficial for prevention of both thrombosis and 
vasospasm (Wihlborg et al., 2004). The stable nucleotide uridine adenosine 
tetraphosphate (Up(4)A) obtained from mechanically stimulated human endothelial 
cells was reported to be the cause of vasoconstriction mediated through P2 receptors in 
an isolated perfused rat kidney (Jankowski et al., 2005). P2Y receptor mediated 
vasocontriction have also been reported from smooth muscle cells of rat pial (cerebral) 
arterioles suggesting that nucleotides circulating in the blood stream probably act 
through vasoconstrictor P2X and P2Y receptors in case of endothelial dysfunction 
(Lewis et al., 2000). In rat cerebral microvessels, UTP stimulation of two different 
classes of P2Y receptors resulted in competition between endothelial and smooth 
muscle receptor stimulation. UTP-induced constriction was mediated via P2Y4 receptors 
in the smooth muscle and dilation mediated possibly by endothelial P2Y2 receptor 
(Horiuchi et al., 2001). P2Y6 mediated vasoconstriction has been observed in 
endothelium-denuded human cerebral arteries in response to UDPβS (Malmsjo et al., 
2003b). The potent contractile effects mediated by P2Y6 receptors have also been 
reported in rat basilar artery smooth muscle cells in response to stable nucleotide 
analogue, uridine 5'-O-thiodiphosphate (UDPβS) (Malmsjo et al., 2003a). 
 
Rho kinase signaling reported to play an important role in eliciting vasoconstriction in 
rat cerebral arteries induced by pyrimidine nucleotides (Luykenaar et al., 2004).  
The vasoconstriction of rat afferent arterioles mediated by activation of P2Y receptor 
was showed to be largely through L-type calcium channel-independent mechanisms 
(Inscho and Cook, 2002). Later studies in vascular smooth muscle cells of rat aorta 
revealed that the responses generated by UTP and to ATP were predominantly mediated 
by P2Y2 receptor (Kumari et al., 2003). In endothelium-denuded human coronary 
arteries, extracellular nucleotides elicited contraction was primarily by activation of 
P2Y2 receptors (Malmsjo et al., 2000). The strong vasoconstriction elicited by the 
selective P2Y6 receptor agonist, UDPβS (uridine 5'-O-thiodiphosphate) in saphenous 
vein (smooth muscle cells) suggested a therapeutic role for P2Y6 antagonists in 
preventing vasospasm and restenosis during and after revascularization surgery (Borna 
et al., 2003). Extracellular nucleotides acting on the P2Y receptors on the smooth 
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muscle cells also induced vasoconstriction in canine and rat coronary vessels 
(Matsumoto et al., 1997; Welsh and Brayden, 2001).  
 
Besides vasoconstriction, the stimulation of P2Y receptors in smooth muscle cells 
regulates development of inflammatory vascular disease and cell proliferation. 
P2Y2 and P2Y6 agonists have shown a concentration-dependent chemotactic (cell 
migration) effect on cultured rat aortic smooth muscle cells (SMCs) via the action of 
osteopontin involving Rho and mitogen-activated protein (MAP) kinase pathways 
(Chaulet et al., 2001; Pillois et al., 2002). ATP-stimulated coronary artery smooth 
muscle cells (CASMC) proliferation shown to be dependent on independent activation 
of both the ERK and PI3K signaling pathways (Wilden et al., 1998). P2Y2 receptor 
agonists were involved in monocyte recruitment by expression of vascular cell adhesion 
molecule-1 (VCAM-1) in human coronary artery endothelial (HCAEC) cells (Seye et 
al., 2003). In rabbit carotid arteries P2Y2 receptors promoted the development of intimal 
hyperplasia associated with atherosclerosis and restenosis (Seye et al., 2002). P2Y2 
receptor was found to be up-regulated in porcine Helloof stented coronary arteries to 
mediate the mitogenic effects of nucleotides (Shen et al., 2004). 
  
These studies suggest the importance of P2Y receptors as a therapeutic target by 
designing drugs to modulate their function to attenuate disease process. To that end, 
P2Y6 receptor has been suggested as a suitable target for the treatment of cerebral 
vasospasm (Malmsjo et al., 2003b). Similarly, targeting P2Y2 receptor with specific 
antagonists has been suggested in the treatment of coronary vasospastic disorders such 
as angina pectoris (Malmsjo et al., 2000). 
 
P2Y1, P2Y2, P2Y6, and P2Y11 receptor mRNA transcripts have been detected in human 
myocardium in both atria and ventricles (Hou et al., 1999). P2Y2 receptors, in particular, 
have been found to be up-regulated in CHF (congestive heart failure) heart (Hou et al., 
1999). P2Y2 and P2Y11 receptors are expressed in Human coronary artery endothelial 
(HCAEC) cells (Moore et al., 2001). In blood, P2Y1, P2Y2, P2Y6 and P2Y11 were 
reported to be expressed by monocytes, B lymphocytes (Di Virgilio et al., 2001). 
Platelets co-express P2Y1, P2Y12 and P2X1  receptors (Hollopeter et al., 2001). P2Y1 and 
P2Y12 receptors are differentially involved in generation of thrombin which in turn 
activates platelets (Leon et al., 2003). Ticlodipine and Clopidogrel which irreversibly 
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inhibit platelet P2Y12 receptor function have been used for the prevention of secondary 
events in acute cardiovascular disease (Quinn and Fitzgerald, 1999; Bhatt and Topol, 
2003). Thus expression of P2Y receptors in heart, blood and blood vessels are involved 
in regulation of physiological process, therefore, may influence the disease process.  
 
1.8.4 P2Y receptors and diabetes 
 
ATP and its analogues have been shown to increase glucose-induced insulin secretion 
through activation of P2Y receptors present on isolated pancreatic ß-cells of rats 
(Bertrand et al., 1987). ADPβS was reported to be a potent insulin inducing agent in 
vivo in rats and dogs dependent upon the nutritional status of the animals and the plasma 
level of glucose. In addition, both ADPβS and ATPαS have been shown to amplify 
glucose-induced insulin secretion by activating beta-cell adenylyl cyclase and the 
subsequent cAMP/protein kinase A signaling pathway in rat pancreatic islets and in the 
INS-1 secreting cell line (Chevassus et al., 2002). Furthermore, ADPβS improved 
glucose tolerance and was effective on oral administration signifying the therapeutic 
importance of the P2Y receptor expressed in the beta cells as a target for antidiabetic 
drugs (Hillaire-Buys et al., 1993). Similarly, glucose dependent insulin release 
stimulated by ADPβS is also reported in human pancreatic islets (Fernandez-Alvarez et 
al., 2001). 
 
In the absence of extracellular Ca2+, ATP was reported to stimulate insulin as an 
intracellular Ca2+ mobilisation agent involving inositol 1,4,5-trisphosphate (IP3) 
(Arkhammar et al., 1990). Extracellular ATP was also shown to raise the cytoplasmic 
free Ca2+ concentration in human pancreatic islets and isolated human insulin-secreting 
cells (Kindmark et al., 1991). Recent studies in rat isolated pancreas has ruled out the 
direct inhibitory effect on ATP-activated K+ (KATP) channels in the P2Y receptor 
activated insulin secretion caused by beta-cell metabolism and a rise in intracellular 
calcium (Farret et al., 2004).  
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Defective P2Y (P2Y2 or P2Y4) receptor function causing reduced uptake of glucose by 
GLUT1 (Glucose transporter) has been proposed in type II diabetics. A high level of 
extracellular ATP is thought to cause desensitisation of P2Y receptors and subsequent 
blocking of GLUT1 in this condition leading to hyperglycaemia (Solini et al., 2003). 
The loss of responsiveness of platelets in patients with type 2 diabetes mellitus (DM2) 
to insulin and increased signaling through P2Y12 has been credited to the hyperactivity 
of platelets observed in patients with DM2 (Ferreira et al., 2006).  
 
1.8.5 P2Y receptors and hepatocytes 
 
In rat hepatocytes, increases in cytosolic free calcium concentration [Ca2+]c in response 
to extracellular nucleotides acting through the phosphoinositide signaling pathway were 
reported to mediate by  P2Y1  and P2Y2 receptors (Dixon, 2000; Dixon et al., 2000). 
Later studies in hepatocytes revealed that stimulation with ADP caused an increase in 
inositol (poly) phosphates following its conversion to ATP suggesting the expression of 
P2Y2 receptor. However, the activation of P2Y1 did not appear to be coupled to inositol 
1,4,5-trisphosphate production (Dixon et al., 2003). 
 
The stimulation of glycogen phosphorylase in freshly isolated rat hepatocytes by 2-
MeSADP has been attributed to the action of  P2Y1 receptors coupled to raised [Ca2+]c, 
and by inhibiting cyclic AMP levels by an unknown Gi-coupled receptor subtype, other 
than P2Y1, P2Y12, or P2Y13 receptors (Dixon et al., 2004). Recent studies, however, 
have reported an absence of responses mediated by P2Y1 receptors in rat hepatocytes. 
Furthermore, in human hepatocytes P2Y receptors control both glycogen metabolism 
and proliferation-associated responses such as increased [Ca2+]c and mitogen-activated 
protein kinase cascades through P2Y2 receptors (Dixon et al., 2005). These studies 
predict an important role for P2Y receptors in regulating hepatocytes and their functions 
including the release of glucose from glycogen stores into the blood stream controlled 
by glycogen phosphorylase enzyme.  
 
1.8.6 P2Y receptors and dry eye syndrome 
 
The identification of functional P2Y2 nucleotide receptors that govern mucin secretion 
in rabbit and human conjunctival cells suggested these receptors might be useful 
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pharmacological targets for therapeutic modulation of tear film mucins in dry-eye 
disorders and/or corneal wound healing (Jumblatt and Jumblatt, 1998). The involvement 
of nucleotides in stimulating Cl- (chloride) secretion by activating P2Y2 and/or the P2Y4 
receptor has been documented in the pigmented rabbit conjunctiva (Hosoya et al., 1999; 
Li et al., 2000). 
 
As a potential therapeutic agent in the treatment of dry eye, the P2Y2 agonist INS365 
was found to increase tear fluid secretion, corneal epithelial resistance, and release of 
glycoprotein-containing moieties from goblet cells as a mark of improved surface health 
in a rat dry eye model (Fujihara et al., 2001). INS365 ophthalmic solution was well-
tolerated when administered as eye drops in normal human subjects (Mundasad et al., 
2001). Diquafosol (INS365), which is a stable derivative of UTP, was found to 
stimulate chloride (Cl-) secretion and increase tear production through stimulation of 
P2Y2 receptors in the rabbit conjunctiva (Murakami et al., 2004). INS365 was well 
tolerated and found to reduce corneal staining and relieve certain patient symptoms in a 
double-blind, placebo-controlled safety and efficacy trial (Tauber et al., 2004). This 
ophthalmic formulation has been undergoing an additional confirmatory clinical phase 
III as a 1% and 2% solution and expected to be approved soon (Nichols et al., 2004). 
Therefore, synthesis of better nucleotide analogues which can manipulate P2Y receptor 
signaling in the eye could help in understanding the ocular physiology and in 
developing better therapeutic strategy in dry eye related disorders.  
 
1.8.7 P2Y receptors and host defence 
 
Studies have shown that stimulation with ATP and UTP enhanced anti-IgE-induced 
histamine release in human lung mast cells (HLMC) implicating the involvement of 
P2Y2 receptors in human allergic and asthmatic reactions (Schulman et al., 1999). The 
expresison of the cysteinyl leukotriene (CysLT1) receptor in human cord-blood-derived 
mast cells (hMCs) with dual ligand specificity to inflammation-derived cys-LTs and 
P2Y receptor ligand UDP is considered to provide link between the inflammatory and 
neurogenic elements of bronchial asthma (Mellor et al., 2001). Acting on the P2Y2 
receptor extracellular nucleotides induce stimulation and activation of neutrophil and act 
as chemoattractants inducing chemotaxis (Verghese et al., 1996). Activation of P2Y2 
subsequently generates leukotrienes like the potent proinflammatory chemokine, 
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LTB(4) which intensifies inflammatory response. In turn the leukotrienes act in both 
autocrine and paracrine manner to amplify the process of chemotaxis in PMN 
(polymorphonuclear neutrophils) by upregulation of Mac-1 expression (Kannan, 2003). 
Furthermore, in the presence of exogenous soluble fibrinogen both ATP and UTP cause 
primary granule release (degranulation) from human neutrophils through the P2Y2 
receptor and through activation of p38 MAPK and ERK1/2 pathway (Kannan, 2004; 
Meshki et al., 2004).  
 
ATP acting on P2Y2 receptor has been reported to promote transcription of IL-6 in 
macrophages (Hanley et al., 2004). Studies have shown that co-ordinated action of P2Y 
and P2X receptors can modulate macrophage production of TNF-alpha, IL-1β and nitric 
oxide (NO) following lipopolysaccharide (LPS) exposure on macrophages (Guerra et 
al., 2003). Studies in mouse J774 macrophages have proposed a regulatory role for UTP 
at inflammatory sites. These studies showed that UTP acting at the P2Y6 receptor, the 
major P2Y receptors in J774 macrophages, potentiates lipopolysaccharide (LPS)-
induced cyclo-oxygenase -2 (COX-2) protein expression and subsequently enhances 
prostaglandin E2 (PGE2) release. Cyclo-oxygenase (COX) is the rate-limiting enzyme in 
the biosynthesis of eicosanoids, which along with arachidonic acid (AA) are the early 
events in macrophage activation by inflammatory stimuli (Chen and Lin, 2000). Earlier 
studies in mouse J774 macrophages found UTP to potentiate the effect of 
lipopolysaccharide (LPS) on inducible nitric oxide synthase (iNOS) induction and nitric 
oxide (NO) production (Chen et al., 1998). UTP also caused iNOS induction 
independent of arachidonic acid metabolites via activation of Ca2+/ calmodulin-
dependent protein kinase and NF-κB (Chen and Lin, 2000). 
 
The activation of P2Y6 receptor by UDP has been shown to stimulate interleukin (IL)-8 
release in human THP-1 monocytic cells (Warny et al., 2001). Further studies suggested 
that human eosinophils stimulated with extracellular nucleotides trigger secretion of 
eosinophil cationic protein (ECP) by possibly stimulating a P2Y2 receptor and that the 
secretion of IL-8 can be due to activation of P2X1 and P2X7 in addition to P2Y6 
receptors (Idzko et al., 2003). Thus, P2Y receptors could play an important role in 
inflammation and innate immune defences and also in the modulation of eosinophil 
functions. 
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 Dendritic cells (DCs) are heterogenous antigen-presenting cells (APCs) that are 
specialized to activate naïve T lymphocytes and play a central role in the initiation and 
regulation of immune responses (Banchereau and Steinman, 1998). UDP has shown to 
regulate dendritic cell functions by stimulating Ca2+ transients, actin polymerization, 
and chemotaxis in immature dendritic cell (DCs). UDP also stimulated the release of the 
CXC-chemokine 8 (CXCL8) from mature DCs (Idzko et al., 2004). UTP acting on P2Y 
nucleotide receptor expressed in CD11c+ murine dendritic cells stimulated an increase 
in intracellular calcium and induced cytokine production (Marriott et al., 1999). In 
immature human dendritic cells ATP was reported to induce chemotactic activity 
mediated by Gi/o-protein-coupled P2Y receptors. However, functional studies in mature 
DCs revealed the down-regulation of Gi/o-coupled P2Y receptor mediated chemotactic 
responsiveness, possibly to facilitate them to migrate to secondary lymphoid organs to 
establish contact with T lymphocytes and to initiate immune responses (Idzko et al., 
2002).  
 
P2Y2 receptor activation on human peripheral blood neutrophils has been shown to 
induce a typical chemotactic response suggesting that P2Y receptor agonists could play 
a regulatory role in inflammation (Verghese et al., 1996; Kannan, 2003). ATP acting on 
the P2Y11 receptor has been shown to mediate the activation, maturation and 
modulation of the functions of human monocyte-derived dendritic cells (Wilkin et al., 
2001; Marteau et al., 2004). P2Y11 receptor agonist synergised with other dendritic cell 
stimuli to modulate cytokine production to favour type 2 helper T cell (Th2) response, 
which play a triggering role in the activation and/or recruitment of IgE antibody-
producing B cells, mast cells and eosinophils, the cell types involved in the allergic 
inflammation (Romagnani, 1997; Maggi, 1998; Wilkin et al., 2002). In mediating 
chemotactic mechanism of dendritic cells, different P2Y receptor subtypes have been 
implicated for a diverse role. At low concentration gradient, the nucleotides stimulate 
the migration of dendritic cells mediated by P2Y2 receptors. However, high 
concentration gradient of nucleotides formed at sites of inflammation inhibit the 
migration of local dendritic cells is mediated by P2Y11 receptor (Schnurr et al., 2003). 
 
Human immature dendritic cells (DCs) have shown to express the UDP-Glucose 
receptor P2Y14. UDP-glucose and other glycolytic metabolites found at high levels in 
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tumour cells and supernatants from necrotic cancer cells have been shown to induce 
maturation characteristics in immature DCs to suggest that increased levels of UDP-
glucose released from necrotic tumor cells might reach a danger threshold and might 
initiate an immune response through P2Y14 receptor mediation together with other 
signaling via the induction of DC maturation (Sauter et al., 2000; Skelton et al., 2003). 
Thus UDP-glucose could be acting as a tumour specific danger signal. 
  
P2Y2 receptor mediated inhibition of inducible NO synthase (iNOS) in rat mesangial 
cells lead the authors to postulate that extracellular nucleotides may regulate the 
generation of nitric oxide (NO) during the glomerular inflammatory response by 
limiting activation of iNOS to prevent excessive tissue damage (Mohaupt et al., 1998). 
Nucleotides induced cell proliferation and functional expression of P2Y2 receptor in 
human keratinocytes suggested a major role for these receptors in epidermal 
homeostasis and as a target for therapy of proliferative disorders of the epidermis such 
as psoriasis (Dixon et al., 1999). Thus, P2Y receptors in immune cells exert their 
influence in host defence mechanism, inflammatory process and in modulating immune 
response. 
 
1.8.8 P2Y receptor and bone 
 
P2Y1, P2Y2, P2Y4, P2Y6 receptor mRNA transcripts have been detected in human bone 
and osteoblastic cell lines (Maier et al., 1997). Functional P2Y receptors, in particular 
P2Y2, have been shown to be expressed in human osteoclastoma, osteoblasts and 
chondrocytes (Hoebertz et al., 2000). Nucleotides acting via P2Y receptors have been 
shown to be potent potentiators of parathyroid hormone-induced signaling and 
transcriptional activation in osteoblasts (Bowler et al., 2001). 
 
Extracellular nucleotides acting on different P2Y receptors have shown to increase bone 
resorption and inhibit bone formation. The powerful stimulatory action of ADP on 
osteoclast (bone-resorbing cells) formation suggested that the activity is mediated by 
P2Y1 receptor, whereas UTP, through the activation of P2Y2 receptor blocks bone 
formation by osteoblasts. Furthermore, ATP has been reported to simultaneously 
stimulate resorption and inhibit bone formation. These studies suggest a role for P2Y 
receptors in bone metabolism and provide novel drug targets for pathological conditions 
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associated with bone loss such as osteoporosis, characterized by low bone mass and 
disruption of bone architecture caused by increased bone resorption over bone 
formation (Hoebertz et al., 2002; Hoebertz et al., 2003). 
 
Nucleotides acting on P2Y2 purinoceptors are found to be responsible for oscillatory 
fluid flow-induced [Ca2+]i mobilization in osteoblastic cells (You et al., 2002).The 
nucleotide stimulation of P2Y6 receptors in osteoclasts, which also express P2Y1, P2Y2 
receptor initiated NF-kappaB signaling, thereby enhancing the survival of osteoclasts 
and enhancing bone resorption. P2Y6 receptor antagonists, therefore, may be useful in 
inflammatory bone diseases such as rheumatoid arthritis and periodontitis, where 
activation of P2Y6 receptors might enhance bone destruction (Korcok et al., 2005). 
 
1.8.9 P2Y receptors and neuroinflammation 
 
P2Y receptor expression coupled to an increase in intracellular calcium has been 
reported in neurons and glia of superior cervical ganglion (SCG) implicating the P2Y 
receptors in the nervous system (Calvert et al., 2004). Neuroprotective properties have 
been attributed to P2Y2 receptors expressed in astrocytes, where activation of P2Y2 
receptors induced anti-apoptotic genes, bcl-2 and bcl-xl expression in to trigger 
survival-signaling cascades in human astrocytic cells (Chorna et al., 2004). P2Y2 
receptors also mediate the up-regulation of the expression of genes for neurotrophins, 
neuropeptides and growth factors and extracellular matrix proteins through the 
activation of the CREB/bcl-2 pathway. In addition, the conditioned media from UTP 
treated 1321N1 cells promoted neurite outgrowth in PC-12 cells. Thus, P2Y2 receptors 
may regulate important physiological or neuroprotective mechanisms in astrocyte 
signaling and nerve tissue regeneration under pathological conditions in the human 
brain (Chorna et al., 2004). 
 
Extracellular ATP through the mediation of P2 receptors has been reported to cause cell 
death of fully differentiated and mature neurons, dissociated primary cells, and 
organotypic cultures possibly comprising both apoptotic and necrotic features of 
degeneration (Volonte et al., 2003). ATP analogues also resulted in an increase of 
inducible cyclooxygenase-2 (COX-2), a pathological feature common in a variety of 
neurodegenerative diseases characterized by inflammation and astrocytic activation 
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(Brambilla and Abbracchio, 2001). Studies in rat astrocytes implicated activation of a 
calcium-independent G-protein-coupled P2Y receptor linked to ERK1/2 and COX-2 
pathway behind reactive gliosis (Brambilla et al., 2002).  
 
The ADPβS-induced proliferation has been inhibited by P2Y1 receptor antibody 
suggesting a regulatory role for P2Y receptors in pathophysiological processes in glial 
cells (Franke et al., 2004). P2Y12 receptor mediation has been implicated in the 
autoinhibition of transmitter release from neuronal cells through an inhibition of 
voltage-gated Ca2+ channels (Lechner et al., 2004). Therefore, selective P2Y receptor 
subtype antagonists that are able to permeate the blood-brain barrier could be very 
useful agents in preventing neurodegenerative processes (Franke and Illes, 2006). A 
possible involvement of P2Y receptors in generating or modulating pain perception is 
also being investigated in animal models (Kennedy et al., 2003). 
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1.9 Cell types used in this study   
    
1.9.1 1321N1 
 
The lack of response of the wild type 1321N1 cells to extracellular nucleotides have 
made them useful a host cell line for purinergic receptor expression (Filtz et al., 1994; 
Schachter et al., 1996). They are reported to express a P1 receptor which mediates a 
relatively weak response by intracellular second messengers (Hughes and Harden, 
1986). 1321N1 human astrocytoma cells have been extensively used for the 
recombinant expression of P2Y receptor subtypes and were used in cloning and 
subsequent stable expression to study the receptor pharmacology of P2Y2, P2Y4 and 
P2Y6 receptors and other subtypes belonging to this receptor class (Parr et al., 1994; 
Communi et al., 1995; Communi et al., 1996b). These cells have also been used to 
generate stable transfectants expressing the mutant P2Y2 receptors in site-directed 
mutagenesis and also to express receptor chimera’s (Erb et al., 1995; Sak and Illes, 
2005).  
 
1.9.2 Human bladder cancer cell line, ECV304  
 
ECV304 is a commercially available bladder cancer epithelial cell line that has been 
purchased from ECACC. Early studies indicated that ECV304 cells express P2Y1, P2Y2 
and a third receptor responding to AMP with increases in [Ca2+]c (Conant et al., 1998). 
ECV304 has been shown to express a P2Y2 - like receptor and therefore proves useful 
for the study of P2Y receptor pharmacology (Brown et al., 2000). Further studies on 
this cell line have shown that P2Y2 receptors through activation of PLC (phospholipase 
C) and mobilisation of intracellular calcium stimulates production of nitric oxide. 
Further studies have shown evidence for the presence of second P2Y receptor coupled 
to adenylate cyclase (AC) stimulation (Brown, 2001). Therefore, ECV304 cells appear 
to be a very useful research tool for studying P2Y receptors that activate two distinct 
signaling pathways.  
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1.9.3 EAhy926 
 
EAhy926 is an established permanent human cell line expresses factor VIII-related 
antigen, a highly differentiated function of vascular endothelium. This cell line was 
derived by fusing human umbilical vein endothelial cells with the permanent human cell 
line A549 (Edgell et al., 1983). Studies in EAhy926 cells have reported the nucleotides 
stimulated activation of MAP kinase in a protein kinase C-dependent manner through 
interaction with a P2Y2 receptor (Graham et al., 1996a). P2Y2 mediated desensitization 
of the MAP kinase signal in EAhy926 cells appear to involve multiple regulatory 
mechanisms involving the induction and regulation of other proteins (Graham et al., 
1996b). This finding was further supported by the fact that UTP stimulated inhibitory 
effect on tumor necrosis factor α (TNFα) - stimulated stress activated protein kinases in 
EAhy926 cells involved Ca2+ independent PKC isoforms and mediation of P2Y2 
receptor (Paul et al., 2000). The expression of P2Y receptors makes this useful research 
tool for the study of P2Y receptor pharmacology in endothelial cells. 
 
1.9.4 Bovine aortic endothelial cells (BAEC)  
 
Since these cells were first cultured in 1975 (Booyse et al., 1975) they have been 
extensively studied. The rank order of agonist potency of 2-methylthio-ATP 
(2MeSATP) > adenosine 5'-O-(3-thiotriphosphate) (ATPγS) > ADP > ATP > β,γ-imido-
ATP > β,γ-methylene-ATP (β,γ -meATP) in accumulating total inositol phosphates was 
reported to be consistent with action at receptors of the P2Y subtype (Allsup and 
Boarder, 1990). On further studies it was suggested that the effect of P2Y receptor 
agonists 2MeSATP and UTP on the accumulation of inositol phosphates were additive, 
whereas the effects of ATP and either UTP or 2MeSATP were not. This together with 
competitive antagonism of suramin for the response to ADPβS and 2MeSATP but not 
the response to UTP indicated the co-existence of two separate receptors expressed. 
P2Y-purinoceptors (responding to purines) and nucleotide receptors (responding to both 
purines and pyrimidines) on bovine aortic endothelial cells (Motte et al., 1993). It was 
thought that purines such as ATP/ADP may regulate aortic endothelial cells by 
interacting with two phospholipase C (PLC)-linked receptors (Wilkinson et al., 1993). 
This activation of PLC caused by these two co-existing receptors was through different 
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routes as it was shown that pattern of Ins (1,4,5)P3 accumulation was dependent on the 
type of receptor stimulated and stimulation was differentially regulated by protein 
kinase C (PKC) (Purkiss et al., 1994). Further, in BAE cells the agonistic activity of 
P2Y1 but not P2Y2 receptor was antagonised by Pyridoxalphosphate-6-azophenyl-2', 4'-
disulphonic acid (PPADS) (Brown et al., 1995). Further studies showed that both P2Y1 
and P2Y2 purinoceptors stimulate endothelial NOS in a manner that is dependent on 
PKC activity (Brown et al., 1996). Investigation of increases in intracellular calcium 
[Ca2+]i in a single BAE cell in primary culture in response to ATP, ADP, AMP, 
adenosine, UTP, 2-MeSATP, 2-methylthio ADP (2-MeSADP) and α,β-methylene ATP 
(α,β-meATP)  further supported that different intracellular signalling pathways could be 
involved in increasing [Ca2+]i (Duchene and Takeda, 1997). Recent studies have 
reported the accumulation of inositol phosphates by 2MeSATP, 2MeSADP and UTP 
suggesting the native expression of P2Y1 and P2Y2 receptors (Brown and Brown, 2002) 
which makes these cells a useful research tool for studying P2Y receptors. 
 
1.9.5 BRIN-BD11 
 
BRIN-BD11 cell line represents an important stable glucose-responsive insulin-
secreting beta-cell line, established after electrofusion of RINm5F cells with New 
England Deaconess Hospital rat pancreatic islet cells (McClenaghan et al., 1996).  
Although there are no reports of P2Y receptor studies involving BRIN-BD11 cells, 
these receptors have been studied in insulin secreting B cells of rat. In isolated perfused 
rat pancreas, ADPβS has been found to be a potent secretory agent (Hillaire-Buys et al., 
1994). P2Y receptors have been reported to potentiate glucose-induced insulin secretion 
in rat pancreatic B cells (Petit et al., 1998). ADPβS have been shown to augment 
glucose-induced insulin secretion by activating beta-cell adenylyl cyclase and the 
subsequent cAMP/protein kinase A signaling pathway in rat pancreatic islets 
(Chevassus et al., 2002). Extracellular ATP has been shown to induce intracellular 
calcium release by activating P2Y receptors in rat pancreatic beta-cells (Zhao et al., 
2003). Both P2Y1 and P2Y2 receptors have been shown to be present in rat pancreas 
(Coutinho-Silva et al., 2001). Rat pancreatic beta cells have been shown to express 
P2Y4 receptors (Coutinho-Silva et al., 2003).  
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Moreover, ATP has been shown to stimulate insulin release in RINm5F cells by 
phospholipase C (PLC) dependent generation of inositol trisphosphate mediated Ca2+ 
mobilization and PLC- independent mechanisms (Li et al., 1991; Cao et al., 1997). Rat 
P2Y1 receptor has been cloned from RINm5F cells (Tokuyama et al., 1995). 
Furthermore, BRIN-BD11 cells have retained attributes of normal insulin-secreting 
cells including two enzymes responsible for glucose phosphorylating activity and 
PLC/PKC and adenylate cyclase/protein kinase A, the regulatory elements of late stages 
of insulin secretiory pathway (McClenaghan and Flatt, 1999). However, whether the 
genetic modification caused by electrofusion has retained the characteristics of 
functional P2Y receptors as observed in rat pancreas and RINm5F cells cannot be 
acertained without pharmacological evidence. Nevertheless, given the asssociation of 
P2Y receptors in insulin release, BRIN-BD11 cells will be useful to study P2Y 
receptors. 
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 1.10 The basis for this research project  
 
Previous work in our lab had lead to the design and synthesis and subsequent evaluation 
of peptides specifically mimicking the extracellular regions of the human P2Y2 receptor. 
These peptides were designed with predominantly hydrophilic residues to enable them 
to enter the nucleotide binding pocket. These tetradecapeptides were designed to 
represent and span the entire extracellular region of the human P2Y2 receptor. Thus, the 
peptide RH1 was made from residues 14-27 of ECI (extracellular region 1), L245 from 
ECII (94-107), L246 from ECIII (174-187), RH2 from ECIII (180-193), L247 from 
ECIV (271-284) and a scrambled version of L247 was synthesised as a control.  
 
Peptides were analysed in second messenger assays where they exhibited “agonist-like” 
properties. Moreover, peptide L247, mimicking the third extra cellular loop of the 
human P2Y2 receptor was shown to be a weak agonist of IP3 production in ECV304 
cells and stimulate stimulate nitric oxide synthase activity in BAE cells. In addition, 
when added simultaneously with ATP, it has shown synergistic effects on inositol 
phosphate production and intracellular calcium release in ECV304 cells (this synergistic 
effect was specific to P2Y agonists with no such effects being observed upon the 
simultaneous addition of L247 and histamine). L247 was equipotent to 100μM ATP in 
activating phospolipase D in porcine aortic endothelial cells. These results suggested 
that L247 acts as allosteric modulator of the P2Y2 receptor (Brown, 2001).  
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1.11 Aims of this project 
 
The above results suggest that the L247 peptide, mimicking the third extracellular loop 
of human P2Y2 receptor, has an effect on modulation of receptor activity when used in 
conjunction with endogenous ligands. This is significant in light of the lack of subtype-
specific agonists and antagonists available and the problems associated with using 
radioligands in studying P2Y receptor pharmacology. The aims of this project are to use 
L247 peptide as an immunogen to generate polyclonal rabbit antibodies to the P2Y2 
receptor. Furthermore, to evaluate EAhy926 and further evaluate ECV304 cells for the 
functional expression of P2Y subtypes with assays for second messengers in addition to 
already characterized BAE cells as research tools. The aim is also to generate a RT-PCR 
screen for P2Y receptor subtype expression by human cells and to use this to confirm 
the proposed P2Y receptor expression derived from pharmacology studies. Finally, to 
purify and fully characterise the polyclonal antibody raised to the L247 peptide.    
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 Materials 
 
i) Equipment 
 
BioLogic HR Chromatography System  Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK 
 
BioVision Imaging Technology  BioGene Ltd., Kimbolton, UK 
 
Block heater       Wolf Laboratories York 
 
Centrifuges  M.S.E Mistral 2000, Fisons 
Instrumentation, U.K. 
Mikro 20, Hettich Zentrifugen, 
D78532 Tutlingen. 
MIkro 22R, Hettich Zentrifugen, 
D78532 Tutlingen.  
Spectrofuge 16M, National Labnet 
Co. Edison, NJ. USA 
International Equipment Company 
Needham Heights, MA, USA 
 
Class II cabinet  Clean Air Techniek b.v., The 
Netherlands 
 
CO2 incubator  Jensons Scientific Inc. Bridgeville, 
PA 15017, USA 
DNA Analyzer      Applied Biosystems, USA 
 
Genequant      Pharmacia Biotech Inc 
       NJ, USA 
 
Hybaid  PCR Express thermocycler Hybaid, Action Court, Middlesex, 
UK 
 53
ImageQuant™ TL 
image analysis software 
GE Healthcare Life Sciences 
Amersham, Bucks, UK 
 
Inverted microscope  Celti, Optical Instruments, Belgium 
 
Labsystems Multiskan MS  Labsystems, Finland 
 
Magnetic Stirrer Hotplate  Stuart Scientific, Beacon Road, 
Staffordshire, UK 
 
Bio-Rad Laboratories Ltd., Hemel  
Hempstead, UK 
 
Electrophoresis system  
Mini-PROTEAN 3 cell  
Mini Trans-Blot cell  Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK 
 
Monomixer   Sarstedt, Nümbrecht, Germany 
 
PhosphorImager™ technology            GE Healthcare Life Sciences 
Amersham, Bucks, UK 
 
Platform Shaker STR6  Stuart Scientific, Beacon Road, 
Staffordshire, UK 
 
PowerPac 1000  Power Supply  Bio-Rad Laboratories Ltd., Hemel 
Hempstead, UK 
 
LC 494 Protein Sequencing System    Applied Biosystems, USA 
 
Rocker       Wolf Laboratories, York, UK 
 
Scintillation counter      Packard, Berkshire, U.K 
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Vortex  Sigma-Aldrich Company Ltd., 
Dorset, UK 
 
Water baths  Grant Instruments (Cambridge) 
Ltd., Cambridge UK 
 
Well washer 4 MK 2      Labsystems, Finland 
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ii) Chemicals 
 
Acetone  BDH Laboratories Supplies, 
Poole, England 
Ammonium formate  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Ammonium sulfate  Sigma-Aldrich Company 
Ltd., Dorset, UK 
AMV reverse transcriptase  Promega UK, Southampton, 
UK 
AMV RT buffer  Promega UK, Southampton, 
UK 
BSA (Bovine Serum Albumin)  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Calcium chloride  BDH Laboratories Supplies, 
Poole, England 
Collagenase (Sigma Type IA)  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Complete, Mini Protease Inhibitor Cocktail Tablets  Roche Diagnostics GmbH, 
Mannheim, Germany 
DAPI  Vector Laboratories, Ltd., 
Peterborough, England 
DC Protein Assay Kit  Bio-Rad Laboratories Ltd., 
Hemel Hempstead, UK 
Decon  BDH Laboratories Supplies, 
Poole, England 
Dietheyl Ether  BDH Laboratories Supplies, 
Poole, England 
DMSO  Sigma-Aldrich Company 
Ltd., Dorset, UK 
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dNTP mix  Promega UK, Southampton, 
UK 
Dowex 1X8-400  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Dulbecco's Modified Eagle's Medium high glucose  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Earles Balanced Salts solution  Sigma-Aldrich Company 
Ltd., Dorset, UK 
ECL Plus™ Western Blotting Detection Reagent   GE Healthcare UK Ltd 
Amersham, Bucks, UK 
Ethanol  BDH Laboratories Supplies, 
Poole, England 
Ethidium bromide  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Ethylene glycol  BDH Laboratories Supplies, 
Poole, England 
Fetal calf serum  PAA Laboratories Ltd, 
Yeovil, Somerset, UK 
GenEluteTM PCR Clean-Up Kit  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Gentamicin  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Glucose  BDH Laboratories Supplies, 
Poole, England 
Hydrochloric Acid  BDH Laboratories Supplies, 
Poole, England  
HEPES  Sigma-Aldrich Company 
Ltd., Dorset, UK 
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‘Hi-Pure’ Low EEO agarose gels   BioGene Ltd., Kimbolton, 
UK 
Hyper Ladder IV – 100bp ladder  Bioline Ltd. Humber Road, 
London 
Lithium chloride  Fluka, Neu-Ulm, 
Switzerland 
L-glutamine  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Magnesium sulphate BDH Laboratories Supplies, 
Poole, England 
Medium 199 with Earle's Salts with L-Glutamine  PAA Laboratories Ltd, 
Somerset, UK 
Methanol  BDH Laboratories Supplies, 
Poole, England 
Minimal essential medium with D-Valine  PAA Laboratories Ltd, 
Somerset, UK 
N-Glycosidase F Deglycosylation Kit  Roche Diagnostics GmbH, 
Mannheim, Germany 
Nuclease-Free Water  Promega UK, Southampton, 
UK 
Oligo(dT)15 Primer Promega UK, Southampton, 
UK 
Penicillin–Streptomycin solution Hybri-Max®  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Potassium chloride BDH Laboratories Supplies, 
Poole, England 
Pre-Aliquoted Reddy MixTM PCR Master-Mix  Abgene Limited, Epsom, 
UK 
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PROSEP-Thiosorb  Millipore (U.K.) Limited, 
Watford, UK 
Protein standard  Sigma-Aldrich Company 
Ltd., Dorset, UK 
ProteoExtract™ Native Membrane Protein Extraction Kit  Merck Chemicals Limited, 
Nottingham, UK 
RNaseZap® RNase Decontamination Solution  Applied Biosystems, 
Warrington, UK 
RNasin Ribonuclease Inhibitor  Promega UK, Southampton, 
UK 
RPMI 1640 without L-Glutamine, with Phenol Red  PAA Laboratories Ltd, 
Yeovil, Somerset, UK 
RQ1-Rnasin Free DNase  Promega UK, Southampton, 
UK 
SeeBlue® Plus2 Pre-Stained Standard  Invitrogen Ltd., Paisley, UK 
Sodium bicarbonate  BDH Laboratories Supplies, 
Poole, England 
Sodium Chloride  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Sodium phosphate monobasic dihydrate BDH Laboratories Supplies, 
Poole, England 
Swine Anti-Rabbit-peroxidase conjugate  Dako UK Ltd. 
Cambridgeshire, UK 
TEMED  Sigma-Aldrich Company 
Ltd., Dorset, UK 
TMB  Sigma-Aldrich Company 
Ltd., Dorset, UK 
TRI reagent  Sigma-Aldrich Company 
Ltd., Dorset, UK 
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Tris-Borate-EDTA buffer  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Trichloroacetic acid (TCA)  BDH Laboratories Supplies, 
Poole, England 
Tris/Glycine/SDS running buffer      Geneflow Ltd., Fradley  
Staffordshire, UK  
Tris/Glycine transfer buffer      Geneflow Ltd., Fradley  
Staffordshire, UK  
Trizma® hydrochloride solution  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Trypsin/EDTA  Sigma-Aldrich Company 
Ltd., Dorset, UK 
Tween – 20  Pharmacia Biotech, 
Uppsala, Sweden 
Ultima Flo AF scintillation fluid  PerkinElmer, Inc. Waltham, 
Massachusetts, USA 
Urea  Sigma-Aldrich Company 
Ltd., Dorset, UK 
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iii) P2 receptor agonists 
 
The following P2 receptor agonists were supplied by Sigma-Aldrich Company Ltd.: 
ADP, ADPβS, 2MeSADP, ATP, 2MeSATP, ATPγS, BzATP, UDP, and UTP 
 
iv) Radioisotopes 
 
The radiochemical [3H]-myo-inositol was supplied by Amersham Pharmacia Biotech 
UK Ltd. 
 
v) Primary cultures and cell lines 
 
Human cell lines, ECV304 and 1321N1, were supplied by European Collection of 
Animal and Cell Cultures (ECACC). EAhy926 human cell line was a gift from 
Professor Helen Griffiths, Professor of Biomedical Sciences, School of Life and Health 
Sciences, Aston University, UK.  Bovine aortic endothelial (BAE) cells were isolated 
preparations from bovine aortae. BRIN-BD11 cell line was a gift to Diabetes Research 
Group from Professor Peter Flatt, University of Ulster, Coleraine. 
 
vi) Culture reagents 
 
Medium 199 with Earle's salts with L-glutamine, Minimal essential medium with D-
Valine  and RPMI 1640 (without L-glutamine, with phenol red) and Fetal calf serum 
were supplied from PAA Laboratories Ltd, Yeovil, UK. The following culture reagents 
were supplied by Sigma-Aldrich Company Ltd., Dorset, UK.: 
Dulbecco's modified eagle's medium high glucose, Earles balanced salts solution, 
Amphotericin B, Gentamicin, L-glutamine and Penicillin–Streptomycin solution Hybri-
Max®.  
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vii) Antibodies 
 
L247 rabbit polyclonal anti-P2Y2 antibody is an in-house antibody. Anti-purinergic 
receptor P2Y12 and P2Y1 antibodies were supplied by Sigma-Aldrich Company Ltd., 
Dorset, UK. Anti-P2Y11 rabbit polyclonal antibody was supplied by Affinity 
BioReagents, Inc. USA. Anti-P2Y13/GPR86/GPR94 antibody was supplied by Acris 
Antibodies GmbH, Hiddenhausen, Germany. Rabbit anti-P2Y2 receptor antibody was 
supplied by Zymed Laboratories Inc. USA. The following anti-purinergic receptor anti-
P2Y2, anti-P2Y4 and anti-P2Y6 rabbit polyclonal antibodies were supplied by Santa 
Cruz Biotechnology, Inc. USA. Polyclonal Swine anti-rabbit-peroxidase conjugate and 
polyclonal Swine anti-rabbit Immunoglobulins/FITC antibody were supplied by Dako 
UK Ltd. Cambridgeshire, UK. 
 
2.2 Cell culture 
 
2.2.1 Isolation of bovine aortic endothelial cells 
 
Bovine aortae, obtained from a local abattoir were transported to the laboratory on ice in 
sterile balanced salt solution (BSS) containing 100U/ml pencillin, 100μg/ml 
streptomycin, 100μg/ml gentamicin and 2.5μg/ml amphoteracin B. Isolation of 
endothelial cells was carried out not more than one hour after collection of the aortae, as 
originally described (Booyse et al, 1975), in sterile conditions in a class II cabinet. The 
aortae were washed in sterile BSS. Collateral arteries were closed off using cotton, prior 
to addition of 0.2% (w/v) collagenase (Sigma Type IA) solution at 370C. The aortae 
were incubated with collagenase for 20 minutes at room temperature to digest the 
endothelial cells away from the arteries. Collagenase was removed from the aortae and 
they were washed in sterile BSS. The detaching endothelial cells were collected in 
minimal essential medium with D-valine, containing 10% (v/v) fetal calf serum (PAA), 
2mM L-glutamine (Sigma), 100μg/ml streptomycin, 100U/ml pencillin, 2.5μg/ml 
amphoteracin B and 100μg/ml gentamicin into 25cm2 flask (Sarstedt). 
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Table 2.1 The Composition of balanced salts solution pH 7.4 
 
 
 
NaCl      125mM 
 
KCl     5.4mM 
 
NaHCO3     16.2mM 
 
HEPES     15mM 
  
NaH2PO4 2H2O    1mM 
 
MgSO4 7H2O    0.8mM 
 
CaCl2 6H2O     1.8mM 
 
Glucose     5.5mM 
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2.2.2 Tissue culture of 1321N1, ECV304, EAhy926, Bovine aortic endothelial 
(BAE) and BRIN-BD11 cells  
 
ECV304 cells (ECACC) were maintained in M199 medium with L-glutamine (Sigma) 
supplemented with 10% foetal calf serum (FCS), 100U/ml pencillin and 100µg/ml 
streptomycin. Bovine aortic endothelial (BAE) cells were maintained in Minimal 
essential medium with D-Valine (PAA) supplemented with 10% foetal calf serum 
(FCS), 100U/ml pencillin and 100µg/ml streptomycin and 2 mM L-Glutamine (Sigma). 
Human brain astrocytoma cells (1321N1) were maintained in Dulbecco's Modified 
Eagle's Medium high glucose (Sigma) supplemented with 2mM Glutamine (Sigma) and 
10% Foetal Bovine Serum (PAA). BRIN-BD11 cells, produced by electrofusion of 
normal rat pancreatic ß-cells and RINm5F cells were cultured in RPMI medium (PAA) 
supplemented with 10% FCS (PAA), 100 units/ml penicillin and 100 µg/ml 
streptomycin. 
 
The cells were subcultured using a standard trypsin/EDTA (Sigma) method once the 
cells were grown into a confluent monolayer either in 2x75 cm2 or 2x175 cm2 tissue 
culture flasks (Sarstedt). Briefly, the growth medium was removed from the cells and 
the cells were washed (3X5ml) with Ca++ and Mg++ free Earles Balanced Salts solution 
(Sigma) to remove all traces of serum. Trypsin /EDTA solution was dispensed into 
culture vessels to completely cover the monolayer and the cells were incubated at 370C 
for 5 minutes to ensure that the cells were detached from the base of the flask. 10 ml of 
medium was added to the flask and the total volume of cell suspension was made up to 
the volume required for next passage in new culture vessels. The cells were incubated in 
a humidified atmosphere of 5% CO2/95% air at 37°C until they were confluent. 
 
2.3 Measurement of second messengers in cells 
 
2.3.1 Measurement of total inositol (poly) phosphates  
 
Cells grown to confluence in 24 well plates were labelled for 24 hours with 0.5μCi 
(17.0 Ci/mmol) (Amersham) per well in 0.5ml serum free medium. The 24 well plates 
containing cells were transfered to a 370C water bath and lithium chloride was added at 
a final concentration of 10mM for 10 minutes. Following incubation with lithium 
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chloride the cells were stimulated for 15 minutes with agonists or incubated with 
antagonists for 15 minutes and then stimulated with with agonists for 15 minutes. The 
stimulation was terminated by removal of stimulation medium and immediate addition 
of 0.5M ice-cold trichloroacetic acid (TCA). The cells were then incubated on ice for 
one hour and extracts transferred to polypropylene tubes and washed with (3X 4 
volumes) water-saturated diethyl ether and then neutralised to pH 7 with 0.6M NaHCO3. 
After the washings, the negatively charged samples were added to positively charged 
1ml Dowex 1X8-400 (Sigma) columns and allowed to drain before adding 10 ml of 
distilled water to remove unincorporated [3H] inositol. After allowing the water to run 
through completely the columns were transfered into serially numbered scintillation 
vials. The fractions containing [3H] IP1-IP4 were recovered by extraction using 5ml of 
2M ammonium formate. 5 ml of Ultima Flo AF scintillation fluid (i.e. at ratio 1:1) was 
added to the vial containing the collected fraction and mixed for 10 seconds before 
counting on a scintillation counter. 
 
2.3.2 Measurement of cAMP production 
 
Cells were grown to confluence in 24 well plates in a CO2 incubator and then 
transferred to a 370C water bath washed twice with warm medium and incubated for 15 
minutes at 370C in BSS. Agonists were added for a further period of 20 minutes, then 
reactions were terminated by washing cells twice in 1 ml of 70% (v/v) ice cold ethanol. 
Cytoplasmic contents were extracted by scraping cells with a pipette tip in 0.5ml/well 
ice cold 70% (v/v) ethanol. Samples were stored on ice for 60 minutes and supernatants 
separated from cell debris by centrifugation. Pelleted material was extracted further and 
the combined supernatants dried under vacuum. Cytoplasmic extracts were dissolved in 
buffer (50mM Tris, 4mM EDTA, pH 7.5) and cAMP measured using an Amersham 
Biotrak assay kit according to the manufacturer’s instructions.  
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2.4 RT-PCR studies 
 
2.4.1 Primer design 
 
The primer sequences for human P2Y1-11 receptors were taken from previously 
published work (Adrian et al., 2000). Primers for human P2Y12, P2Y13 and P2Y14 
receptors were designed and analysed using a program called PrimerSelect (DNASTAR 
Lasergene software). The primers were selected from a list of suggested primers 
evaluated on the thermodynamic properties for annealing reactions.  
 
2.4.2 RT-PCR studies for P2Y (P2Y1-14) receptor mRNA transcripts  
 
Total RNA was isolated from cultured cells by adding the appropriate amount of TRI 
reagent, RNasin Ribonuclease Inhibitor and RQ1-Rnasin Free DNase. The quantity of 
RNA was determined photometrically at 260nm using Genequant. 1μg total RNA was 
reverse transcribed to cDNA in a 50µl reaction volume containing nuclease free water, 
AMV RT buffer, Oligodt primer, dNTP mix and AMV reverse transcriptase (all reagents 
from Promega). Nuclease free water was used as negative control. The PCR reactions 
were performed in 50μl final volume containing Pre-Aliquoted Reddy MixTM PCR 
Master-Mix, 3 μl cDNA from RT stage/ nuclease free water as negative control, 7.5 
pmol of primers GAPDH, P2Y1, P2Y2, P2Y4, P2Y6 (10 pmol in the case of P2Y11). 
After initial denaturation for 2 min at 940C, amplifications were carried out for 35 
cycles as follows: denaturation at 940C for 45 seconds, annealing at primer specific 
temperature for 45 seconds, and extension at 720C for 90 seconds. After the final PCR 
cycle the final extension was at 720C for 15 minutes. Ethidium bromide stained ‘Hi-
Pure’ Low EEO agarose gels (Bio/Gene) of PCR products were analysed against DNA 
Markers (Hyper Ladder IV – Bioline, 100bp ladder) and by scanning with a BIO 
VISIONTM UV imager. 
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2.4.3 PCR product purification 
 
The PCR amplification products were purified using GenEluteTM PCR Clean-Up Kit 
(Sigma). GenElute Miniprep Binding Column (with a blue o-ring) was inserted into the 
collection tube provided. 0.5 ml of the Column Preparation Solution (which maximizes 
binding of the DNA to the membrane resulting in more consistent yields) was added to 
each miniprep column which was centrifuged at 12,000 x g for 1 minute and the eluate 
was discarded. 5 volumes of Binding Solution were added to 1 volume of the PCR 
reaction and mix. The solution was transferred into the binding column and the column 
centrifuged at 16,000 x g for 1 minute. The eluate was discarded and the collection tube 
was retained. The binding column was replaced into the collection tube. 0.5 ml of 
diluted Wash Solution was applied to the column and it was centrifuged at maximum 
speed (16,000 x g) for 1 minute. The eluate was discarded retaining the collection tube. 
The column was replaced into the collection tube and the column was centrifuged at 
maximum speed (16,000 x g) for 2 minutes, without any additional wash solution, to 
remove excess ethanol. The collection tube was retained and any residual eluate was 
discarded. The column was transferred to a fresh 2 ml collection tube. 50 μl of Elution 
Solution was applied to the centre of each column and they were incubated at room 
temperature for 1 minute. The column was centrifuged at maximum speed (16,000 x g) 
for 1 minute to elute the DNA. The PCR amplification product present in the eluate was 
stored at –20°C. 
 
2.4.4 DNA sequencing 
 
Depending on the template type (i.e. the size of PCR product) 5-20 ng of the purified 
PCR product per reaction with a minimum of 30µl of template (enough for two 
reactions) and 3.2 picomoles (a minimum of 10µl) of Primer per reaction were prepared 
in dilution in Nuclease-Free Water (Promega). DNA sequencing was performed by the 
Sequencing Service (School of Life Sciences, University of Dundee, Scotland, 
www.dnaseq.co.uk) using Applied Biosystems Big-Dye Ver 3.1 chemistry on an 
Applied Biosystems model 3730 automated capillary DNA sequencer.  
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2.5 Purification of antibody 
 
2.5.1 L247 polyclonal antibody production 
 
The polyclonal antisera was produced  in rabbit by Severn Biotech Ltd. using L247 
peptide (RSLDLSCHTLNAIN) designed to mimic the specific region of the third 
extracellular loop of human P2Y2 receptor. 2.5ml of test bleed, 10ml of production 
bleed and 50ml of terminal bleed were obtained as the final volumes of anti sera. 
 
 2.5.2 Purification of L247 polyclonal antibodies  
 
The polyclonal antisera was purified by affinity chromatography using a BioLogic HR 
Chromatography System (Bio-Rad) and PROSEP-Thiosorb (Millipore) affinity 
adsorbent columns. Sufficient reagent was added to the starting material (serum or cell 
culture supernatant) so that it contained 20 mM HEPES, 7.5% (NH4)2 SO4 and 0.5M 
NaCl. The pH of the solutions was adjusted to 7.5 using 5M NaOH and the solution was 
filtered through a 0.45 or a 0.2 μm filter. After loading the sample on to the column the 
bound antibody fractions were eluted using three elution conditions including elution 
buffer 1 (20mM HEPES, 1M NaCl, pH 7.5), elution buffer 2 (20mM HEPES, 2M NaCl, 
pH 7.5) and elution buffer 3 (60% Ethylene glycol).  
 
2.5.3 Dialysis 
 
The purified fractions were then dialysed for 24 hours against multiple buffer 
(Phosphate Buffered Saline, pH 7.5) changes using SnakeSkin™ Dialysis Tubing 
(Pierce) before storing them in aliquots at -200C. 
 
2.5.4 Protein quantification 
 
Antibody concentrations in the purified fractions of terminal bleed of L247 polyclonal 
antisera were quantified using a Bicinchoninic Acid (BCA) Protein Assay Kit (BCA1-
Sigma). The concentration of the unknown sample (L247 Ab fraction I and II) was 
determined by comparing its absorbance at 562 nm to the standard curve prepared using 
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BSA (Bovine Serum Albumin) protein standards. This standard assay was performed in 
a test tube. The required amount of BCA Working Reagent needed for the assays was 
prepared by mixing 50 parts of Reagent A with 1 part of Reagent B. The BCA Working 
Reagent was mixed until it was light green in colour. BSA protein standards of different 
concentrations ranging from 200-1,000 μg/ml (20-100 μg of total protein) were 
prepared by making serial dilutions starting from the 1 mg/ml standard, and then using 
0.1 ml of each diluted standard in the assay. Dilutions were carried out in the same 
buffer as the unknown sample. For protein samples with unknown concentrations, a 
dilution scheme was prepared to ensure the concentration fall within the linear range of 
200-1,000 μg/ml.  2 ml of the BCA Working Reagent was added to 0.1 ml of each BSA 
protein standard, blank, and unknown sample (Antibody fractions). The contents of the 
test tube were thoroughly mixed and incubated at 370C for 30 minutes. The absorbance 
of the solution was recorded at 562 nm immediately after incubation. The assay table 
and a standard curve based on either the BSA protein standard concentration or on the 
amount of protein present in the BSA protein standard was created (Figure 2.1). The 
protein concentrations were determined by comparison of the absorbance of the 
unknown samples to the standard curve prepared using the BSA protein standards.  
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        Figure 2.1 Bovine Serum Albumin (BSA) protein standard curve 
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2.5.5 Indirect ELISA 
 
Each well of a 96-well plate was coated with 50μl of L247 peptide 
(RSLDLSCHTLNAIN) diluted in distilled water at the required concentration and 
incubated overnight at 370C (24 hrs) without a lid to enable water to evaporate which 
enabled maximum peptide binding per well. The wells were washed in phosphate 
buffered saline (Well washer 4 MK 2- Labsystems). Remaining sites in the well were 
blocked with 2% BSA in PBS 50μl per well and incubated for 1 hour at 370C.  After 
washing three times with 0.1% Tween – 20 in PBS, primary antibody in diluant (0.05% 
Tween- 20/ 1% BSA in PBS) was added at required dilution (50μl per well) and 
incubated for 1 hour at 370C. After washing three times with 0.1% Tween- 20 in PBS, 
secondary antibody was added to all wells at the required dilution (0.1% Tween – 20 / 
2% BSA in PBS) and incubated for 1 hour at 370C (in dark if light sensitive). After 
washing 3 times with 0.1% Tween- 20 in PBS 50μl of 3, 3’, 5, 5’ – Tetramethyl 
Benzidine (TMB) Liquid Substrate system for ELISA was used at the required 
incubation/development period. The reaction was stopped using 2N HCl. The 
absorbancy was read using a Labsystems Multiscan MS plate reader. 
 
2.6 Western blot studies 
 
2.6.1 Protein extraction 
 
The extraction of membrane proteins from ECV304, EAhy926, BAEC, 1321N1 and BRIN-
BD11cells was carried out using ProteoExtract™ Native Membrane Protein Extraction Kit 
(Calbiochem). The cells were grown to approximately 80 % confluency and the growth 
medium was removed carefully without disturbing the cell monolayer. The cells were washed 
carefully overlaying the cell monolayer with 2 ml ice cold Wash Buffer. The Wash Buffer 
was aspirated completely without disturbing the cell monolayer. The washing step was 
repeated to remove contaminating media components. 10 μl of Protease Inhibitor Cocktail 
was added to the wall of the cell container and immediately 2 ml ice cold Extraction Buffer I 
was added. The components were mixed by swirling the flask without disturbing the 
monolayer and incubated for 10 min at 4°C under gentle agitation. The supernatant (enriched 
in “soluble” proteins) was set aside using a pipette without disturbing the cell layer. 5 μl 
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Protease Inhibitor Cocktail was added to the wall of the cell container and immediately 1 ml 
ice cold Extraction Buffer II was added. The components were mixed by swirling the flask 
without disturbing the monolayer and incubated for 30 min at 4°C under gentle agitation. The 
supernatant (membrane fraction) enriched in integral membrane and membrane associated 
proteins were transfered into a sample tube using a pipette without disturbing the cell debris. 
The insoluble material was centrifuged at 16,000 x g and 4°C for 15 min. The extract was 
quantified using DC Protein Assay Kit (BIO-RAD).  For long-term usage samples were 
stored at or below –20° C in aliquots of convenient size. 
 
2.6.2 Protein quantification 
 
Protein concentrations from extracted membrane protein fractions were quantified using 
a DC Protein Assay Kit (BIO-RAD). The concentration of the unknown sample was 
determined by comparing its absorbance at 690 nm to the standard curve prepared using 
BSA (Bovine Serum Albumin) protein standards. 
 
2.6.3 SDS-PAGE and western blot analysis 
 
The protein extracts from cultured cells were mixed with SDS-sample buffer (125 mM 
Tris-HCl, pH 6.8, 10% glycerol (v/v), 2% SDS (w/v), 5% β-mercaptoethanol (v/v), 
0.01% bromophenol blue (w/v)) and heated at 950C for 5 minutes. The protein samples 
were analyzed in a 10% sodium dodecyl sulfate-polyacrylamide gel in the Mini-
PROTEAN 3 cell Electrophoresis system (Bio-Rad) using Tris/Glycine/SDS running 
buffer (Geneflow). 40µg of total protein was loaded in each well. After electrophoresis 
the proteins were transferred electrophoretically to nitrocellulose membranes using 
Tris/Glycine transfer buffer (Geneflow) in Mini Trans-Blot cell (Bio-Rad) for 1hour. 
Following the transfer the nitrocellulose membrane was blocked for 1 h with 5% nonfat 
dry milk in TBS-0.2% Tween 20 (TBS-T), followed by three washes with TBS-T for 15 
minutes each. The membrane was then incubated with Primary (anti-P2Y receptor 
subtype) antibody in 5% nonfat dry milk in TBS-T overnight at 4°C with gentle 
agitation. The membrane was washed three times for 15 minutes and incubated with 
secondary antibody (Swine Anti-Rabbit-peroxidase (Dako) conjugate) at 1:3000 
dilutions for an hour at room temperature. The membrane was washed three times for 
15 min with TBS-T before adding the ECL Plus™ Western Blotting Detection Reagent 
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(GE Healthcare). The chemifluorescent signal was detected on Storm™  imaging 
system based on PhosphorImager™ technology (GE Healthcare) and analysed using 
ImageQuant™ TL image analysis software (GE Healthcare). 
 
2.6.4 Antibodies 
 
The immunogenic peptide sequences of L247 anti-P2Y2 antibody and all anti-P2Y 
receptor rabbit polyclonal antibodies used in this study were compared with protein 
sequence databases using blastp (protein-protein BLAST) program of the Basic Local 
Alignment Search Tool (BLAST) to find regions of local similarity and to find 
significance of such matches.  
 
Anti- P2Y1 antibody (P6487-Sigma) is developed in rabbit using a highly purified 
peptide (C)RALIYKDLDNSPLRRKS corresponding to amino acid residues 242-258 of 
the rat or human P2Y1 receptor protein, with an additional N-terminal cysteine, 
conjugated to KLH as the immunogen. The antibody is affinity isolated using 
immobilized immunogen. According to the data sheet this antibody recognizes P2Y1 
protein (66 kDa) from human platelets and rat brain membranes by immunoblotting. 
 
The immunogenic peptide used to raise this anti-P2Y1 antibody corresponds to amino 
acid residues 242-258 of the human P2Y1 receptor protein.  Likewise, the immunogenic 
sequence also corresponds to P2Y1 receptor amino acid residues 129-145 of Chinese 
hamster (Cricetulus griseus-gi:20384813), 233-249 of pig (Sus scrofa-gi:58618069), 
242-258 of cattle (Bos taurus-gi:27806041), 242-258 of domestic guinea pig (Cavia 
porcellus-gi:33413446), 242-258 of Norway rat (Rattus norvegicus-gi:25742733),  231-
247 of chicken (Gallus gallus-gi:45384488), 242-258 of dog (Canis familiaris- 
gi:52788591), 242-258 of house mouse (Mus musculus-gi:6679193), 230-246 of 
African clawed frog (Xenopus laevis-gi:16660636). 
 
Anti-P2Y2 polyclonal antibody raised in rabbit using L247 peptide as an immunogen 
and affinity purified from rabbit antiserum. L247 peptide, H-RSLDLSCHTLNAIN has 
been shown to mimic the third extracellular loop of human P2Y2 receptor. The 
immunogenic peptide sequence also corresponds to P2Y2 receptor amino acid residues 
272- 285 of house mouse (Mus musculus-gi:13879282), 271-284 of Norway rat (Rattus 
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norvegicus-gi:38197686) and 144-157 of Chinese hamster (Cricetulus griseus-
gi:20450943).  
 
Anti- P2Y2 (H-70) rabbit polyclonal antibody (sc20124-Santa Cruz Biotechnology) 
raised against amino acids 308-370 mapping at the C-terminus of P2Y2 of human origin. 
This antibody has been shown to recognise P2Y2 expression in AML-193 whole cell 
lysate. The immunogenic sequence mapping the C-terminus of P2Y2 receptor closely 
matches the sequence of P2Y2 receptors of chimpanzee and rhesus monkey. 
 
Anti- P2Y2 polyclonal antibody (34-7600-Zymed) is epitope-affinity-purified from 
rabbit antiserum developed using a synthetic peptide derived from the C-terminal region 
of the human P2Y2 receptor protein. This antibody reacts with the human P2Y2 receptor 
protein and has been reported to exhibit a strong single band ~45-47 kDa in western 
blots. According to notes from the supplier this antibody is not expected to react with 
mouse or rat based on amino acid sequence homology. 
 
Anti-P2Y4 (H-60) rabbit polyclonal antibody (sc20125-Santa Cruz Biotechnology) 
raised against amino acids 306-365 mapping at the C-terminus of P2Y4 of human 
origin. This immunogenic peptide sequence also corresponds to P2Y4 receptor amino 
acid residues 322-381 of chimpanzee (Pan troglodytes-gi:55663355), 96% of amino 
acid residues 306-365 of predicted sequence of P2Y4 receptor of rhesus monkey 
(Macaca mulatta-gi:109131105), 70% of amino acid residues 306-365 of cattle (Bos 
taurus-gi:61868522),  68% of amino acid residues of 302-361 of Norway rat (Rattus 
norvegicus-gi:13928944), 60% of amino acid residues of 302-361 of  house mouse 
(Mus musculus-gi:111600884),  59% of amino acid residues of 109-135 of Mongolian 
gerbil (Meriones unguiculatus-gi:12751143). 
 
Anti-P2Y6 (H-70) rabbit polyclonal antibody (sc20127-Santa Cruz Biotechnology) 
raised against amino acids 1-70 mapping at the N-terminus of P2Y6 of human origin. 
This immunogenic peptide sequence also corresponds to hypothetical protein amino 
acid residues 1-70 of orangutan (Pongo pygmaeus), 1-70 of predicted pyrimidinergic 
P2Y6 receptor of chimpanzee (Pan troglodytes), 97% amino acid residues of 1-70 of 
predicted pyrimidinergic receptor P2Y6 isoform 8 of rhesus monkey (Macaca mulatta), 
97% amino acid residues of 1-70 of predicted sequence similar to P2Y6 purinoceptor of 
 74
dog (Canis familiaris),  81%  amino acid residues of 1-70 of Norway rat (Rattus 
norvegicus-gi:47938969), 81%  amino acid residues of 1-70 of house mouse (Mus 
musculus-gi:39795717), 55%  amino acid residues of 1-70 of zebrafish (Danio rerio-
gi:68366846),  39% of  amino acid residues 1-89 of  cattle G protein-coupled receptor 8 
cattle (Bos taurus-gi:27806597).  
 
Anti-P2Y11 rabbit polyclonal antibody (OPA1-15632 –ABR) was developed using a 
synthetic peptide (KLH conjugated) corresponding to the 3rd extracellular loop and 
detects P2Y11 from human samples.  
 
Anti-Purinergic Receptor P2Y12 antibody (P4871-Sigma) is developed in rabbit using a 
highly purified peptide KTTRPFKTSNPKNLLGAK, corresponding to amino acid 
residues 125-142 of human P2Y12 with an additional N-terminal cysteine as the 
immunogen. The epitope is highly conserved in rat and mouse (16/18 residues 
identical). The antibody was affinity isolated on immobilized immunogen. Anti-
Purinergic Receptor P2Y12 specifically recognizes P2Y12 protein in rat brain membranes 
and human platelets by immunoblotting.  
 
This immunogenic peptide sequence also corresponds to hypothetical protein amino 
acid residues 125-142 of crab-eating macaque (Macaca fascicularis-gi:14388397),  
similar to 125-142 amino acid residues of purinergic receptor P2Y12 isoform 4 of rhesus 
monkey (Macaca mulatta-gi:109048722), 94% amino acid residues 75-92 of pig (Sus 
scrofa-gi:58618077),  88% amino acid residues 122-139 of cattle purinergic G-Protein 
coupled receptor (Bos taurus-gi:46019617), 88% amino acid residues 122-139 of dog 
(Canis familiaris-gi:50979232), 88% amino acid residues 131-148 of unnamed protein 
product of house mouse(Mus musculus-gi:26329111), 88% amino acid residues 131-
148 of P2ry12 protein of house mouse (Mus musculus-gi:20073303),  88% amino acid 
residues 131-148 of Norway rat (Rattus norvegicus-gi:12248187). 
 
Anti-P2Y13/GPR86/GPR94 antibody (SP4616P-Acris Antibodies) which was developed 
in rabbit using a synthetic peptide (KLH conjugated) corresponds to the second 
extracellular domain of the receptor. This antibody is peptide immunogen affinity 
purified immunoglobulin fraction and the immunizing peptide sequence shows 93% 
identity (93% homology) with mouse P2Y13 receptor. 
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2.6.5 Enzymatic N- deglycosylation  
 
5 μl of reduced denaturation buffer was added to each vial containing 5 μl of 
glycoprotein or control glycoprotein. After mixing the contents the protein samples 
were incubated for 3 min at 95°C. After heating the contents were centrifuged down. 10 
μl of Reaction buffer was added to each vial and mixed. 10 μl of reconstituted N-
glycosidase F was added to all vials containing glycoproteins (both test and control) to 
be deglycosylated. 10 μl of Reaction buffer was added to all vials containing 
glycoproteins not to be deglycosylated. All the vials were incubated for 1 hour at 37°C. 
The glycoprotein samples were mixed with an equal amount of SDS-sample buffer and 
heated for 3 min to 95°C. After the heating all the protein samples were analyzed in a 
10% sodium dodecyl sulfate-polyacrylamide gel in the Mini-PROTEAN 3 cell 
Electrophoresis system (Bio-Rad) using Tris/Glycine/SDS running buffer (Geneflow). 
 
2.6.6 Protein sequencing 
 
The deglycosylated protein fractions were analysed in a 10% sodium dodecyl sulfate-
polyacrylamide gel and were transferred electrophoretically to Sequi Blot PVDF 
membranes (Bio-Rad). The Sequi Blot PVDF membrane was divided in two halves and 
one half is used in western blotting analysis using anti P2Y2 primary antibody. On 
detecting the chemifluorescent signal the corresponding region on the non used 
membrane was cut and placed in a vial and sent for protein sequencing. The protein 
sequencing was performed by Alta Biosciences, University of Birmingham using an 
Applied Biosystems 'Procise' 494HT machine by the established technique of Edman 
degradation. 
 
2.6.7 Receptor desensitisation 
 
ECV304 cells were grown to 90% confluency in 75cm2 flasks under conditions 
described in section 2.2.2. The cells were incubated with 300μM UTP or histamine for 1 
hour and 24 hour time periods at 37°C. Control cells were incubated without UTP. Cells 
were removed from the flasks and the protein was extracted and quantified as described 
in section 2.6.1 and 2.6.2 respectively. 
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 2.7 Immunofluorescence analysis 
 
Autoclaved coverslips were placed in 6-well plates and cultured cells were seeded on 
coverslips at approximately 5 x 106 cells per well and allowed to attach overnight. The 
media was removed and the cells were rinsed with PBS (Phosphate buffered saline). 
The slides were fixed (immobilising the antigens by removing lipids to dehydrate the 
cells and precipitate the proteins on the cellular architecture) with 1:1 acetone:methanol 
for 5-6 minutes. The coverslips were washed twice with PBS and blocked by adding 3% 
BSA in PBS-T for 30 minutes. Primary antibody was diluted in 1% BSA PBS-T in 
appropriate dilution range and added to each well containing coverslips and incubated at 
room temperature for 1 hour. The antibody was removed and the coverslips were 
washed four times with 1% BSA PBS-T on rocker. Fluorescein (FITC) conjugated 
secondary antibody was diluted as per instructions in 1% BSA PBS-T and incubated for 
1 hour in the dark and on a shaker. The secondary antibody was removed and the 
coverslips were washed 4 times with 1% BSA PBS-T in the dark on a shaker. The 
excess fluid was removed by blotting and a small drop (25μl) of VECTASHIELD® 
Mounting Medium with DAPI (4',6 diamidino-2-phenylindole)  was placed on each 
slide. The coverslips were then inverted and gently laid on top of vectorshield. The 
edges of the coverslips were sealed using a clear nail varnish and allowed to dry in the 
dark for 10-15 minutes before analysing them using a confocal microsope. 
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CHAPTER 3  
 
 
PHARMACOLOGICAL CHARACTERISATION OF P2Y RECEPTORS 
IN ECV304 AND EAhy926 CELLS 
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3.1 Introduction 
 
Analysis of P2Y receptors has been compromised by the lack of selective agents 
including radioligands. Studies with radiolabelled nucleotides have shown that they 
bind to non P2 receptor proteins and are metabolically unstable (Laubinger and Reiser, 
1998; Chambers et al., 2000b). In addition, until recently, a lack of P2Y subtype 
selective antibodies has complicated the study of the P2Y receptor family. Therefore 
functional studies, e.g.,  measurement of inositol phosphates, measurement of 
intracellular calcium concentration (Erb et al., 1995; Czubayko and Reiser, 1996) and 
determining agonist stimulated cAMP  production in receptors coupled to adenylate 
cyclase (Chambers et al., 2000b) has been the predominant method for studying P2Y 
receptors. Recent binding studies have employed solubilised and purified receptor 
proteins as they are more suitable due to the way they bind to P2- receptor ligands in a 
GTPγS sensitive manner (Bodor et al., 2003; Waldo and Harden, 2004). More recently, 
receptor-specific, high affinity radioligands have been utilised to study P2Y1 and P2Y12 
receptor activity. CHO cells transfected with human P2Y12 receptors displayed a strong 
affinity similar to that observed on platelets to 33P-2MeS-ADP, a stable analogue of 
ADP (Savi et al., 2001). MRS2279, a selective high-affinity non-nucleotide antagonist 
for the P2Y1 receptor radiolabeled with tritium ([3H] MRS2279) has been reported to be 
a reliable radioactive probe able to bind with high selectivity to the P2Y1 receptor 
(Waldo et al., 2002). However, high affinity, subtype specific agents still remains a 
desideratum. 
 
3.1.1 Human bladder cancer epithelial cell line ECV304 
 
Previous studies of ECV304 cells showed an increase in intracellular calcium in 
response to UTP, ATP and 2MeSATP suggesting the presence of at least two P2Y 
receptors (Conant et al., 1998). Recent studies have further evaluated these cells for the 
functional expression of P2Y receptors. The stimulation of ECV304 cells with 
nucleotides suggested that UTP and ATP were equipotent agonists at the P2Y2 
receptors. The desensitisation caused by UTP and ATP for the subsequent action of 
ATP and UTP respectively strongly suggested the expression of P2Y2 receptor (Brown 
et al., 2000). Furthermore, stimulation of cAMP by ADPβS indicated the existence of 
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P2Y11 receptors coupled to adenylate cyclase (AC) (Brown et al., 2000; Brown, 2001). 
The aim of current study was to further evaluate these cells with P2Y11 subtype specific 
nucleotides to confirm the expression of this receptor subtype and use the functional 
expression data in conjunction with the RT-PCR results for mRNA expression to set the 
basis for western blot analysis with P2Y receptor subtype specific antibodies. 
 
3.1.2 Endothelial Eahy926 cells 
 
Previous studies in EAhy926 cells reported that nucleotides stimulate activation of 
MAP kinase in a protein kinase C-dependent manner through interaction with a P2U-
purinoceptor (Graham et al., 1996a; Graham et al., 1996b). This finding was further 
supported by the fact that the inhibitory effect of UTP on tumor necrosis factor α 
(TNFα) - stimulated stress activated protein kinases in EAhy926 cells involved Ca2+ 
independent PKC isoforms and mediation of the P2Y2 receptor (Paul et al., 2000). Thus, 
it is necessary to fully characterize the EAhy926 cells for functional expression of P2Y 
receptor subtypes based on their responses to natural agonists and also to confirm 
previously published P2Y receptor pharmacology in these cells. This will provide a 
basic expression profile of P2Y receptors and a platform to carry out RT-PCR studies to 
determine the mRNA expression and western blot analysis using P2Y receptor subtype 
specific antibodies. 
 
3.1.3 Bovine aortic endothelial (BAE) cells 
 
In addition to the above cells, Bovine aortic endothelial cells have been studied for P2Y 
receptor expression. The rank order of agonist potency of responses to natural agonists 
were consistent with action at receptors of P2Y1 and P2Y2 subtype in bovine aortic 
endothelial cells (Allsup and Boarder, 1990). The additive and desensitizing responses 
for the nucleotides further indicated the expression of P2Y1 and P2Y2 receptors in these 
cells (Pirotton et al., 1996). These receptors were thought to stimulate endothelial nitric 
oxide synthase (NOS) in a manner that is dependent on protein kinase C (PKC) activity 
(Brown et al., 1996). Investigation of increases in intracellular calcium ([Ca2+]i) in 
single BAE cells in  response to agonists further supported the hypothesis that different 
intracellular signaling pathways could be involved in increasing [Ca2+]i (Duchene and 
Takeda, 1997). More recently, studies have reported the accumulation of inositol 
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phosphates by 2MeSATP, 2MeSADP and UTP suggesting the native expression of 
P2Y1 and P2Y2 receptors in these cells (Brown and Brown, 2002). Therefore, because of 
the native expression of P2Y1 and P2Y2 receptors, BAE cells will be used to analyse 
whether human P2Y receptor specific primers could be used to detect the presence of 
mRNA transcripts and to study the cross species reactivity of P2Y2 specific antibodies. 
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3.2 Materials and Methods 
 
3.2.1 Tissue culture 
 
Human ECV304, EAhy926 and bovine aortic endothelial (BAE) cells were cultured as 
described in section 2.2.2 
 
3.2.2 Measurement of total inositol (poly) phosphates 
 
The protocol for the measurement of total inositol (poly) phosphates was described in 
section 2.3.1. Cells were stimulated with agonists for 15 minutes. 
 
3.2.3 Measurement of cAMP production 
 
The protocol for the measurement of cAMP production was described in section 2.3.2 
 
3.2.4 Statistical analysis 
 
Statistical analysis was performed using the GraphPad Prism analysis program (San 
Diego, USA). The equation built-in to Prism is defined in terms of the log(EC50), so 
Prism finds the best-fit value of the log(EC50) along with its SE and 95% CI. Prism 
reports the EC50 and its 95% CI by taking the antilog of the log(EC50) and both ends of 
the 95% CI. Therefore, caution need to be taken when interpreting data as values for 
EC50 will still be calculated for curves that do not plateau. Data are expressed as mean 
values ± SEM. 
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3.3 Results 
 
3.3.1 Measurement of inositol phosphate accumulation in ECV304 cells in response 
to BzATP and ATPγS 
 
The method of measuring inositol phosphates was modified from a previously published 
method (Brown et al., 2000). A dose-dependent accumulation of [3H] InsP1- 4 was also 
induced by BzATP and ATPγS in ECV304 cells (Figure 3.1) with mean EC50 values of 
1.51 ± 0.09 x 10-6 M for BzATP and 1.39 ± 0.08 x 10-6 M for ATPγS 
 
 
Basal 
Figure 3.1. Dose-dependent accumulation of [3H] IP3 in 
ECV304 cells in response to BzATP (■) and ATPγS (▼). Data 
are ± SEM from three experiments performed in triplicate. 
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3.3.2 Measurement of cAMP production in ECV304 cells in response to ADPβS 
and ATPγS 
 
 
ECV304 cells produced a dose-dependent accumulation of cAMP in response to 
ADPβS and ATPγS (Figure 3.2) with mean EC50 values of 2.5 ± 0.02 x 10-3 M for 
ADPβS and 2.2 ± 0.01 x 10-4 M for ATPγS. (EC50 values calculated by GraphPad 
Prism, these values are estimates only since neither response reaches plateau and so 
cannot ba taken as absolute values and highlights a limitation of this software). 
Basal 
Figure 3.2. Dose-dependent accumulation of cAMP in ECV304 cells 
in response to ADPβS (■) and ATPγS (▲). Data are ± SEM from 
three experiments performed in triplicate. 
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3.3.3 Measurement of total inositol (poly) phosphates in ECV304 cells in response 
to UTP, ATP and ADP 
 
Figure 3.3 shows that ECV304 cells accumulated inositol phosphates ([3H] InsP1- 4) in 
response to UTP, ATP and hexokinase-treated ADP with mean EC50 values of 3.04 x 
10-6 M, 6.85 x 10-6 M and 0.0001667 respectively. This figure is reproduced with kind 
permssion from the author (Brown, 2001). 
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Figure 3.3 Dose-dependent accumulation of [3H] Inositol phosphates 
in response to UTP ( ?), ATP (?) and ADP (?) in ECV304 cells. 
Data are mean results ± SEM from a representative experiment 
performed in triplicate.  
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3.3.4 Measurement of total inositol (poly) phosphates in EAhy926 cells in response 
to BzATP 
 
 
The method of measuring inositol phosphates was carried out as per the previously 
published method (Brown et al., 2000). BzATP did not induce a dose-dependent 
accumulation of [3H] InsP1- 4 in EAhy926 cells (Figure 3.4).  
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 Figure 3.4 Dose dependent accumulations of [3H] InsP 1-4 in 
EAhy926 cells in response to BzATP. Data are ± SEM from 
three experiments performed in triplicate. 
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3.3.5 Measurement of total inositol (poly) phosphates in EAhy926 cells in response 
to UTP and ATP 
 
Figure 3.5 shows that EAhy926 cells accumulated inositol phosphates ([3H] InsP1- 4) in 
response to UTP and ATP with mean EC50 values of 2.46x10-5 M and 4.01x 10-6M 
respectively. 
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Figure 3.5 Dose dependent accumulations of [3H] InsP 1-4 in 
EAhy926 cells in response to UTP (■) and ATP (▲). Data are ± 
SEM from three experiments performed in triplicate. 
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3.3.6 Measurement of total inositol (poly) phosphates in EAhy926 cells in response 
to 2MeSATP 
 
2MeSATP did not result in a dose-dependent accumulation of [3H] InsP1- 4 in 
EAhy926 cells (Figure 3.6).  However, small increase was observed at the highest 
concentration of 2MeSATP. It was not possible to calculate EC50, which is >10-4M.  
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Figure 3.6 Dose dependent accumulations of [3H] InsP 1-4 
in EAhy926 cells in response to 2MeSATP. Data are ± 
SEM from three experiments performed in triplicate. 
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3.3.7 Measurement of total inositol (poly) phosphates in EAhy926 cells in response 
to ADP 
 
ADP did not result in a dose-dependent accumulation of [3H] InsP1- 4 in EAhy926 cells 
(Figure 3.7).  
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Figure 3.7 Dose dependent accumulations of [3H] InsP 1-4 in 
EAhy926 cells in response to ADP. Data are ± SEM from 
three experiments performed in triplicate. 
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3.3.8 Measurement of total inositol (poly) phosphates in EAhy926 cells in response 
to UDP 
 
Figure 3.8 shows that EAhy926 cells accumulated inositol phosphates ([3H] InsP1- 4) in 
response to UDP with mean EC50 values of 1.62x 10-5M 
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Figure 3.8 Dose dependent accumulations of [3H] InsP 1-4 in 
EAhy926 cells in response to UDP. Data are ± SEM from three 
experiments performed in triplicate. 
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3.3.9 Measurement of total inositol (poly) phosphates in BAE cells in response to      
UTP 
 
Figure 3.9 shows that BAE cells accumulated inositol phosphates ([3H] InsP1- 4) in 
response to UTP with mean EC50 values of 2.06 x 10-5 M. This figure is reproduced with 
kind permssion from the author (Brown and Brown, 2002). 
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Figure 3.9 Dose-dependent accumulation of inositol phosphates 
in response to UTP (?) in bovine aortic endothelial cells. Data 
are mean results ± SEM from three experiments. 
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3.3.10 Measurement of total inositol (poly) phosphates in BAE cells in response to 
2MeSADP and 2MeSATP 
 
Figure 3.10 shows that BAE cells accumulated inositol phosphates ([3H] InsP1- 4) in 
response to 2MeSADP and 2MeSATP with mean EC50 values of 2.51 x 10-6 M and 2.77 
x 10-6 M respectively. This figure is reproduced with kind permssion from the author 
(Brown and Brown, 2002). 
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Figure 3.10 Dose-dependent accumulation of inositol 
phosphates in response to 2MeSADP (?) and 2MeSATP (▲) in 
bovine aortic endothelial cells. Data are mean results ± SEM 
from three experiments. 
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Table 3.1 Summary of functional responses induced by P2Y receptor agonists in  
ECV304, EAhy926 and BAE cells 
+: Positive stimulation;  -: No stimulation 
Agonists induced Response Cell Type 
 ADP ADPβS 2MeSADP ATP ATPγS 2MeSATP BzATP UDP UTP 
IP3 
Assay  +  +   +  +    -  +  - + 
[Ca2+]i 
Release  +  +   +  +     -   - + 
cAMP 
Assay   +    +     
 
 
 
ECV304 
 
 
 NOS Activity    +     + 
EAhy926 IP3 Assay -    +     - - + + 
IP3 
Assay +    +     +    + 
BAE 
NOS 
Activity     +    +    + 
The data for agonists induced [Ca2+]i release and NOS activity is obtained with kind 
permssion from the author (Brown, 2001). 
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3.4 Discussion 
 
The accumulation of inositol phosphates in response to BzATP and ATPγS, the potent 
agonists of P2Y11 receptors, strongly suggests the presence of P2Y11 receptors in 
ECV304 cells. In addition, the dose-dependent accumulation of cAMP in ECV304 cells 
in response to ADPβS and ATPγS further supports the presence of functional human 
P2Y11 receptors. High concentrations of ADPβS, the partial agonist at human P2Y11 
receptor has also been reported to evoke inositol phosphate accumulation and 
intracellular calcium release (Brown, 2001). Previous studies have reported an identical 
rank order potency of ATPγS and BzATP for two pathways. That is the potency of 
ATPγS and BzATP were almost identical in inositol trisphosphate measurements and 
cyclic AMP assays respectively in two different cell lines expressing human P2Y11 
receptor (Communi et al., 1999b).  
 
Previous studies in ECV304 cells have shown evidence for the expression of P2Y1 
receptors (Conant et al., 1998). Further studies with the potent P2Y1 agonist 2MeSATP 
produced cytosolic calcium responses but not inositol phosphate accumulation (Conant 
et al., 1998; Brown et al., 2000). The P2Y1 selective agonist 2MeSADP was without 
effect suggesting the possibility that either 2MeSATP is acting on the same receptor to 
induce intracellular Ca2+ by different mechanisms or is having effects on different 
receptors altogether (Brown, 2001). Similar responses have been seen with human 
P2Y11 receptors expressed in 1321N1 cells where UTP  acted as a Ca2+- mobilizing 
agonist with a potency and maximal response similar to ATP but was without effect on 
inositol phosphate accumulation, whilst ATP was a potent agonist (White et al., 2003). 
Furthermore, recent studies have reported a biphasic stimulation of [Ca2+]i increase 
produced by activation of the P2Y1 receptor; the initial transient phase was IP3 
dependent and the second sustained phase was dependent on  pertussis toxin-sensitive 
kinases such as calcium calmodulin kinase II (CaMKII) and protein kinase C (PKC) 
(Paredes-Gamero et al., 2006). However, the analysis of agonist specific signaling 
pathways is not the objective of this study. Furthermore, given the inconclusive agonist 
mediated response with P2Y1 agonists and for the purpose of establishing the functional 
expression, these results should be analyzed together with results obtained with RT-
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PCR studies and western blot analysis to detect the presence of mRNA and expression 
of P2Y1 receptors in these cells. 
 
Previous reports showed the presence of  P2Y2  receptors in ECV304 cells as both UTP 
and ATP, the equipotent agonists at P2Y2  receptors induced inositol phosphate 
accumulation and calcium mobilisation (Brown et al., 2000). In experiments measuring 
intracellular calcium release the maximal concentration of ATP desensitized the 
receptor for subsequent UTP mediated action; and the maximal concentration of UTP 
desensitized the receptor for ATP mediated action suggesting both ATP and UTP acted 
at the same receptor thus excluding the possibility of the presence of P2Y4 receptor in 
ECV304 cells (Brown, 2001). 
 
Hexokinase – treated UDP failed to elicit accumulation inositol phosphates and 
cytosolic calcium response in ECV304 cells suggesting the absence of P2Y6 receptors 
(Brown et al., 2000). These results will be confirmed by RT-PCR studies for the 
presence of mRNA and western blot studies with anti-P2Y6 antibodies. 
 
Previous studies with ADP, the potent agonist of P2Y12 and P2Y13 receptors has shown 
weak agonistic potency in ECV304 cells (Brown et al., 2000). In addition, ADPβS, an 
agonist of lower potency at P2Y13 receptor evoked the accumulation of inositol 
phosphates and a rise in intracellular calcium release in ECV304 cells. However, 
2MeSADP, the potent agonist of P2Y1, P2Y12 and P2Y13 receptors was without effect, 
and 2MeSATP induced a small increase in the intracellular calcium release in ECV304 
cells (Brown, 2001). Thus, it is not possible to establish the functional expression of 
P2Y1, P2Y12 and P2Y13 receptors in ECV304 cells from these data. Moreover, it is 
possible that the responses obtained by ADP, ADPβS and 2MeSATP may be mediated 
by P2Y1 or P2Y11 or both. These results highlight the difficulty in studying 
pharmacology of P2Y receptors, and in the absence of receptor specific agonists or 
antagonists, the need for other approaches such as RT-PCR and western blot analysis to 
determine their presence and expression. However, based on these results it could be 
hypothesized that P2Y2 and P2Y11 receptors are expressed in ECV304 cells. 
Nevertheless, RT-PCR studies and western blot studies with receptor specific antibodies 
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will be explored in order to reach a definitive profile of P2Y receptors expressed in 
these cells. 
 
The results obtained with EAhy926 cells are consistent with previous reports suggesting 
the expression of P2Y2 receptors in these cells (Graham et al., 1996a; Graham et al., 
1996b; Paul et al., 2000). In this study the P2Y2 receptor selective agonist, UTP showed 
a dose dependent accumulation of inositol phosphates in EAhy926 cells. The non 
selective agonist, ATP also showed a similar response in these studies. However these 
results may also suggest that these cells express P2Y4 receptor, for which UTP is a full 
agonist. Previous studies involving these agonists reported that UTP as being 50-fold 
more potent than ATP at P2Y4 receptor (Nicholas et al., 1996). Measurement of 
intracellular calcium with ATP and UTP and studies to determine if the maximal 
concentration of ATP or UTP desensitizes the receptor for subsequent action of UTP or 
ATP might determine the functional expression of P2Y4 in EAhy926 cells. At the same 
time, the detection of mRNA transcripts for P2Y2 and P2Y4 receptor using RT-PCR 
studies should determine the existence of either P2Y2/P2Y4 or both. Furthermore, 
results obtained from inositol phosphate assays and RT-PCR studies would be 
compared to the results of the western blot analysis using anti-P2Y2 and anti-P2Y4 
antibodies. 
 
The dose-dependent accumulation of inositol phosphates in response to UDP, a potent 
agonist of P2Y6 suggests the presence of P2Y6 receptor in EAhy926 cells.  2MeSATP, a 
potent agonist of both P2Y1 and P2Y11 did not show any significant dose-dependent 
accumulation of inositol phosphates. Furthermore, BzATP, which is a full agonist of 
P2Y11, also did not result in significant agonist response. The lack of response to either 
2MeSATP or the potent agonist BzATP suggests the absence of P2Y11 receptors in 
these cells. However, these results will be confirmed with RT-PCR studies using 
primers specific for human P2Y11 primers to investigate the presence of P2Y11 mRNA 
transcripts in these cells. In addition, western blot analysis of these cell extracts using 
anti-P2Y11 antibodies will give further evidence in determining the functional 
expression of P2Y11 receptor. The lack of any significant stimulation of inositol 
phosphates to ADP, a potent agonist of P2Y12 and P2Y13 receptors seem to suggest their 
absence in these cells. However RT-PCR and western blot analysis will be used to 
further determine whether these receptors are functionally expressed in EAhy926 cells.  
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 This study suggests that EAhy926 cells express P2Y2/P2Y4 and P2Y6 receptors. To 
confirm these findings, future work will involve RT-PCR studies to determine the 
mRNA expression of P2Y receptors in these cells. Immunodetection techniques such as 
immunohistochemistry and immunofluorescence could be used to study the binding and 
cellular localisation of anti-P2Y2 and anti-P2Y6 antibodies in EAhy926 cells. Functional 
studies may also be extended to determine the ability of receptor specific antibodies to 
inhibit/augment responses of natural agonists. These, together with other commercially 
available polyclonal antibodies to P2Y receptor subtypes will be investigated in western 
blot analysis. 
 
In single bovine aortic endothelial cells ATP, 2MeSATP and UTP produced inositol 
accumulation suggesting the expression of P2Y1 and P2Y2 receptors (Duchene and 
Takeda, 1997). Further studies reported that 2MeSADP and 2MeSATP were equipotent 
in evoking the accumulation of inositol phophates suggesting the expression of P2Y1 
receptor (Brown and Brown, 2002). In the same study 2MeSATP, the agonist of P2Y11 
failed to elicit a cAMP response suggesting that the inositol phosphate accumulation in 
response to 2MeSATP was mediated by P2Y1. Furthermore, UTP also stimulated a 
strong dose dependent inositol phosphate response suggesting the expression of P2Y2 
receptors (Brown and Brown, 2002). 
 
 Results from these studies and previous studies have provided an expression profile of 
functional P2Y receptor subtypes in ECV304, EAhy926 and BAE cells. These 
preliminary results have provided the basis for further investigation using RT-PCR to 
determine the presence of mRNA transcripts and western blot analysis to verify the 
functional expression of P2Y receptor subtypes.  
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CHAPTER 4 
 
ESTABLISHING THE MOLECULAR IDENTITY OF P2Y 
RECEPTORS IN ECV304 AND EAhy926 CELLS 
 98
4.1 Introduction 
 
The extracellular nucleotides regulate cellular function and resultant physiological 
responses through the activation of P2Y receptors. The P2Y receptor belonging to the 
super family of G-protein-coupled receptors family consists of eight cloned and 
functionally defined receptor subtypes namely P2Y1, P2Y2, P2Y4,P2Y6, P2Y11,P2Y12, 
P2Y13 and P2Y14 based on their specific pharmacological selectivities for different 
nucleotides (Ralevic and Burnstock, 1998; von Kügelgen and Wetter, 2000; Jacobson et 
al., 2002; Abbracchio et al., 2003). The pharmacological and functional studies of P2Y 
receptor subtypes in both endothelial and epithelial cells are of great physiological 
importance. Studies of these cells derived from human and animals have shown a 
potential regulatory role for the P2Y receptor subtypes in various physiological 
processes (see Section 1.8).  
 
P2Y receptor subtypes have been shown to be expressed in endothelial cells of human 
myocardium, human coronary artery graft vessels including internal mammary artery, 
radial artery and saphenous vein and in human umbilical veins at the mRNA and protein 
levels (Jin et al., 1998b; Hou et al., 1999; Moore et al., 2001; Ray et al., 2002; Wang et 
al., 2002). In addition, the P2Y2 receptor has been found to be up-regulated in CHF 
(congestive heart failure) heart (Hou et al., 1999). Furthermore, stimulation of P2Y1, 
P2Y2/4 and P2Y6 receptors have been shown to cause vasodilation in human vessels 
(Wihlborg et al., 2003). 
 
Activation of P2Y receptors has been shown to regulate ion transport in human airway 
epithelial tissues (Leipziger, 2003), gastrointestinal epithelium including human cystic 
fibrosis pancreatic adenocarcinoma cell line (CFPAC-1) (Chan et al., 1996), pancreatic 
duct epithelial cells of dogs (Nguyen et al., 1998), rat distal colonic mucosa (Kerstan et 
al., 1998), secretory epithelium of the equine sweat gland (Wilson et al., 1998), trachea 
and gall bladder of mice (Cressman et al., 1999; Clarke et al., 2000) rat bile duct 
epithelia (Dranoff et al., 2001) and rabbit conjunctival epithelium (Li et al., 2001). 
Furthermore, P2Y receptors have been implicated in the process of wound healing in 
human corneal epithelial cells (Klepeis et al., 2004). Recent studies have reported the 
polarised expression of human P2Y receptor subtypes in epithelial cells from kidney, 
lung, and colon (Qi et al., 2005; Wolff et al., 2005). Therefore, it is desirable to be able 
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to determine the molecular identity of P2Y receptors in endothelial and epithelial cell 
types used in this study.  
 
Functional studies have revealed that human bladder cancer epithelial cell line, ECV304 
express a P2Y2-like receptor (Brown et al., 2000). Further studies on this cell line have 
shown that P2Y2 receptors, through activation of PLC (phospholipase C) and 
mobilisation of intracellular calcium, stimulate production of nitric oxide. In addition, 
these studies reported evidence of the presence of a second P2Y receptor coupled to 
adenylate cyclase (AC) stimulation (Brown, 2001). 
 
Studies of the human endothelial cell line EAhy926 reported that nucleotides stimulate 
activation of MAP kinase in a protein kinase C-dependent manner through interaction 
with a P2Y2 receptor (Graham et al., 1996a). Furthermore, the P2Y2 agonist UTP 
stimulated inhibitory effect on tumor necrosis factor α (TNFα) - stimulated stress 
activated protein kinases such as JNK and p38 MAP kinase activity in EAhy926 cells 
was thought to involve Ca2+ independent PKC isoforms and the mediation of the P2Y2 
receptor (Paul et al., 2000). Furthermore, ATP, UTP and UDP showed a dose dependent 
accumulation of inositol phosphates in EAhy926 cells suggesting the presence of 
P2Y2/P2Y4 or both and P2Y6 receptor in these studies (see Chapter 3). 
 
The expression of receptors of the P2Y subtype in bovine aortic endothelial (BAE) cells 
is well established with reported effects being mediated via P2Y1 and P2Y2 receptors 
(see Chapter 3). Although the functional responses ascribed to receptor agonists indicate 
the type of receptor expressed, the pharmacology is confusing as a single agonist 
activates more than one receptor. Thus, in order to characterise the endothelial and 
epithelial cells for their P2Y receptor subtype expression and also to confirm or verify 
previously published pharmacology a complete expression profile is necessary.  
Therefore, RT-PCR studies were used to determine the expression of mRNA transcripts 
of P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12, P2Y13 and P2Y14 receptors in ECV304, 
EAhy926 and BAE cells. These studies also included 1321N1, human astrocytoma cells 
as a null cell line and BRIN-BD11, insulin-secreting cell line. Currently, there are no 
reports to indicate that BRIN-BD11 cells express any functional P2Y receptors.  
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4.2 Materials and Methods 
 
4.2.1 Tissue culture of 1321N1, ECV304, EAhy926, BAE and BRIN-BD11 cells 
 
1321N1, ECV304, EAhy926, BAE and BRIN-BD11 cells were maintained as described 
in section 2.2.2. 
 
4.2.2 Primer design 
 
The primer sequences for P2Y1-P2Y11 and GAPDH (Table 4.1) were taken from 
previously published work (Adrian et al., 2000) and  the sequences for P2Y12- P2Y14 
were designed using the program Lasergene DNA Star as described in section 2.4.1. 
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Table 4.1   P2Y1-11 receptor specific primers (Adrian et al., 2000) 
 
Primer Strand Sequence Corresponds 
to nt 
GeneBank 
accession no. 
S 5’- cac cac cat gga gaa ggc tgg-3’ 366-386 GAPDH 
AS 5’- gaa gtc aga gga gac cac cag-3’ 918-898 
M33197 
S 5’- cgg tcc ggg ttc gtc c-3’ 194-209 P2Y1 
AS 5’- cgg acc ccg gta cct-3’ 721-707 
U42030 
S 5’- ctc tac ttt gtc acc  acc agc g-3’ 750-777 P2Y2 
AS 5’- ttc tgc tcc tac agc cga atg tcc-3’ 1387-1364 
S74902 
(U07225) 
S 5’- cca cct ggc att gtc aga cac c-3’ 405-426 P2Y4 
AS 5’- gag tga cca ggc agg gca cgc-3’ 829-809 
X91852 
S 5’- cgc ttc ctc ttc tat gcc aac-3’ 510-531 P2Y6 
AS 5’- cca tcc tgg cgg cac agg cgg c-3’ 874-853 
U52464 
S 5- cag cgt cat ctt cat cac c-3’ 336-354 P2Y11 
AS 5’- gct ata cgc tct gta ggc -3’ 608-593 
AF030335 
S: sense oligonucleotide; AS: antisense oligonucleotide 
  
 
 
Table 4.2 P2Y12-14 receptor specific primers 
 
Primer Strand Sequence Corresponds to 
nt 
GeneBank 
accession no. 
P2Y12 S 5’-ctg ggc att cat gtt ctt act ctc-3’ 688-711 
 AS 5’-att ggg gca ctt cag cat act ta-3’ 1195-1173 
BC017898  
P2Y13 S 5’-caa gcc aag aaa atc ata gca gtc-3’ 1126-1149 
 AS 5’-tta agg ggc aca aaa gca gta gt-3’ 1567-1545 
NM_023914     
P2Y14 S 5’-gct cac tgg gca aaa cac ct-3’ 125-144 
 AS 5’-gat gag ccc aaa gaa cac aat g-3’ 557-536 
NM_014879     
S: sense oligonucleotide; AS: antisense oligonucleotide 
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 4.2.3 RT-PCR 
 
The protocol for RT-PCR studies for P2Y (P2Y1-14) receptor mRNA transcripts is 
described in section 2.4.2. 
 
4.2.4 Agarose gel electrophoresis 
 
RT-PCR products were analysed by ethidium bromide stained 2%‘Hi-Pure’ Low EEO 
agarose gels (Bio/Gene) as described in section 2.4.2. 
 
4.2.5 PCR product purification 
 
The PCR products were purified using GenEluteTM PCR Clean-Up Kit as described in 
section 2.4.3.  
 
4.2.6 DNA sequencing 
 
DNA sequencing of the purified PCR products  was performed by the Sequencing 
Service at the School of Life Sciences of University of Dundee as described in section 
2.4.4. 
 
4.2.7 Database search 
 
The DNA sequence of the PCR products for P2Y receptor subtypes were used to run a 
database search. They were aligned with the reference mRNA sequence used for primer 
designing using BLAST bl2seq sequence alignment program. 
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4.3 Results 
 
4.3.1 RT-PCR studies on 1321N1, ECV304, EAhy926, BAEC and BRIN-BD11 cells 
 
Expression of cloned human P2Y receptors were analysed in RNA samples from 
1321N1, ECV304, EAhy926, BAEC and BRIN-BD11 by a semi quantitative RT-PCR 
assay using P2Y receptor subtype specific primers. The mRNA expression was also 
determined for GAPDH, a housekeeping gene in these cells.  The resultant RT- PCR 
products were eluted from the ethidium bromide stained 2%‘Hi-Pure’ Low EEO 
agarose and analysed by sequencing. All the experiments were repeated three times 
using independent batches of cells.  
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4.3.2 Determining the presence of P2Y1 transcripts 
 
Evidence of P2Y1 mRNA transcripts with a strong band of the expected size of 527bp 
was detected only in ECV304 cells (Figure 4.1). However, 1321N1 (Figure 4.1), 
EAhy926, BAEC and BRIN-BD11 cells did not show evidence of P2Y1 transcripts 
(Figure 4.2). Both the images represent one run of the experiment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 2 3 4 5 1 2 3 4 5
Figure 4.1 RT-PCR analysis of P2Y1 
(527bp) mRNA  transcripts. Lane 1. 
100bp markers. Lane 2. GAPDH 
(552bp); Lane 3.  1321N1 sample; 
Lane 4. ECV304 sample (527bp); 
Lane 5. 100bp markers.  
Figure 4.2 RT-PCR analysis of P2Y1 
(527bp) mRNA  transcripts.  Lane 1. 
100bp markers; Lane 2. EAhy926 
sample; Lane 3. BAE sample; Lane 4. 
BRIN-BD11 sample. Lane 5. 100bp 
markers. 
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4.3.3 Determining the presence of P2Y2 transcripts 
 
P2Y2 mRNA transcripts with strong bands of 637bp size were detected in ECV304 
(Lane 4. Figure 4.3) and EAhy926 cells (Lane 2. Figure 4.4). Evidence of P2Y2 mRNA 
transcripts was not detected in 1321N1 (Figure 4.3), BAEC and BRIN-BD11 cells 
(Figure 4.4). Both the images represent one run of the experiment. 
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Figure 4.3 RT-PCR analysis of P2Y2 
(637bp) mRNA  transcripts.  Lane 1. 
100bp markers. Lane 2. GAPDH 
(552bp); Lane 3.  1321N1 sample; 
Lane 4. ECV304 sample (637bp); 
Lane 5. 100bp markers.  
Figure 4.4 -PCR analysis of P2Y2 
(637bp) mRNA transcripts.  Lane 1. 
100bp markers; Lane 2. EAhy926 
sample (637bp); Lane 3. BAE 
sample; Lane 4. BRIN-BD11 sample. 
Lane 5. 100bp markers. 
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4.3.4 Determining the presence of P2Y4 transcripts 
 
P2Y4 mRNA transcripts with a strong band of 424bp were observed in ECV304 cells 
(Lane 4. Figure 4.5). However, 1321N1 (Figure 4.5), EAhy926, BAEC and BRIN-
BD11 cells did not show evidence of P2Y4 mRNA transcripts (Figure 4.6). Both the 
images represent one run of the experiment. 
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Figure 4.5 RT-PCR analysis of 
P2Y4 (424bp) mRNA  transcripts.  
Lane 1. 100bp markers. Lane 2. 
GAPDH (552bp); Lane 3.  1321N1 
sample; Lane 4. ECV304 sample 
(424bp). 
Figure 4.6 RT-PCR analysis of P2Y4 
(424bp) mRNA  transcripts.  Lane 1. 
100bp markers; Lane 2. EAhy926 
sample; Lane 3. BAE sample; Lane 4. 
BRIN-BD11 sample. Lane 5. 100bp 
markers. 
 
 
 
 
 
 
 
 
              
 
  
                        
 107
4.3.5 Determining the presence of P2Y6 transcripts 
 
P2Y6 mRNA transcripts with bands in expected size of 365bp were detected in ECV304 
(Lane 4. Figure 4.7) and EAhy926 cells (Lane 2. Figure 4.8). However, 1321N1 (Figure 
4.7), BAEC and BRIN-BD11 cells did not show evidence of P2Y6 mRNA transcripts 
(Figure 4.8). Both the images represent one run of the experiment. 
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Figure 4.7 RT-PCR analysis of P2Y6 
(365bp) mRNA  transcripts. Lane 1. 
100bp markers. Lane 2. GAPDH 
(552bp); Lane 3.  1321N1 sample; Lane 
4. ECV304 sample (365bp). 
Figure 4.8 RT-PCR analysis of P2Y6 
(365bp) mRNA  transcripts.  Lane 1. 
100bp markers. Lane 2. EAhy926 
sample (365bp); Lane 3. BAE 
sample; Lane 4. BRIN-BD11 sample.  
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4.3.6 Determining the presence of P2Y11 transcripts 
 
Evidence for P2Y11 mRNA transcripts with a weak band of 272bp was observed in 
ECV304 cells (Lane 3. Figure 4.9). There was no evidence for P2Y11 mRNA transcripts 
in 1321N1 (Figure 4.9), EAhy926, BAEC and BRIN-BD11 cells (Figure 4.10). Both the 
images represent one run of the experiment. 
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Figure 4.9 RT-PCR analysis of P2Y11 
(272bp) mRNA  transcripts.  Lane 1. 
100bp markers. Lane 2. GAPDH 
(552bp); Lane 3. ECV304 sample 
(272bp); Lane 4.  1321N1 sample. 
Figure 4.10 RT-PCR analysis of P2Y11 
(272bp) mRNA  transcripts.  Lane 1. 
100bp markers. Lane 2. EAhy926 
sample; Lane 3. BAE sample; Lane 4. 
BRIN-BD11 sample. Lane 5. 100bp 
markers.
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4.3.7 Determining the presence of P2Y12 transcripts 
 
P2Y12 mRNA transcripts with band of 507bp were detected in ECV304 cells (Lane 4. 
Figure 4.11). However, 1321N1 (Figure 4.11), EAhy926, BAEC and BRIN-BD11 cells 
did not show evidence of P2Y12 mRNA transcripts (Figure 4.12). Both the images 
represent one run of the experiment. 
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Figure 4.11 RT-PCR analysis of 
P2Y12 (507bp) mRNA  transcripts. 
Lane 1. 100bp markers. Lane 2. 
GAPDH (552bp); Lane 3.  1321N1 
sample; Lane 4. ECV304 sample 
(507bp); Lane 5. 100bp markers.  
Figure 4.12 RT-PCR analysis of 
P2Y12 (507bp) mRNA  transcripts.  
Lane 1. 100bp markers. Lane 2. 
EAhy926 sample; Lane 3. BAE 
sample; Lane 4. BRIN-BD11 sample. 
Lane 5. 100bp markers. 
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4.3.8 Determining the presence of P2Y13 transcripts 
 
P2Y13 mRNA transcripts with a strong band of 441bp were detected in ECV304 cells 
(Lane 4. Figure 4.13). However, 1321N1 (Figure 4.13), EAhy926, BAEC and BRIN-
BD11 cells did not show evidence of P2Y13 mRNA transcripts (Figure 4.14). Both the 
images represent one run of the experiment. 
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Figure 4.13 RT-PCR analysis of 
P2Y13 (441bp) mRNA  transcripts.  
Lane 1. 100bp markers. Lane 2. 
GAPDH (552bp); Lane 3.  1321N1 
sample; Lane 4. ECV304 sample 
(441bp); Lane 5. 100bp markers.  
Figure 4.14 RT-PCR analysis of 
P2Y13 (441bp) mRNA  transcripts.  
Lane 1. 100bp markers. Lane 2. 
EAhy926 sample; Lane 3. BAE 
sample; Lane 4. BRIN-BD11 sample. 
Lane 5. 100bp markers. 
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4.3.9 Determining the presence of P2Y14 transcripts 
 
P2Y14 mRNA transcripts ( the PCR product size of 432bp) were not detected in1321N1, 
ECV304, EAhy926, BAEC and BRIN-BD11 cells after amplification with P2Y14 
specific primers (Figure 4.15 and Figure 4.16). Both the images represent one run of the 
experiment. 
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Figure 4.15 RT-PCR analysis of 
P2Y14 (432bp) mRNA  transcripts.  
Lane 1. 100bp markers; Lane 2. 
GAPDH (552bp); Lane 3.  1321N1 
sample; Lane 4. ECV304 sample; 
Lane 5. 100bp markers.  
Figure 4.16 RT-PCR analysis of 
P2Y14 (433bp) mRNA transcripts.  
Lane 1. 100bp markers. Lane 2. 
EAhy926 sample; Lane 3. BAE 
sample; Lane 4. BRIN-BD11 sample. 
Lane 5. 100bp markers. 
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Table 4.3 Summary of RT-PCR results of P2Y receptor subtypes in 1321N1,  
ECV304, EAhy926, BAEC and BRIN-BD11 cells 
 
Receptor Type Cell Type 
 1321N1 ECV304 EAhy926 BAEC BRIN-BD11 
P2Y1   - + - - - 
P2Y2 - + + - - 
P2Y4 
 
- + - - - 
P2Y6 
 
- + + - - 
P2Y11 
 
- + - - - 
P2Y12 
 
- + - - - 
P2Y13 
 
- + - - - 
P2Y14 
 
- - - - - 
 +: Presence of P2Y receptor subtype transcripts;   
- : Absence of P2Y receptor subtype transcripts 
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4.3.10 Database search 
 
The DNA sequence of the RT-PCR products for P2Y receptor subtypes aligned with the 
reference mRNA sequence used for primer designing using BLAST bl2seq sequence 
alignment program shows the sequence similarity as below. 
 
 
Table 4.4 Summary of RT-PCR-DNA sequence alignment of  
P2Y receptor subtypes with reference sequence in ECV304 cells   
 
RT-PCR 
Product 
Primer 
Strand 
bl2seq Alignment: Percent 
Sequence Identities 
S 404/463 (87%)  P2Y1 
AS 474/480 (98%)  
S 593/597 (99%)  P2Y2 
AS 574/579 (99%), Gaps = 1/579 (0%)  
S 352/364 (96%), Gaps = 4/364 (1%)  P2Y4 
AS 371/374 (99%), Gaps = 3/374 (0%)  
S 232/238 (97%), Gaps = 2/238 (0%)  
P2Y6 
AS 
275/278 (98%), Gaps = 2/278 (0%) 
S 223/227 (98%), Gaps = 2/227 (0%)  P2Y11 
AS 224/228 (98%), Gaps = 1/228 (0%)  
S 455/458 (99%) 
P2Y12 AS 456/457 (99%), Gaps = 1/457 (0%)  
S 324/396 (81%), Gaps = 1/396 (0%) P2Y13 AS 331/374 (88%) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S: sense oligonucleotide; AS: antisense oligonucleotide 
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Table 4.5 Summary of RT-PCR-DNA sequence alignment of  
P2Y receptor subtypes with reference sequence in EAhy926 cells   
 
RT-PCR 
Product 
Primer 
Strand 
bl2seq Alignment: Percent 
Sequence Identities  
S 416/487 (85%)  P2Y2 
AS 439/515 (85%)  
S 214/249 (85%) 
P2Y6 AS 258/296 (87%)  
S: sense oligonucleotide; AS: antisense oligonucleotide 
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4.4 Discussion 
 
These results establish the presence of mRNA transcripts for P2Y1, P2Y2, P2Y4, P2Y6, 
P2Y11, P2Y12 and P2Y13 in ECV304 cells. The presence of P2Y1 mRNA in ECV304 
cells could be supported by previous published results (Conant et al., 1998). However, 
these receptor subtypes were also shown to be absent in ECV304 cells based on 
functional responses to 2MeSATP, a potent agonist of P2Y1 (Conant et al., 1998).  This 
inconsistency in the ability of the agonist to produce cytosolic calcium responses but not 
to induce inositol phoshphate accumulation had been attributed to a sub – population or 
passage specific effect on these cells (Conant et al., 1998; Brown et al., 2000). 
Similarly, 2MeSATP has been reported to induce a small increase in the intracellular 
calcium release whereas the P2Y1 selective agonist 2MeSADP was without effect 
(Brown, 2001).  
 
 However, in this study the presence of P2Y1 mRNA was consistent in cells taken from 
different batches. In addition, the DNA sequence results for RT-PCR product of the 
P2Y1 receptor in ECV304 cells when aligned with the primer specific mRNA sequence 
using the BLAST bl2seq sequence alignment program, showed a high percentage 
(>85%) of sequence similarity. Western blot studies with an anti-P2Y1 antibody could 
clarify whether the transcribed receptor has been translated into functional receptor. It 
may be that the transcribed P2Y1 receptor has a low receptor reserve. The receptor 
reserve is reported to affect the degree of agonist/antagonist activity that has been 
reported for P2Y1 receptor (Palmer et al., 1998). 
 
The detection of P2Y2 mRNA and the subsequent DNA sequence results in ECV304 
cells is consistent with previous reports which showed UTP and ATP as equipotent 
agonists at P2Y2  receptors which  induced inositol phosphate accumulation and 
calcium mobilisation (Brown et al., 2000). In this study P2Y4 and P2Y6 mRNA were 
observed in ECV304 cells and RT-PCR-DNA sequence alignment with reference 
sequence showed >95% similarity. However, previous studies with the potent P2Y6 
agonist, UDP failed to elicit accumulation inositol phosphates and cytosolic calcium 
response in ECV304 cells (Brown et al., 2000). This needs to be clarified with 
immunoblotting studies with anti-P2Y6 antibodies. 
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The detection of P2Y11 mRNA in ECV304 cells in these studies is consistent with 
previous pharmacological studies of dose-dependent accumulation of inositol 
phosphates in these cells in response to ADPβS, a P2Y1 and P2Y11 agonist (Communi et 
al., 1999b; Brown, 2001). Previous studies on ECV304 cells reported that these cells 
express receptors coupled to adenylyl cyclase (Brown et al., 2000). Later studies have 
reported the accumulation of cAMP in response to ADPβS in ECV304 cells (Brown, 
2001). Furthermore, the small increase in the intracellular calcium release by 2MeSATP 
reported in ECV304 cells may be mediated by P2Y11 receptors (Brown, 2001). Finally, 
DNA sequence results for RT-PCR product of P2Y11 receptor showed >98% similarity 
with primer specific mRNA sequence. 
 
 Previous studies with human P2Y11 receptors stably expressed in Chinese hamster 
ovary cells (CHO-K1) and 1321N1 human astrocytoma cells showed the potency order 
ATPγS  2MeSATP  ATP ≈ ADPβS > 2MeSADP > ADP in promoting both inositol 
phosphate and cyclic AMP accumulation (Qi et al., 2001). These studies suggested that 
human P2Y11 receptor was potently activated by adenosine triphosphate nucleotides 
rather than their corresponding diphosphates, which acted as partial agonists. This 
further supports the idea that increases in the intracellular calcium release observed in 
response to 2MeSATP reported in ECV304 cells was mediated by P2Y11 receptors 
(Brown, 2001). Furthermore, the dose dependent functional responses observed in these 
studies with more selective P2Y11 agonists like BzATP and ATPγS provide evidence for 
the functional expression of this receptor (see Chapter 3).  
 
The DNA sequence results for RT-PCR product showed >99% (P2Y12) and >81% 
(P2Y13) similarity with primer specific mRNA sequences. So far, there are no published 
reports which suggest that P2Y12 and P2Y13 receptors are expressed in ECV304 cells 
and/or these cells express receptors that are coupled to the inhibition of adenylyl 
cyclase. Previous studies did not find evidence for expression of P2Y receptors linked 
to the inhibition of adenylate cyclase in these cells (Brown et al., 2000). Nonetheless, 
the potent agonist of these receptors, ADP, has shown weak agonistic potency in 
ECV304 cells (Brown et al., 2000; Zhang et al., 2001). In addition, accumulation of 
inositol phosphates and a rise in intracellular calcium release is evoked by ADPβS, a 
common agonist of P2Y12 and P2Y13 receptors. However, previous studies on ECV304 
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cells also reported that 2MeSADP, the potent agonist of P2Y1, P2Y12 and P2Y13 
receptors was without effect. Furthermore, 2MeSATP induced only a small increase in 
the intracellular calcium release, thus highlighting the inability of nucleotides to 
produce conclusive pharmacological evidence to determine the existence of the 
functional P2Y receptors (Brown, 2001). It would be interesting to see if stimulation of 
ECV304 cells with 2MeSADP and 2MeSATP reduce the levels of cAMP in order to 
determine whether ECV304 cells express functional receptors that are coupled to the 
inhibition of adenylyl cyclase.  
 
According to this study EAhy926 cells show the presence of mRNA for P2Y2 and P2Y6 
receptors. In addition, the DNA sequence of the RT-PCR products for P2Y2 and P2Y6 
receptor subtypes when aligned with the reference mRNA sequence used for primer 
designing using BLAST bl2seq sequence alignment program has shown a high 
percentage (>85%) of similarity. The presence of P2Y2 in EAhy926 supports previous 
reports that nucleotides stimulate activation of MAP kinase in a protein kinase C-
dependent manner through interaction with a P2Y receptor (Graham et al., 1996a). 
Further studies have also reported that P2Y2 receptor mediated inhibitory effect on 
tumor necrosis factor α (TNFα) - stimulated stress activated protein kinases such as 
JNK and p38 MAP kinase activity in EAhy926 cells involving Ca2+ independent PKC 
isoforms. The P2Y6 receptor agonist UDP, however, was ineffective in this cell line 
(Paul et al., 2000). However, studies have shown a dose-dependent accumulation of 
inositol phosphates in response to UDP in EAhy926 cells (see Chapter 3).  
 
Bovine aortic endothelial cells have been shown to express of both P2Y1 and P2Y2 
receptors coupled to Gq/G11 and G1 proteins  (Wilkinson et al., 1993; Pirotton et al., 
1996). However, P2Y transcripts were not observed in these cells under the conditions 
which showed presence of mRNA for P2Y receptors in ECV304 and EAhy926 cells 
when human P2Y receptor sequence specific primers were used. Further RT-PCR 
studies with bovine P2Y receptor specific primers in these cells are needed to 
investigate the expression of P2Y receptor mRNA transcripts. Bovine corneal 
endothelial cells (BCECs) showed expression of mRNAs for P2Y1 and P2Y2 receptors 
(Gomes et al., 2005).  
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Expression for P2Y receptor transcripts in 1321N1 and BRIN-BD11 cells were not 
observed. However, previous reports of the presence mRNA for P2Y6 and P2Y11 in 
1321N1 cells using TaqMan – quantitative RT–PCR analysis is said to be due to the 
clonal variations in the cells used in that study (Moore et al., 2001). The P2Y primer 
sequences were compared with the Genbank using Basic Local Alignment Search Tool 
(BLAST). No significant similarities were found between human P2Y primer pair 
sequence with bovine P2Y receptors. Similarly, the human P2Y primer pair sequences 
showed no homology to the rat P2Y receptor gene suggesting that these primers are not 
suitable for amplifying bovine and rat P2Y PCR products.  
 
Overall, these RT-PCR studies have given a thorough profile of the P2Y receptor 
transcripts in 1321NI, ECV304 and EAhy926 cells. It has been observed that the studies 
to determine the presence of mRNA transcripts should only be used to indicate the 
presence or absence of receptor transcripts and not to prove the functional level of 
protein expression (Moore et al., 2001). That may be one of the reasons why P2Y1, 
P2Y6, P2Y12 and P2Y13 receptor selective agonists were unable to stimulate second 
messengers in EV304 cells. Further studies with selective ligands or western blot 
analysis using P2Y receptor specific antibodies would help to determine the functional 
level of protein expression. Moreover, RT-PCR studies with species specific P2Y 
primers could elucidate the expression of P2Y receptor subtypes in BAE and BRIN-
BD11 cells. 
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CHAPTER 5  
 
PURIFICATION OF POLYCLONAL ANTIBODIES 
 120
5.1 Introduction 
 
Peptides designed to mimic the defined regions of extracellular loops of peptide 
receptor (rat liver V1a vasopressin receptor), which share the sequence homology with 
P2Y receptor, have been shown to act like functional agonists, suggesting a role for 
extracellular loops in ligand binding (Van Rhee et al., 1995; Howl and Wheatley, 1996). 
Further studies indicated that for peptide receptors the neuropeptide binding involves 
residues on the top of several transmembrane domains and in extracellular loops of the 
receptors while the non peptide type ligands to the same receptors tend to bind deeper in 
the plane of the membrane, between several transmembrane domains suggesting the 
importance of the extracellular loops (ELs) for ligand recognition (Berthold and Bartfai, 
1997). 
 
For human P2Y1 receptors, it has been shown that positively charged and other 
conserved residues in transmembrane (TM) regions 3, TM6, and TM7 e.g. Arg128, 
Arg310, and Ser314, are critical for the activation by nucleotides (Moro et al., 1998).  
Mutational analysis of P2Y1 receptors suggested that positively charged residues on the 
exofacial side of TM3 and TM7 are involved in binding the negatively charged 
phosphate groups of nucleotides (Jiang et al., 1997; Jacobson et al., 1999). The 
mutation of the basic amino acid lysine (Lys280) on TM6 of the human P2Y1 receptor 
has also shown to affect the potency and affinity of receptor antagonists (Guo et al., 
2002). Site-directed mutagenesis of P2Y2 receptors suggested that positively charged 
amino acids histidine262 and arginine265 on TM6 and TM7 are involved in nucleotide 
binding (Erb et al., 1995). Additionally, it was also reported that the presence of two 
critical disulfide bridges (first between the EL2 and TM3 and the second between EL3 
and the N-terminal domain) and charged residues in the extracellular domains are 
involved in ligand recognition and activation of P2Y1 receptor (Hoffmann et al., 1999).  
 
Based on this evidence, previous work in the lab had focussed on design, synthesis and 
subsequent evaluation of peptides specifically mimicking the extracellular regions of the 
human P2Y2 receptor (these peptides were designed to be specific to the extracellular 
loops of the human P2Y2 receptor subtype). In particular, a peptide (L247) mimicking 
the third extra cellular loop has been shown to stimulate nitric oxide synthase activity in 
BAE cells (Brown, 2001). In addition, L247 was reported to act like a weak agonist of 
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inositol phosphate production when added alone, but when added simultaneously with 
ATP has shown synergistic effects on inositol phosphate production and intracellular 
calcium release in ECV304 cells. This synergistic effect was specific to purinergic and 
pyrimidinergic agonists with no such effects being observed upon the simultaneous 
addition of L247 and histamine. L247 was equipotent to 100μM ATP in activating 
phospolipase D in porcine aortic endothelial cells (Brown, 2001).  
 
These results prompted the commissioning of polyclonal antisera from a commercial 
source (Severn Biotech) which were raised in rabbit using L247 peptide as an 
immunogen. This study presents purification of this antisera by affinity chromatography 
and evaluation by indirect ELISA. Affinity purification has been used as the method of 
choice for antibody purification; this relies on the structure of immunoglobulin and its 
specificity for the antigen (Huse et al., 2002). However, ligands other than those used 
for immunization have been used effectively for affinity purification. For example, 
thiophilic-adsorption chromatography, in which the presence of high concentrations of 
lyotropic salts facilitate selective adsorption of proteins on to thiophilic adsorbents. This 
has been used for the purification of murine monoclonal antibodies from hybridoma cell 
culture (Finger et al., 1996) and in the separation of immunoglobulins from bovine 
colostrum and milk whey (Hutchens et al., 1990; Konecny et al., 1994). Thiophilic 
chromatography has also been used to separate antibodies from cell-culture supernatants 
and ascites fluids (Belew et al., 1987; Sulk et al., 1992; Bog-Hansen, 1997).  
 
PROSEP-Thiosorb, a thiophilic affinity adsorbent is prepared by the covalent 
attachment of a nonbiological thiophilic ligand to a porous glass (glass particles 
permeated by interconnecting pores of uniform and precisely controlled size) of 75 -125 
micron. PROSEP-Thiosorb selectively binds protein regions common to all 
immunoglobulins and has a static binding capacity of 8 mg/ml for polyclonal Rabbit 
IgG.  This matrix binds antibodies in the presence of high concentrations of lyotropic 
salts such as ammonium sulphate or potassium sulphate which influences the strength of 
the interaction. Due to the nonbiological nature of ligand, the possible contamination by 
leachable protein is eliminated. Furthermore, synthetic adsorbent ligands have been 
shown to retain binding capacity even after subjecting them to thorough cleaning after 
the run (Bak and Thomas, 2007). Furthermore, mouse MAbs (Monoclonal antibodies) 
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from cell culture supernatants have been successfully affinity purified using PROSEP-
Thiosorb M and has been optimized for the purification of both monoclonal and 
polyclonal imuunoglobulin M (IgM) (Waldron et al., 2002; Nelson et al., 2005). 
Therefore, PROSEP-Thiosorb was used in this study to purify rabbit polyclonal 
antibody by employing thiophilic-adsorption chromatography technique.   
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5.2 Materials and Methods 
 
5.2.1 Buffer preparation 
 
Wash Buffer: 20 mM HEPES, 7.5% (NH4)2 SO4 and 0.5M NaCl, pH 7.5 
Elution Buffer 1(A): 20mM HEPES, 1M NaCl, pH 7.5 
Elution Buffer 2(B): 20mM HEPES, 2M NaCl, pH 7.5 
Elution Buffer 3: 60% Ethylene glycol) 
Regeneration Solution: 6M Urea 
 
5.2.2 Sample preparation 
 
Sufficient reagent was added to the starting material (serum or cell culture supernatant) 
so that it contained 20 mM HEPES, 7.5% (NH4)2 SO4 and 0.5M NaCl. The pH of the 
solutions were adjusted to 7.5 using 5M NaOH and the solution was filtered through a 
0.45 or 0.2 μm filter 
 
5.2.3 Affinity chromatography 
 
The polyclonal antisera was purified by affinity chromatography as described in section 
2.5.2. 
 
5.2.4 Dialysis 
 
The purified fractions were then dialysed as described in section 2.5.3. 
 
5.2.5 Bicinchoninic acid protein assay 
 
The concentration of purified antibody fractions was quantified by Bicinchoninic Acid 
Protein Assay as described in section 2.5.4. 
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5.2.6 Indirect ELISA 
 
Indirect ELISA was performed as described in section 2.5.5. 
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5.3 Results 
 
5.3.1 Thiophilic-adsorption chromatography 
 
The terminal bleed of L247 polyclonal antisera was affinity purified using a PROSEP- 
Thosorb (Millipore) affinity adsorbent column in BioLogic HR Chromatography 
System (Bio-Rad). Table 5.1 elucidates the gradual plan of sample injection and buffer 
loading on BioLogic HR Chromatography System. Various fractions were collected 
during the elution stages and were analysed for protein contents and assayed for 
antibody immunoreactivity by indirect Elisa.  
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Table 5.1 Biologic HR run report 
Step 
Number 
Start  
(h:m) 
Step 
1 0:00.0 Collect Fractions of size 1.00 m above 0.1000 threshold during 
entire run 
2 0:00.0 Turn UV lamp on 
3 0:00.0 Set UV baseline to 0.0 
4 0:00.0 Turn Chart Recorder ON 
5 0:00.0 Set UV baseline to 0.0 
6 0:00.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 15.0 min 
7 0:15.0 Static loop: inject 5.0 ml sample at 1.00 ml/min for 5.0 min 
8 0:20.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 5.0 min 
9 0:25.0 Static loop: inject 5.0 ml sample at 1.00 ml/min for 5.0 min 
10 0:30.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 5.0 min 
11 0:35.0 Static loop: inject 5.0 ml sample at 1.00 ml/min for 5.0 min 
12 0:40.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 5.0 min 
13 0:45.0 Static loop: inject 5.0 ml sample at 1.00 ml/min for 5.0 min 
14 0:50.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 5.0 min 
15 0:55.0 Static loop: inject 5.0 ml sample at 1.00 ml/min for 5.0 min 
16 1:00.0 Isocratic Flow with Wash Buffer at 1.50 ml/min for 45.0 min 
17 1:45.0 Linear Gradient with 0% to 100% Elution Buffer 2 (100% to 
0% Elution Buffer 1) at 1.50 ml/min for 30.0 min 
18 2:15.0 Linear Gradient with 100% to 0% Elution Buffer 2 (0% to 
100% Elution Buffer 1) at 1.50 ml/min for 30.0 min 
19 2:45.0 Isocratic Flow with Elution Buffer 3 at 1.50 ml/min for 30.0 
min 
20 3:15.0 Turn Chart Recorder ON 
21 3:15.0 Sound Alarm 
22 3:15.0 End of Protocol 
23 3.15.0 Isocratic Flow with Regeneration Solution at 1.50 ml/min for 
30.0 min 
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Elution of unbound 
material with wash 
buffer 
Elution buffers 
1&2 
Figure 5.1 A profile of thiophilic-adsorption chromatography run performed on L247 polyclonal 
antisera using a BioLogic HR Chromatography System (Bio-Rad) and PROSEP- Thosorb (Millipore) 
affinity adsorbent column. 
 
Elution buffer 3 Elution of bound 
antibody fractions 1 & 2 
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5.3.2 Protein quantification 
 
Eluted bound fractions of 1ml each were collected corresponding to the positive UV 
value peak in the profile run (Fig 5.1) and quantified for the protein/antibody 
concentration using a Bicinchoninic Acid Protein Assay Kit (BCA1-Sigma). The 
concentration of the unknown sample was determined by comparing its absorbance at 
562 nm to the standard curve prepared using BSA (Bovine Serum Albumin) protein 
standards. The concentration of fraction I was 1.6mg/ml and that of fraction ΙΙ was 
2.3mg/ml. 
 
5.3.3 Indirect ELISA 
 
Fraction I and fraction II were analyzed for their binding efficiency to L247 peptide by 
the indirect ELISA method. As expected the antibody fractions at serially diluted 
concentrations bound to 30μg/ml of L247 peptide in a dose-related manner (Figures. 5.2 
and 5.3). Significantly, the binding observed for fraction II was four fold higher than 
that observed for fraction I (Figure 5.4). Control experiments using an unrelated peptide 
designed to Human endogenous retrovirus K env (HERV-K env: GKTCPKETPKGKNI) 
confirmed the specificity of binding to L247 peptide (at 30μg/ml peptide: absorbance 
0.036 units for HERV-K env peptide versus 0.586 for L247 peptide; and absorbance 
1.065 for HERV-K env peptide versus 2.670 for L247 peptide). Moreover, there were 
no significant similarities when L247 peptide sequence (RSLDLSCHTLNAIN) was 
aligned with HERV-K env protein suggesting that the binding of antibody with HERV-
K env peptide may have been due to non-specific immunoglobulins.
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Figure 5.2 Reactivity of serially diluted L247 antibody fraction I 
against 30μg/ml of L247 peptide and 30μg/ml of L247 antibody 
fraction I against 30μg/ml of HERV-K env peptide. Data are mean 
results ± SEM performed in triplicate and one representation of three 
experiments. 
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Figure 5.3 Reactivity of serially diluted L247 antibody fraction II against 
30μg/ml of L247 peptide and 30ug/ml of L247 antibody fraction II 
against 30μg/ml of HERV-K env peptide. Data are mean results ± SEM 
performed in triplicate and one representation of three experiments.
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Figure 5.4 Comparison of the relative reactivity of the serially 
diluted L247 Antibody fraction I ( ) & II ( ) against 30μg/ml of 
L247 peptide. Data are mean results ± SEM performed in 
triplicate and one representation of three experiments. 
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5.4 Discussion 
 
The rabbit polyclonal antiserum was affinity purified using a BioLogic HR 
Chromatography System (Bio-Rad) and PROSEP- Thiosorb affinity adsorbent columns. 
Prior to elution of adsorbed protein, the affinity adsorbent columns were washed to 
remove all the traces of albumin and other contaminants present as non-adsorbed or 
unbound content. After elution of the unbound material the adsorbed material was 
eluted to yield two fractions, corresponding to the two elution buffers suggested by 
adsorbent column manufacturers for the elution of IgG. The incorporation of different 
elution buffers will have eluted these antibody fractions with differing affinity to the 
adsorbent column (Muronetz and Korpela, 2003). The purified fractions were then 
dialysed against multiple buffer changes for the required time before storing them in 
aliquots at -200C.  
 
The protein substance of the adsorbed fractions showed that the concentration of 
fraction II was twice that of fraction I. This may be due to the degree of severity of the 
elution buffer on bound protein to the columns. To check whether the immunoreactivity 
of the antibody fractions with the antigen remained unscathed after affinity purification 
was ascertained with indirect ELISA using immobilized antigen (L247 peptide). The 
antibody fraction I and fraction II at serially diluted concentrations bound strongly to 
L247 peptide in a dose-related manner suggests the reaction specificity of the antibody 
to antigenic immunogen. Significantly, the binding observed for fraction II was four 
fold higher than that observed for fraction I. Control experiments using an unrelated 
peptide (designed to HERV-K env) confirmed the specificity of binding to L247 
peptide. The minimal binding that occurred with HERV-K peptide may be due to cross 
reactivity of antibody fractions. The presence of non specific immunoglobulins in the 
fraction II may have accounted for this minimal binding. Isolation of these antibodies 
with different specificities using chromatography on immobilized synthetic antigen 
would provide the antibody with desired specificity (Muronetz and Korpela, 2003).  
 
The results from indirect ELISA suggest the successful generation of sequence specific 
antibody to L247 peptide designed to mimic specific region in the extracellular domain 
of the human P2Y2 receptor (Brown, 2001). The ability of the antibody fraction to bind 
strongly with the antigen (immunogen) suggests the reliability of the purification 
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system. However, SDS–PAGE, western blot analysis and immunohistochemistry or 
immunofluorescence experiments should be able to determine whether the purified 
fractions detect the immunogenic peptide in denatured as well as in their native 
environment in cells expressing human P2Y2 receptors.  
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CHAPTER 6 
 
WESTERN BLOT ANALYSIS OF P2Y RECEPTOR SUBTYPES 
 135
 
 
6.1 Introduction 
  
RT-PCR studies have shown the presence of mRNA transcripts for P2Y1, P2Y2, P2Y4, 
P2Y6, P2Y11, P2Y12 and P2Y13 in ECV304 cells. Likewise, RT-PCR studies of 
EAhy926 cells have indicated the presence of mRNA transcripts for P2Y2 and P2Y6 
which seems to confirm the predicted profile from the functional studies (Chapter 3). 
These studies provide a detailed profile of the P2Y receptor transcripts in 1321N1, 
ECV304 and EAhy926 cells. However, RT-PCR studies do not conclusively prove the 
functional level of protein expression (Moore et al., 2001). This has been confirmed by 
both the pharmacological studies and western blot analysis. Therefore, western blot 
analysis using P2Y receptor specific antibodies will be used to determine the functional 
protein expression. A point to note is that there were no antibodies available at the 
beginning of this project; which have subsequently became available during the course 
of the study. 
 
Thus western blot analysis will be carried out using polyclonal anti-P2Y antibodies for 
P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 obtained from commercial sources to 
establish which P2Y subtypes are expressed and to confirm the pharmacological data 
and expression of P2Y receptor mRNA transcripts. The novel antibody being used in 
this investigation is L247 anti-P2Y2 antibody, which is a rabbit polyclonal antibody, 
raised to immunogenic peptide L247, which is designed to mimic a specific region of 
third extracellular loop of human P2Y2 receptor. Therefore, the main aim of this study is 
the analysis and characteriszation of the anti-P2Y2 antibody by western blot analysis of 
epithelial ECV304 and endothelial cells EAhy926 and BAE cells, whivch known to 
express P2Y2 receptor. Thus western blot analysis will use immunogenic peptide in the 
native protein i.e in cells expressing human P2Y2 receptor to determine the specificity 
of the antibody fractions. In addition, L247 anti-P2Y2 antibody will be compared with 
two other polyclonal anti-P2Y2 antibodies obtained commercially. These studies have 
also included 1321N1 cell line as negative control. BRIN-BD11 cells will also be used 
in addition to BAE cells to study the cross species reactivity of the antibodies. 
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Moreover, this study is aimed to categorically establish the immunospecificity of L247 
anti-P2Y2 antibody with respect to others. 
 
It is well documented that the consensus pattern for a potential N-glycosylation is Asn-
Xaa-Ser/Thr or N – [P] - [ST] – [P], where – Asn (Asparagine) or (N) is the 
glycosylation site and –Xaa- represents a variable amino acid. However, the presence of 
the consensus tripeptide is not sufficient to conclude that an Asparagine residue is 
glycosylated, due to the fact that the folding of the protein plays an important role in the 
regulation of N-glycosylation (Pless and Lennarz, 1977). The presence of Proline 
between Asparagine (Asn) and Serine/ Threonine (Ser/Thr) has been shown to inhibit 
N-glycosylation (Bause, 1983; Gavel and Heijne, 1990). Three potential N-
glycosylation sites have been identified in P2Y2 receptors. These sites are situated at 
amino acid residues, 9 – 12 (NDTI), 13 – 16 (NGTW), 66 – 69 (NAST). Moreover, the 
importance of phosphorylation sites in the third intracellular loop and C-terminal tail of 
the P2Y2 receptor for agonist induced desensitisation has been well documented (Flores 
et al., 2005). Therefore it is possible for anti-P2Y2 antibodies to detect the receptor 
protein at higher molecular mass. Increased molecular mass has been attributed to N-
linked glycosylations in the extracellular domains in P2Y1 and P2Y2 receptors (Wang et 
al., 2002).  Likewise, a non–uniform distribution of P2Y2 receptor at higher molecular 
mass than that predicted has been reported in HA-tagged P2Y2 receptors in 1321N1 
cells, again ascribed to heterogeneous complex glycosylation (Flores et al., 2005). 
Moreover, recent studies have shown that N-linked glycosylation of the P2Y12 receptor 
is essential for signal transduction but not for ligand binding or cell surface expression 
(Zhong et al., 2004).  
 
Hence this study will incorporate potential deglycosylation analysis and subsequent 
protein sequencing of protein blots stained by L247 anti-P2Y2 and other anti-P2Y2 
antibodies to see if the resultant sequence matches that with human P2Y2 receptor. 
Alternatively, agonist induced desensitisation will be used to determine the 
immunospecificity of anti-P2Y2 antibodies. Additionally immunofluorescence analysis 
will be used to compare and analyse P2Y2 receptor localisation. 
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6.2 Materials and Methods 
 
6.2.1 Tissue culture 
 
ECV304, EAhy926, BAEC, 1321N1 and BRIN-BD11 cells were maintained as 
described in section 2.2.2. 
 
6.2.2 Protein extraction 
 
The extraction of membrane protein from ECV304, EAhy926, BAEC, 1321N1 and 
BRIN-BD11cells was carried out as described in section 2.6.1. 
 
6.2.3 Protein quantification 
 
Extracted membrane protein fractions were quantified for the protein concentration 
using a DC Protein Assay Kit (BIO-RAD). The concentration of the unknown sample 
was determined by comparing its absorbance at 690 nm to the standard curve prepared 
using BSA (Bovine Serum Albumin) protein standards as described in section 2.6.2. 
 
6.2.4 SDS-PAGE and western blot analysis 
 
The protein fractions were analysed by by loading 40µg of total protein in each well and 
reducing them in 10% Sodium dodecyl sulphate-polyacrylamide gel. The protein was 
then transferred electrophoretically onto nitrocellulose membranes and western blot 
analysis was performed on these membranes to determine the specificity of antibodies 
to P2Y receptors and to verify their expression in both human and bovine endothelial 
cells as described in section 2.6.3. 
  
6.2.5 Antibodies 
 
For details of antibodies used in this investigation see section 2.6.4. 
 
 138
6.2.6 Enzymatic N- deglycosylation 
 
ECV304 cells were deglycosylated using an N-Glycosidase F Deglycosylation Kit as 
described in section 2.6.5. 
 
6.2.7 Protein sequencing 
 
The protein sequencing was achieved by the established technique of Edman 
degradation as described in section 2.6.6 and was carried out by Alta Biosciences, 
University of Birmingham. 
 
6.2.8 Receptor desensitisation 
 
ECV304 cells were grown to 90% confluency in 75cm2 flasks under conditions 
described in section 2.2.2. The cells were incubated with 300μM of UTP and histamine 
for various time periods. Control cells were incubated without UTP to allow the normal 
binding of the antibody to the P2Y2 receptor. Cells were removed from the flasks and 
the protein was extracted and quantified as described in sections 2.6.1 and 2.6.2 
respectively. 
 
6.2.9 Immunofluorescence analysis 
 
The immunofluorescence analysis was performed as described in section 2.7. 
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6.3 Results 
 
6.3.1 Protein quantification 
 
The membrane protein fractions from ECV304, EAhy926, BAEC, 1321N1 and BRIN-
BD11cells were quantified for their protein concentration using the Bio-Rad DC 
(detergent compatible) protein assay kit. The concentration of the unknown sample was 
determined by comparing its absorbance at 690 nm to the standard curve prepared using 
BSA (Bovine Serum Albumin) protein standards, measured with a standard laboratory 
spectrophotometer or microplate reader. 
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Figure 6.1 A representative BSA (Bovine Serum Albumin) protein 
standards curve generated to determine the concentration of the unknown 
protein sample by comparing its absorbance at 690 nm. 
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6.3.2 Western blot analysis for protein loading control with α-Tubulin 
 
All the Western blotting experiments were performed on at least three different protein 
extractions from each cell type. As a protein loading control the western blot was 
performed for α-Tubulin and a strong single band at 50-64kDa (Fig 6.2) was observed 
in all the cell types.  
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Figure 6.2 Western blot analysis of cell extracts using Mouse 
Monoclonal Anti- α- Tubulin Clone B-5-1-2 AT 1:2500 dilution as a 
protein loading control. Lane 1. Pre Stained Standards; Lane 2. 
1321N1 cell extracts; Lane 3. ECV304 cell extracts; Lane 4. EAhy926 
cell extracts; Lane 5. BAE cell extracts; Lane 6. BRIN-BD11 cell 
extracts. Data are representative of three independent experiments. 
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 6.3.3 Western blot analysis using anti-P2Y2 antibodies 
 
Western blot analysis was performed using L247 anti-P2Y2 antibody, the novel 
antibody used in this study which was raised in rabbit to a peptide 
(RSLDLSCHTLNAIN) designed to the third extracellular loop of the human P2Y2 
receptor. ImageQuantTm TL software was used to detect and to calibrate the molecular 
weights of the bands in western blot analysis using anti-P2Y antibodies. Once the 
values are assigned to the bands of the standard lane (lane with known values of 
molecular weight for its bands), the software interpolate and extrapolate contour lines of 
known molecular weight horizontally across the gel image. After the horizontal 
contours have been determined, the software uses the selected curve-fitting algorithm to 
determine the relationship of molecular size to a position along the lane for all the 
points in all the lanes to determine the molecular size of any given band in any of the 
lanes. 
 
Results show that no band was observed in the extracts of cell line, 1321N1. A single 
band was observed at 84 kDa in ECV304 and EAhy926 cell extracts and a single band 
was observed at 92 kDa in BAEC and BRIN-BD11 cell extracts (Figure 6.3). In western 
blots where membranes had been preincubated with L247 peptide, bands were observed 
in BAEC and BRIN-BD11 cell extracts at 92 kDa (Figure 6.4). 
 
Western blot analysis using rabbit anti-P2Y2 receptor antibody from Santacruz 
Biotechnology (Sc-20124) showed a strong band in addition to multiple bands in all cell 
extracts including 1321N1 cells, where these cell extracts showed a strong band at 52 
kDa with other weak bands at 57 kDa and 76 kDa. A strong band was detected at 53 
kDa and a weaker band detected at 77 kDa in ECV304 cell extracts. A strong band was 
detected at 52 kDa and weaker bands detected at 47 kDa and 78 kDa in EAhy926 cell 
extract. A strong band was detected at 54 kDa in BAE cell extracts. Two strong bands 
were detected at 49 kDa and 54 kDa in BRIN-BD11 cell extracts (Figure 6.5). Western 
blot analysis with rabbit anti-P2Y2 receptor antibody obtained from Zymed Laboratories 
(34-7600) detected a strong band at 148 kDa in ECV304 cell extracts. However, a weak 
band was also detected at 58 kDa in Eahy926 cell extracts. A weak band at 210 kDa was 
also detected in BAE cell extracts, whilst weak bands were observed at 57 kDa, 65 kDa, 
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94 kDa, 150 kDa and 199 kDa in BRIN-BD11 cell extracts (Figure 6.6). Western blot 
analysis using swine anti-rabbit HRP as a negative control for all rabbit P2Y receptor 
subtype polyclonal antibodies did not produce any bands (data not shown). 
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Figure 6.3 Western blot analysis of cell extracts using 5 μg/ml of 
anti-L247 antibody to the P2Y2 receptor.  Lane 1. Pre Stained 
Standards;  Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell 
extracts;  Lane 4. EAhy926 cell extracts;  Lane 5. BAE cell 
extracts; Lane 6. BRIN-BD11 cell extracts. Data are representative 
of three independent experiments.
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Figure 6.4 Western blot analysis of cell extracts using 5 μg/ml of anti- 
L247 antibody to the P2Y2 receptor with peptide control (Anti-P2Y2 
antibody preabsorbed with peptide antigen). Lane 1. Pre Stained 
Standards;  Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell 
extracts;  Lane 4. EAhy926 cell extracts;  Lane 5. BAE cell extracts; 
Lane 6. BRIN-BD11 cell extracts.  Data are representative of three 
independent experiments. 
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Figure 6.5 Western blot analysis of cell extracts using 2 μg/ml of anti- 
P2Y2 antibody (Santa Cruz Biotechnology).  Lane 1. Pre Stained 
Standards;  Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell 
extracts;  Lane 4. EAhy926 cell extracts;  Lane 5. BAE cell extracts; 
Lane 6. BRIN-BD11 cell extracts. Data are representative of three 
independent experiments. 
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Figure 6.6 Western blot analysis of cell extracts using 10 μg/ml of 
anti-P2Y2 antibody (Zymed).  Lane 1. Pre Stained Standards;  Lane 
2. 1321N1 cell extracts;  Lane 3. ECV304 cell extracts;  Lane 4. 
EAhy926 cell extracts;  Lane 5. BAE cell extracts; Lane 6. BRIN-
BD11 cell extracts. Data are representative of three independent 
experiments. 
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  6.3.4 Western blot analysis using anti-P2Y2 antibodies for protein sequencing 
 
Western blot analysis was performed using L247 anti-P2Y2 antibody and other anti-
P2Y2 receptor rabbit polyclonal antibodies on PVDF membrane for protein sequencing. 
All the anti-P2Y2 antibodies including L247 anti-P2Y2 antibody showed bands in the 
same region as reported in section 6.3.3. The anti-P2Y2 antibody raised to L247 peptide 
mimicking the third extracelluar loop of P2Y2 receptor revealed a strong band of 84 kDa 
(Figure 6.7). Western blot analysis with rabbit anti-P2Y2 receptor antibody from 
Santacruz Biotechnology (Sc-20124) yielded a strong band at 52 kDa and another very 
faint band at 76 kDa (Figure 6.8, Lane 3). Western blot analysis with a high 
concentration (10μg/ml) of rabbit anti-P2Y2 receptor antibody obtained from Zymed 
Laboratories (34-7600) yielded a strong band at 148 kDa and a weaker band at 65 kDa 
(Figure 6.9, Lane 3). The protein blots from the unused sections of PVDF membranes 
corresponding to the region stained with anti-P2Y2 antibodies were used for protein 
sequencing. 
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Figure 6.7 Western blot analysis of ECV304 cell extracts 
using L247 anti-P2Y2 antibody.  Lane 1. Pre Stained 
Standards; Lane 2. ECV304 cell extracts (non western blot 
membrane for Micro Sequencing); Lane 3. ECV304 cell 
extracts;  Lane 4. Pre Stained Standards. Data are 
representative of three independent experiments.
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Figure 6.8 Western blot analysis of ECV304 cell extracts 
using anti-P2Y2 antibody (Santa Cruz Biotechnology). Lane 1. 
Pre Stained Standards; Lane 2. ECV304 cell extracts (non 
western blot membrane for Micro Sequencing);  Lane 3. 
ECV304 cell extracts;  Lane 4. Pre Stained Standards. Data 
are representative of three independent experiments. 
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Figure 6.9 Western blot analysis of ECV304 cell extracts 
using anti-P2Y2 antibody (Zymed). Lane 1. Pre Stained 
Standards; Lane 2. ECV304 cell extracts (non western blot 
membrane for Micro Sequencing);  Lane 3. ECV304 cell 
extracts;  Lane 4. Pre Stained Standards. Data are 
representative of three independent experiments. 
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6.3.5 Protein sequencing 
 
The protein sequencing with the blot corresponding to the region stained with L247 
anti-P2Y2 antibody did not detect any amino acid residues. Large amounts of glycine 
were observed in the first few cycles. As the signals with other anti-P2Y2 antibodies 
from Santacruz Biotechnology (Figure 6.8) and Zymed Laboratories (Figure 6.9) were 
weaker than those obtained for L247 anti-P2Y2 antibody the blots corresponding those 
weaker regions were not sequenced. 
 
6.3.6 Western blot analysis of digested cell extracts using L247 anti-P2Y2 antibody  
 
The western blot analysis for P2Y2 receptor in ECV304 cell extracts with L247 Anti-
P2Y2 antibody revealed a strong protein band at 84 kDa (Figure 6.10). However, in the 
digested (upon digestion with N-glycosidase F Kit) ECV304 cell extracts 
(deglycosylated receptor protein), the band was weaker and was reduced to 80 kDa 
(Figure 6.10). 
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Figure 6.10 Western blot analysis of ECV304 cell extracts for 
deglycosylated P2Y2 receptor using L247 anti-P2Y2 antibody. 
Lane 1. Protein Molecuar Weight Markers;  Lane 2. 
Undigested control glycoproteins;  Lane 3. Digested control 
glycoproteins; Lane 4. Undigested ECV304 cell extracts;  Lane 
5. Digested ECV304 cell extracts. Data are representative of 
three independent experiments. 
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6.3.7 Western blot analysis of digested cell extracts using anti-P2Y2 antibodies for 
protein sequencing 
 
The protein fractions from a sodium dodecyl sulphate-polyacrylamide gel were 
transferred onto Sequi-Blot PVDF membrane (BIO RAD) for protein sequencing. As 
reported in section 6.3.6 the digested ECV304 protein extracts showed a weaker band at 
80 kDa with L247 anti-P2Y2 antibody (Figure 6.11). The anti-P2Y2 antibody obtained 
from Santacruz Biotechnology detected two bands in ECV304 cell extracts which, 
however, did not change from those observed in undigested ECV304 cell extracts 
(Figure 6.12). The results with anti-P2Y2 antibody obtained from Zymed yielded two 
very weak bands at a concentration of 10μg/ml also did not change from those observed 
in undigested ECV304 cell extracts (Figure 6.13). For the purpose of microsequencing, 
pictures of the blots were taken immediately using digital camera and the blots were 
stored in -200C. The poor quality of the pictures was due to the translucent nature of 
Sequi-Blot PVDF membrane resulting in the poor capture of the protein bands by digital 
photography. The protein blots from Sequi-Blot PVDF membranes (not used for 
western blot analysis) corresponding to the region stained with anti-P2Y2 antibodies 
were used for protein sequencing. 
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Figure 6.11 Western blot analysis of deglycosylated P2Y2 receptor 
with L247 anti-P2Y2 antibody in ECV304 cell extracts. Lane 1. 
Protein Molecuar Weight Markers;  Lane 2. See Blue Plus 2 Pre 
Stained Standards; Lane 3. Undigested control glycoproteins;  
Lane 4. Digested control glycoproteins; Lane 5. Undigested 
ECV304 cell extracts;  Lane 6. Digested ECV304 cell extracts. Lane 
7. See Blue Plus 2 Pre Stained Standards; Lane 8. Digested 
ECV304 cell extarcts for Micro Sequencing. Data are 
representative of three independent experiments. 
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  Figure 6.12 Western blot analysis of deglycosylated P2Y2 with anti-
P2Y2 antibody (Santa Cruz Biotechnology) in ECV304 cell extracts. 
Lane 1. See Blue Plus 2 Pre Stained Standards; Lane 2. Undigested 
ECV304 cell extracts;  Lane 3. Digested ECV304 cell extracts. Lane 
4. See Blue Plus 2 Pre Stained Standards; Lane 5. Digested ECV304 
cell extracts for Micro Sequencing. Data are representative of three 
independent experiments. 
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 Figure 6.13 Western blot analysis of deglycosylated P2Y2 with anti-
P2Y2 antibody (Zymed) in ECV304 cell extracts. Lane 1. See Blue 
Plus 2 Pre Stained Standards; Lane 2. Undigested ECV304 cell 
extracts;  Lane 3. Digested ECV304 cell extracts. Lane 4. See Blue 
Plus 2 Pre Stained Standards; Lane 5. Digested ECV304 cell extracts 
for Micro Sequencing. Data are representative of three independent 
experiments. 
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6.3.8 Protein sequencing of deglycosylated P2Y2 receptor 
 
The results of protein sequencing of the protein blot corresponding to the region stained 
with L247 anti-P2Y2 antibody (5μg/ml) in western blot analysis detected the following 
amino acid residues. However, the micro sequencing of protein blots corresponding to 
the region stained with anti-P2Y2 antibody from Santa Cruz Biotechnology did not 
detect any amino acid residues. As the protein band produced by anti-P2Y2 antibody 
from Zymed was very weak even at higher concentration of the antibody used 
(10μg/ml), the blot was not sequenced as advised by the service provider. 
 
 
 
 
 
 
 
 
 
  
Residue Amino Acid Single Letter Code 
1 --- --- 
2 Asp? D 
3 Arg R 
4 Ile I 
5 Lys K 
6 Asp D 
7 Glu E 
8 Phe F 
9 Gln Q 
10 Leu? L 
Table 6.1 Amino acid residues obtained after N-
terminal protein sequencing by Alta Biosciences. The 
identity of Asp and Leu is not certain. 
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 The above sequence was used to identify and find similarity between matching protein 
sequences using Basic Local Alignment Search Tool (BLAST). The results indicate that 
the sequence (DRIKDEFQL) matches the amino acid residues 94-102 of human amino-
terminal enhancer of split isoform a (gi number: 39812019), 27-35 of human amino-
terminal enhancer of split isoform c (gi number: 39812027), 27-35 of amino-terminal 
enhancer of split isoform b (gi number: 5706731), 26-34 of gp130 associated protein 
GAM (gi number: 3309589), 27-34 of transducin-like enhancer of split 3 splice variant 
2 (gi number: 46391802), 27-34 of transducin-like enhancer of split 3 splice variant 1 
(gi number: 46391800), 27-34 of TLE3 protein (gi number: 34783362), 27-34 of 
Transducin-like enhancer protein 3 (gi number: 20532417), 27-34 of transducin-like 
enhancer protein 3 (gi number: 4827030), 33-40 of TLE3 protein (gi number: 
27469815), 130-137 of KIAA1547 protein (gi number: 10047159), 54-61 (87%) of 
transducin-like enhancer protein 1 variant (gi number: 62089294). 
 
6.3.9 Receptor desensitisation 
 
The P2Y2 receptor was subjected to agonist induced desensitisation and the cell extracts 
expressing the P2Y2 receptor were used in western blot analysis. The results of western 
blot analysis suggested that extracellular UTP caused P2Y2 receptor desensitisation 
after a 1 hour incubation with 300μM UTP (Figure 6.14) as the protein staining bands in 
the cells incubated with UTP for an hour were almost abolished. However, the protein 
staining bands in control cells were unaffected (Figure 6.14). Notably, the cells 
incubated with UTP for 24 hours showed a prominent binding in response to anti-P2Y2 
antibody and appeared to be of higher intensity (Figure 6.14). However, incubation of 
the cells with histamine for similar time periods shows no such masking of protein 
staining bands both in cells incubated for 1 hour and 24 hours (Figure 6.15). Altough 
the bands in lane 2 and 3 (Figure 6.15) are eclipsed by a blot, ImageQuantTm TL 
software was used to detect and to calibrate the molecular weights of the bands. 
 
This receptor desensitisation study was also used to investigate receptor specificity of 
anti-P2Y2 antibody obtained from Santa Cruz Biotechnology. This anti-P2Y2 receptor 
antibody detected a strong band at 52 kDa and a weaker band at 76 kDa (Figure 6.16). 
There was no observed desensitisation of the weak band as there was no difference in 
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the protein staining between control cells and cells incubated with UTP for 1 hour 
(Figure 6.16). However, the cells incubated with UTP for 24 hours showed prominent 
bands (Figure 6.16). Similarly, in the case of the strong band at 52 kDa there was no 
noticeable desensitisation effect. There appeared to be no difference in the band 
intensity between cells incubated with UTP for an hour and control cells (Figure 6.16). 
In this case too, the protein staining bands were prominent in cells incubated with UTP 
for 24 hours (Figure 6.16). Interestingly, in the cells incubated with histamine the bands 
produced at 52 kDa and 76 kDa were almost identical (Figure 6.17). Moreover, there 
was no discernible difference in protein staining bands between control cells and cells 
incubated for an hour or 24 hours (Figure 6.17). 
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 Figure 6.14 Western blot analysis of ECV304 cell extracts using 5 
μg/ml of L247 anti-P2Y2 antibody. Lane 1. See Blue Plus 2 Pre 
Stained Standards; Lane 2&3. Untreated ECV304 cell extracts;  
Lane 4&5. ECV304 cell extracts incubated with 300μM UTP for 1 
hour;  Lane 6&7. ECV304 cell extracts incubated with 300μM U
for 24 hours; Data are representative of three independent 
experiments. 
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Figure 6.15 Western blot analysis of ECV304 cell extracts using 5 
μg/ml of L247 anti-P2Y2 antibody. 1. See Blue Plus 2 Pre Stained 
Standards; Lane 2&3. Untreated ECV304 cell extracts;  Lane 4&5. 
ECV304 cell extracts incubated with 300μM Histamine for 1 hour;  
Lane 6&7. ECV304 cell extracts incubated with 300μM Histamine 
for 24 hours; Data are representative of three independent 
experiments. 
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  Figure 6.16 Western blotting analysis for P2Y2 with anti-P2Y2 
antibody (Santa Cruz Biotechnology) in ECV304 cells. 1. See Blue 
Plus 2 Pre Stained Standards; Lane 2&3. Untreated ECV304 cells;  
Lane 4&5. ECV304 cells incubated with 300μM UTP for 1 hour;  
Lane 6&7. ECV304 cells incubated with 300μM UTP for 24 hours; 
Data are representative of three independent experiments. 
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Figure 6.17 Western blotting analysis for P2Y2 with anti-P2Y2 
antibody (Santa Cruz Biotechnology) in ECV304 cells. 1. See Blue 
Plus 2 Pre Stained Standards; Lane 2&3. Untreated ECV304 cells;  
Lane 4&5. ECV304 cells incubated with 300μM Histamine for 1 
hour;  Lane 6&7. ECV304 cells incubated with 300μM Histamine for 
24 hours; Data are representative of three independent experiments. 
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6.3.10 Western blot analysis using anti-P2Y1 antibody 
 
Western blot analysis of the electrophoretically transferred protein extracts with anti-
P2Y1 antibody (P6487-Sigma) showed no band in 1321N1, ECV304 and BAE cells. 
However, strong bands were detected at 52 kDa in both EAhy926 and BRIN-BD11 cell 
extracts (Figure 6.18). 
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Figure 6.18 Western blot analysis of cell extracts using anti-P2Y1 
antibody (Sigma) at 1μg/ml.  Lane 1. Pre Stained Standards;  Lane 2. 
1321N1 cell extracts;  Lane 3. ECV304 cell extracts;  Lane 4. EAhy926 
cell extracts;  Lane 5. BAE cell extracts; Lane 6. BRIN-BD11 cell 
extracts. Data are representative of three independent experiments. 
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6.3.11 Western blot analysis using anti-P2Y4 antibody  
 
Western blot analysis using rabbit anti-P2Y4 receptor antibody from Santacruz 
Biotechnology showed strong multiple bands in all cell extracts including 1321N1 cells. 
Results show strong protein bands at 37 kDa, 51 kDa, 55 kDa, 64 kDa, 78 kDa in 
1321N1 cell extracts (Figure 6.19). Strong bands were detected at 36 kDa, 50 kDa, 58 
kDa and 70 kDa in ECV304 cell extracts while strong bands were detected at 51 kDa, 
60 kDa, and 64 kDa in EAhy926 cell extracts (Figure 6.19). Strong bands were detected 
at 51 kDa, 53 kDa and 58 kDa in BAE cell extracts and at 35 kDa, 50 kDa and 63 kDa 
in BRIN-BD11 cell extracts (Figure 6.19). 
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Figure 6.19 Western blot analysis of cell extracts using anti-P2Y4 antibody 
(Santacruz Biotechnology) at 4μg/ml.  Lane 1. Pre Stained Standards;  
Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell extracts;  Lane 4. 
EAhy926 cell extracts;  Lane 5. BAE cell extracts; Lane 6. BRIN-BD11 
cell extracts. Data are representative of three independent experiments. 
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6.3.12 Western blot analysis using anti-P2Y6 antibody  
 
Results of the western blot studies using rabbit anti-P2Y6 receptor antibody from 
Santacruz Biotechnology show strong protein bands in all cell extracts used including 
1321N1. Strong bands were detected at 51 kDa, 62 kDa and 78 kDa in 1321N1 cells 
(Figure 6.20). Likewise, strong bands were detected at 39 kDa, 53 kDa, 65 kDa and 80 
kDa in ECV304 cell extracts and at 52 kDa, 71 kDa and 83 kDa in EAhy926 cell 
extracts (Figure 6.20). Strong bands were detected at 53 kDa, 61 kDa, 69 kDa and 83 
kDa in BAE cell extracts and at 52 kDa, 61 kDa, 72 kDa, 82 kDa and 122 kDa in 
BRIN-BD11 cell extracts (Figure 6.20).  
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Figure 6.20 Western blot analysis of cell extracts using anti-P2Y6 
antibody (Santacruz Biotechnology) at 3.5μg/ml. Lane 1. Pre Stained 
Standards;  Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell 
extracts;  Lane 4. EAhy926 cell extracts;  Lane 5. BAE cell extracts; 
Lane 6. BRIN-BD11 cell extracts. Data are representative of three 
independent experiments. 
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6.3.13 Western blot analysis using anti-P2Y11 antibody  
 
Western blot analysis using rabbit anti-P2Y11 receptor antibody from Affinity 
Bioreagents did not yield any strong protein bands in any of the samples of cell extracts. 
However, some weak bands were observed at 101 kDa and 114 kDa in 1321N1 cell 
extracts, at 44 kDa and 60 kDa in ECV304 cell extracts, at 60 kDa, 88 kDa, 114 kDa 
and 132 kDa in EAhy926 cell extracts, at 65.12 kDa in BAE cell extracts and at 120 
kDa in BRIN-BD11 cell extracts (Figure 6.21).  
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Figure 6.21 Western blot analysis of cell extracts using anti-P2Y11 
antibody (Affinity Bioreagents). Lane 1. Pre Stained Standards;  
Lane 2. 1321N1 cell extracts;  Lane 3. ECV304 cell extracts;  Lane 4. 
EAhy926 cell extracts;  Lane 5. BAE cell extracts; Lane 6. BRIN-
BD11 cell extracts. Data are representative of three independent 
experiments. 
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6.3.14 Western blot analysis using anti-P2Y12 antibody 
 
Results of the western blot studies using rabbit anti-P2Y12 receptor antibody from 
Sigma  did not detect any bands in 1321N1, ECV304, EAhy926, BAEC or BRIN-BD11 
cell extracts (Figure 6.22).  
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 Figure 6.22 Western blot analysis of cell extracts using anti-P2Y12 
antibody (Sigma). Lane 1. Pre Stained Standards;  Lane 2. 1321N1 cell 
extracts;  Lane 3. ECV304 cell extracts;  Lane 4. EAhy926 cell 
extracts;  Lane 5. BAE cell extracts; Lane 6. BRIN-BD11 cell extracts. 
Data are representative of three independent experiments. 
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6.3.15 Western blot analysis using anti-P2Y13 antibody  
 
Western blot analysis using rabbit anti-P2Y13 receptor antibody from Acris Antibodies 
detected strong bands at 115 kDa in 1321N1 cell extracts. Strong bands were detected at 
115 kDa and weaker bands at 47 kDa and 79 kDa in ECV304 cell extracts. Strong bands 
were detected at 74 kDa and 120 kDa in EAhy926 cell extracts.  A strong band was 
detected at 123 kDa in BAE cell extracts and weaker bands were detected at 49 kDa and 
118 kDa in BRIN-BD11 cell extracts (Figure 6.23).  
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Figure 6.23 Western blot analysis of cell extracts using anti-P2Y13 
antibody (Acris). Lane 1. Pre Stained Standards;  Lane 2. 1321N1 cell 
extracts;  Lane 3. ECV304 cell extracts;  Lane 4. EAhy926 cell extracts;  
Lane 5. BAE cell extracts; Lane 6. BRIN-BD11 cell extracts. Data are 
representative of three independent experiments. 
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Table 6.2 Summary of RT-PCR and western blot results of P2Y receptor 
subtypes in 1321N1, ECV304, EAhy926, BAE and BRIN-BD11 cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Receptor 
Type Cell Type 
 1321N1 ECV304 EAhy926 BAEC BRIN-BD11
 PCR WB PCR WB PCR WB PCR WB PCR WB 
P2Y1 - - + - - + - - - + 
P2Y2 - - + + + + - + - + 
P2Y4 
 - + + + - + - + - + 
P2Y6 
 - + + + + + - + - + 
P2Y11 
 - + + + - + - + - + 
P2Y12 
 - - + - - - - - - - 
P2Y13 
 - + + + - + - + - + 
P2Y14 
 -  -  -  -  -  
+: Positive result; -: Negative result 
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6.3.16 Immunofluorescence analysis of  ECV304 cells using anti-P2Y2 antibodies 
 
Immunofluorescence analysis was performed in ECV304 cells using anti-P2Y2 
antibodies. The data obtained using L247 anti-P2Y2 antibody suggests that this antibody  
detects proteins in the cell membrane and the nucleus (Figure 6.24). However, it is 
difficult to quantify the degree of binding with these results. These studies were also 
extended to other anti-P2Y2 antibodies and the results suggest that the antibodies 
obtained from Santacruz Biotechnology and Zymed (Figure 6.26 & 6.27) stain the cells 
in a manner similar to L247 anti-P2Y2 antibody. In the control experiments no signal 
was observed when only the secondary antibody was used (Figure 6.25). 
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Figure 6.24 Immunofluorescence analysis of P2Y2 receptor using L247 
anti-P2Y2 antibody at 1:200 dilution range in ECV304 cells. Data are 
representative of three independent experiments. 
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Figure 6.25 Negative control for immunofluorescence analysis of P2Y2 
receptor in ECV304 cells. Data are representative of three independent 
experiments. 
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 Figure 6.26 Immunofluorescence analysis of P2Y2 receptor using anti-
P2Y2 antibody (Santa Cruz Biotechnology) at 1:400 dilution range in 
ECV304 cells. Data are representative of three independent experiments. 
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Figure 6.27 Immunofluorescence analysis of P2Y2 receptor using anti-
P2Y2 antibody (Zymed) at 3μg/ml dilution range in ECV304 cells. Data 
are representative of three independent experiments. 
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6.4 Discussion 
 
This study aimed to evaluate the expression of P2Y receptors in human epithelial and 
endothelial cells using western blot analysis. Rabbit anti-P2Y receptor subtype 
antibodies were used including a rabbit polyclonal anti-P2Y2 antibody raised to L247 
peptide (a peptide that mimics the third extracelluar loop of the human P2Y2 receptor).  
 
Anti-P2Y2 antibody raised against the peptide L247 revealed strong immunoreactivity 
in ECV304, EAhy926, BAEC and BRIN-BD11 cells. These responses were antigen 
specific in ECV304 and EAhy926 cell extracts as the pre-absorption with the 
immunogenic peptide abolished these responses.  This suggests that the antibody is 
immunogen specific and that it recognises human P2Y2 receptor reported to be 
expressed in ECV304 and EAhy926 cells  (Graham et al., 1996a; Graham et al., 1996b; 
Brown et al., 2000; Paul et al., 2000; Brown, 2001). Furthermore, ECV304 and 
EAhy926 cells have also been shown to transcribe P2Y2 mRNA (Chapter 4). The band 
observed for BAE cells, however, after pre-absorption with immunogenic peptide did 
not disappear. Pharmacological studies using BAE cell extracts have been reported that 
they express P2Y2-like receptors. However, molecular biology studies with bovine P2Y 
receptor specific primers and antibodies are necessary to determine expression of P2Y 
receptors in these cells. The calculated molecular weight of the human P2Y2 receptor is 
42.14 kDa. Studies have reported a band size of 45-47 kDa (Santacruz Biotech). 
Immunoreactivity at higher molecular masses has been reported in response to anti-
P2Y2 antibodies in endothelial cells (36 and 50 kDa) and is possibly due to 
glycosylation (Wang et al., 2002).  
 
Immunoprecipitation of HA-tagged P2Y2 receptor expressed in 1321N1 cells has shown 
a non–uniform distribution of the receptor (57-76 kDa and a single band of 45 kDa) 
because of heterogeneous complex glycosylation (Flores et al., 2005). The bands 
observed in BRIN-BD11 cell extracts may be of non specific nature. The immunogenic 
peptide sequence also corresponds to amino acid residues 271-284 of P2Y2 receptor of 
Norway rat (gi: 38197686), which may explain the cross species reactivity in BRIN-
BD11 cells.  
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Rabbit anti-P2Y2 receptor antibodies from commercial sources produced 
immunoreactive profiles with multiple bands (at different molecular mass) in ECV304 
and EAhy926 cells. The immunoreactive profile was different than that yielded by L247 
anti-P2Y2 antibody and without peptide control it is not possible to characterise the 
specificity of these antibodies. These antibodies also showed immunoreactivity with 
1321N1, BAEC and BRIN-BD11 cells. The results obtained with commercial 
antibodies show a different immunoreactivity profile and do not appear to be receptor 
specific. In conclusion, these results suggest that L247 anti-P2Y2 antibody is receptor 
specific. However, western blot analysis with peptide control is necessary to 
characterise the immunoreactivity of commercial antibodies.  
 
Immunofluorescence analysis using anti-P2Y2 antibodies in ECV304 cells show that 
L247 anti-P2Y2 antibody strongly binds to these cells. The widespread binding makes it 
difficult to localise cellular compartments and the degree of binding with these results. 
However, based on this result it appears that this antibody strongly stains the membrane 
and the nucleus. Immunofluorescence results obtained using other commercial anti-
P2Y2 antibodies suggest that they too bind to the cell membrane and nucleus in a 
manner similar to L247 anti-P2Y2 antibody. Most of these commercially available 
antibodies are poorly characterised with only immunohistochemistry or 
immunfluorescence assays. These assays only confirm immunoreactivity of these 
antibodies with the non-denatured (intact) receptor. Therefore, even though these 
antibodies may be recepor specific their lack of immunoreactivity with denatured 
receptor in western blot analysis limit their usefulness as a diagnostic tool in receptor 
pharmacology.  
 
Based on results of western blot analysis of ECV304 cell extracts, it appears that the 
P2Y2 receptor protein is glycosylated in these cells. The reduced band size from 84 kDa 
to 80 kDa of the protein post-deglycosylation confirms this. Glycosylation of P2Y 
receptors has been reported in previous studies where immunoprecipiation of the HA-
tagged P2Y2 receptor expressed in 1321N1 cells revealed a non uniform distribution of 
the receptor protein typical of membrane glycoproteins with heterogenous complex 
glycosylation. Asparagine linked high mannose carbohydrates as well as hybrid and 
complex oligosaccharides were proposed to be the glycoproteins (Flores et al., 2005).  
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The agonist induced P2Y2 receptor sequestration/down-regulation studies were used to 
analyse the immunospecificity of anti-P2Y2 antibody. The reduction in the ability of the 
anti-P2Y2 antibody to stain protein bands as a result of sequestration/down-regulation in 
protein extract from ECV304 cells after 1 hour preincubation with 300μM UTP suggest 
that the L247 anti-P2Y2 antibody is P2Y2 receptor specific. However, L247 anti-P2Y2 
antibody produced strong immunoreactivity in cells after a prolonged (24 hour) agonist 
incubation which appears to be of higher intensity. Further investigations are required to 
determine why this happens. The pre-treatment of cells with agonist causes the rapid 
weakening of the stimulated response known as receptor desensitisation. This may also 
lead to receptor sequestration whereby the receptor selectively loses its capacity to bind 
hydrophilic (membrane-impermeable ligands) but not hydrophobic ligands due to rapid 
internalization of the surface receptor. Furthermore, the prolonged incubation (>1 h) 
with the agonist is shown to cause the down-regulation of the receptor, resulting in 
reduction in the receptor number (Yu et al., 1993). Desensitisation and sequestration are 
thought to be reversible upon the removal of agonist (Yu et al., 1993). However, the 
results from this study suggest that because of the nature of prolonged incubation, the 
agonist may have been degraded by ectonucleotidases and therefore not present at 24 
hours. This may explain the strong immunoreactivity seen with cell extracts after 
prolonged (24 hour) agonist incubation. 
 
Phosphorylation of β2- adrenergic receptors has been reported in agonist induced 
desensitisation and sequestration of the receptors from the cell surface. These studies 
suggested that the desensitisation of β2- adrenergic receptors was independent of 
sequestration (Hausdorff et al., 1990; Campbell et al., 1991). Sequestration is thought to 
be essential to facilitate resensitization of the receptors by a process involving 
dephosphorylation and subsequent recycling of the receptor back to the cell surface. 
Sequestration-defective mutant β2- adrenergic receptors were unable to resensitise 
(Barak et al., 1994). Agonist-induced desensitisation and internalization (sequestration) 
of P2Y2 receptors has also been reported in HA-tagged P2Y2 receptors expressed in 
1321N1 cells. Removal of agonist from the medium resulted in recovery of cell surface 
immunoreactivity to control levels within approximately 1 hour.  Desensitisation was 
more rapid and occurred to a greater extent than the agonist induced loss of surface 
receptors (Sromek and Harden, 1998). 
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  Human P2Y2 receptors have also been reported to undergo UTP induced homologous 
receptor desensitization in receptors expressed in 1321N1 astrocytoma cells as well as 
in human A431 cells which endogenously express P2Y2 receptor (Velázquez et al., 
2000). Furthermore, potent P2Y2 receptor desensitization observed in human 1321N1 
astrocytoma cells expressing recombinant wild type and C-terminal truncation mutants 
of the P2Y2 receptor was not related to depletion of calcium from intracellular stores. 
The same study also reported that the phosphorylation / dephosphorylation regulate 
receptor desensitization/resensitization; and phosphorylation of the C-terminus of the 
P2Y2 receptor by protein kinases other than protein kinase C mediates agonist-induced 
receptor desensitization (Otero et al., 2000). The involvement of protein kinase C 
(PKC) has also been ruled out in sequestration of P2Y2 receptor after co-incubation with 
protein kinase C activator, phorbol 12-myristate 13-acetate (PMA) and UTP produced 
sequestration similar to that obtained with UTP alone (Garrad et al., 1998).  
 
Wild-type P2Y2 receptor expressed in 1321N1 cells have been shown to desensitise and 
sequester in a time-dependant manner when treated with UTP. These studies also 
reported resensitisation of a sequestered receptor truncated by 30 amino acids from C-
terminal to resist desensitisation. Notably, this mutant P2Y2 receptor was treated for 
more than 3 hours with agonist to bring about sequestration, which might have involved 
receptor down-regulation (Garrad et al., 1998). 
 
Later studies, however, reported that phosphorylation leads to receptor desensitisation 
and internalisation. Truncation of three potential GRK and PKC phosphorylation sites 
in C-terminus and the third intracellular loop (S243, T344, S356) to alanine reduced 
agonist-induced receptor phosphorylation as well as the efficacy of UTP to desensitize 
P2Y2 receptor signalling to intracellular calcium mobilization, a finding suggestive of 
the importance of C-terminus for receptor desensitation and sequestration (Garrad et al., 
1998). Agonist induced desensitisation involving an increase in receptor 
phosphorylation was reported in HA-tagged P2Y2 receptor expressed in 1321N1 cells in 
which agonist induced internalisation of the P2Y2 receptor was impaired after truncation 
of potential phosphorylation sites (Flores et al., 2005).  
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Notably, in the above study an unphosphorylated 45 kDa protein band was produced in 
agonist stimulated, detergent solubilised, total cell extracts suggesting unglycosylated 
receptors from intracellular membranes are not accessible to phosphorylation (Flores et 
al., 2005). However in this study no bands were observed at lower molecular mass 
which may be due to the fact that specially extracted membrane protein were used in 
this study. As reported by Garrad, et al., 1998, where P2Y2 receptors were resensitised 
even after 3hours of agonist stimulation, in this study too P2Y2 receptors which 
underwent prolonged agonist stimulation (24 hours) were resensitised. This may suggest 
that UTP stimulation for an hour just causes the cells to sequester/internalise so they are 
inaccessible for L247 anti-P2Y2 antibody. However, over a period of 24 hours the 
receptors are recycled back to the surface and hence the binding with the antibody. 
 
Irrespective of whether internalisation was due to sequstration or down-regulation or 
whether this process involves receptor phosphorylation, it is true that the antibody 
exhibits immunospecificity with the P2Y2 receptor. In addition to the results obtained 
with antigen control, these studies strongly suggest that L247 anti-P2Y2 antibody shows 
strong immunoreactivity with P2Y2 receptors. Besides, the protein extract from the cells 
preincubated with histamine for similar time periods showed no such masking of 
protein staining as observed by their strong bands. However, the desensitisation effect 
was not observed in protein extracts using anti-P2Y2 antibody from Santa Cruz 
Biotechnology. There was no visible difference between the bands produced by the 
antibody in control cells and cells challenged with agonist for 1 hour. Thus, suggesting 
that this antibody may not be binding to the P2Y2 receptor. 
In this study, the sequence obtained through Edman sequencing does not show 
homology with the P2Y2 receptor sequence. This is probably as a result of sequencing 
of some other protein expressed in close proximity to P2Y2 receptor molecular range 
and/or which may be present in higher concentration. However, based on this result it 
cannot be said if the rank order of protein quantity determines the sequence during 
Edman sequencing. Alternatively, based on the protein sequencing results it may also 
appear that P2Y2 receptor protein is associated with some other protein as the resultant 
amino acid residues from protein sequencing do not match the sequence of P2Y2 
receptor. 
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Furthermore, the sequence DRIKDEFQL or RIKDEFQ - as the identity of D and L is 
not certain - aligned with the human amino-terminal enhancer of split isoform a, b and c 
(gi: 39812019; gi: 5706731; gi: 39812027). The protein encoded by this gene is similar 
in sequence to the amino terminus of Drosophila enhancer of split groucho, a protein 
involved in neurogenesis during embryonic development. This protein belonging to the 
groucho/TLE family of proteins can function as a homo-oligomer or as a hetero-
oligomer with other family members to dominantly repress the expression of other 
family member genes (Chen and Courey, 2000). The predicted molecular mass of this 
protein is 28.96 kDa and in digested ECV304 cell extracts the protein band detected by 
L247 anti-P2Y2 antibody had a molecular mass of 80 kDa. It is possible that this protein 
is associated with the P2Y2 receptor. Post-translational modifications such as 
glycosylation, ubiquitination, and sumoylation are known to increase the mass of a 
protein (Ahmad et al., 2005). The variability in the molecular weight of P2Y2 receptor 
in ECV304 cells could be due to the fact that the P2Y2 protein may have had post-
translational modifications that are different for different tissues (Sage and Marcus, 
2002).  
 
The P2Y2 receptor has been reported to exist as homo-oligomer in non-hematopoietic 
and hematopoietic cells (Kotevic et al., 2005). Moreover, human amino-terminal 
enhancer of split isoform protein may be present as a homo or hetro-oligomer. 
However, under reducing conditions of SDS-PAGE it is unlikely for a homo or hetero-
oligomeric P2Y2 receptor complex to remain intact. Nevertheless, it is possible that the 
native quaternary structure of P2Y2 receptor may not have been dissociated by SDS as 
resistance to dissociation by SDS has been reported by other membrane proteins such as 
tetrameric AqpZ aquaporin from E. coli, the prokaryotic K+ channel and the calcium 
regulatory protein phospholamban (Fujii et al., 1989; Heginbotham et al., 1997; 
Borgnia et al., 1999). However, the dissociation has been achieved in membrane 
proteins, phospholamban and E. coli AmtB by boiling of the protein prior to SDS-
PAGE (Fujii et al., 1989; Blakey et al., 2002). Dopamine D1 receptor and dopamine D2 
receptors have been shown to be capable of forming homo-oligomers (Ng et al., 1994a; 
Ng et al., 1994b). Homodimers in G-protein coupled receptors such as β2 adrenergic 
receptors have also been reported to resist SDS dissociation (Hebert et al., 1996). 
Furthermore, the larger protein bands detecting the dopamine D3 receptor oligomers 
expressed in brain tissues of rodent, primate and human appeared to be multiples of 
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monomers and were resistant to both SDS and heat (Nimchinsky et al., 1997). In this 
study, the protein was heated for 3 minutes at 950C before SDS-PAGE and results from 
both the peptide control and desensitisation studies suggest that the band detected in 
ECV304 cell extracts was that of P2Y2 receptor. Furthermore, L247 anti-P2Y2 antibody 
detected only a single band, thus suggesting that P2Y2 receptor may exist as a homo-
oligomer or hetero-oligomer in ECV304 cells. Therefore, it appears that either the P2Y2 
protein is partially deglcosylated in digested ECV304 cell extracts or that the receptor is 
part of a complex that is SDS-resistant and thermostable. Proteins like arrestins that 
promote the processes of desensitization, internalization, down-regulation, and 
resensitization of G protein-coupled receptors may be forming a complex with P2Y2 
receptors (Krupnick and Benovic, 1998). However, studies have reported that the 
desensitization of the P2Y1 and P2Y2 receptors was unaffected when arrestin levels 
were reduced in HEK293 cells (Mundell and Benovic, 2000). Moreover, A1 adenosine 
receptor has been shown to form a heteromeric complex with P2Y1 receptor in 
heterologously transfected cells and rat brain tissues generating an adenosine receptor 
with P2Y-like agonistic pharmacology (Yoshioka et al., 2001; Yoshioka et al., 2002a; 
Yoshioka et al., 2002b; Nakata et al., 2005). Therefore, it is possible that P2Y2 receptor 
may form heteromeric association with different G protein-coupled receptors to regulate 
its functional activity.  
 
Furthermore, the resultant sequence also aligned with gp130 associated protein GAM 
(gi: 3309589), transducin-like enhancer of split 3 splice variant 1, 2 (gi: 46391800; gi: 
46391802), Transducin-like enhancer protein 3 (TLE3) (gi: 34783362; gi: 27469815; gi: 
20532417; gi: 4827030), KIAA1547 protein (gi: 10047159).  Transducin-like enhancer 
protein 3 is a transcriptional corepressor that binds to a number of transcription factors. 
Inhibits the transcriptional activation mediated by CTNNB1 and TCF (transcriptional 
co-activator of T cell factor) family members in Wnt signaling. The effects of full-
length TLE family members may be modulated by association with dominant-negative 
AES (amino-terminal enhancer of split proteins). The predicted molecular mass of 
Transducin-like enhancer protein 3 is 83.41 kDa (swissprot: locus TLE3_HUMAN, 
accession Q04726). However, there is no basis for L247 anti-P2Y2 antibody to cross 
react with this protein as the immunogenic peptide (RSLDLSCHTLNAIN) when 
aligned with above protein sequences no significant similarity was found suggesting the 
antibodies are not directed to these protein sequences.  
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The first extracellular loop of the P2Y2 receptor  has been reported to bind to integrins 
through the cell attachment site RGD (Arg-Gly-Asp) motif; and RGD along with Leu108 
is reported to be involved in apical targeting of the P2Y2 receptor (Ruoslahti, 1996; Qi 
et al., 2005). RGD sequence in the first extracellular loop has also been reported to 
facilitate the interaction of P2Y2 nucleotide receptor with vitronectin receptors 
(Gonzalez et al., 2005). This interaction has been shown to be essential for effective 
signal transduction to activate mitogen-activated protein kinases ERK1/2, to mobilize 
intracellular calcium stores via activation of phospholipase C, protein kinase C 
isoforms, and to activate focal adhesion kinase and other signaling events. Ligation of 
vitronectin receptors with specific antibodies caused an inhibition of P2Y2 receptor-
induced ERK1/2 and p38 phosphorylation and P2Y2 receptor-induced cytoskeleton 
rearrangement and DNA synthesis (Gonzalez et al., 2005). Activated P2Y2 receptors 
through RGD have also been reported to bind αvβ3/β5 integrins and stimulate integrin 
signalling pathways that regulates cytoskeletal reorganization and cell motility 
(Weisman et al., 2005). 
 
However, human amino-terminal enhancer of split isoforms a, b and c, gp130 associated 
protein GAM, transducin-like enhancer of split 3 splice variants 1 and 2, TLE3 protein, 
Transducin-like enhancer protein 3 do not have a RGD motif in their structure. 
Moreover, the protein was sequenced from the unstained section of PVDF membrane 
area (not used in western blot analysis), which was corresponding to the band detected 
with anti-P2Y2 antibody. Therefore, it is possible that Transducin-like enhancer protein 
3 may have been sequenced instead of P2Y2 receptor. Thus, it is not clear from these 
studies if P2Y2 receptor protein is associated with some other protein or exists as a 
separate entity in ECV304 cells. Therefore, the identity of other proteins in the complex 
may provide information of any regulatory role played by these proteins on P2Y2 
receptors. Nevertheless, above results strongly support the immunospecifity of L247 
anti-P2Y2 antibody to human P2Y2 receptor. 
 
The western blot analysis using anti-P2Y1 antibody showed immunoreactive bands in 
the cell extracts of EAhy926 and BRIN-BD11 cells. In EAhy926 cells the 
immunoreactive bands were of higher molecular mass than 42 kDa expected for wild-
type P2Y1 receptor (Hoffmann et al., 1999). However, this antibody has been reported 
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to recognize P2Y1 protein at 66 kDa from human platelets and rat brain membranes by 
immunoblotting (Sigma). These results obtained here are in contrast with those obtained 
with RT-PCR studies (Chapter 4) where the presence of P2Y1 receptor mRNA 
transcripts has been reported in ECV304 cells. Moreover, previous studies have 
supported the functional expression of P2Y1 receptor in ECV304 cells based on P2Y1 
receptor mediated agonist responses (Conant et al., 1998; Brown et al., 2000; Brown, 
2001).  
 
In EAhy926 this antibody produced a strong immunoreactive band at 52 kDa. However, 
it is to be noted that 2MeSATP, a potent agonist of P2Y1 did not show (Chapter 3) any 
significant dose-dependent accumulation of inositol phosphates (Graham et al., 1996a). 
Besides, under the experimental conditions RT-PCR studies did not provide evidence 
for mRNA expression of P2Y1 receptors (Chapter 4). Therefore, this antibody may not 
be recognising the P2Y1 receptor. No bands were observed in  BAE cell extracts, which 
are known to express P2Y1 receptors (Brown and Brown, 2002).  
 
RT-PCR studies (Chapter 4) did not show evidence for the expression of P2Y receptor 
subtypes in 1321N1 cells and there are no published studies to relate the expression of 
P2Y receptors in BRIN-BD11 cells. The similar profile in EAhy926 and BRIN-BD11 
cells, given the absence of mRNA data for P2Y1 receptors suggest non-specific binding 
of this antibody. Moreover, the immunogenic peptide used to raise this antibody also 
corresponds to amino acid residues 242-258 of bovine and rat P2Y1 receptor protein, 
which may explain the cross species immunoreactivity observed in BRIN-BD11 cells. 
 
Polyclonal antibodies to human P2Y1 receptors have also been reported to bind P2Y1 
protein in human and rat brain membranes at 63 kDa (Moore et al., 2000). 
Antibody to rat P2Y1 receptor (330-345 amino acid residues of C-terminus) has been 
reported to show immunoreactivity in rat and bovine brain at 42 kDa (Moran-Jimenez 
and Matute, 2000). Sheep anti-P2Y1 antibody raised to 36-51 amino acid residues of rat 
N-terminal segment (also corresponding to human P2Y1 varied by 2 residues) bound rat 
brain at 65 kDa (Fong et al., 2002). Furthermore, the higher bands (increased molecular 
mass) observed for anti-P2Y1 antibody has been attributed to glycosylation of the 
receptor in its extracellular domain (Wang et al., 2002).  Therefore, further western blot 
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studies should include antigen control and analysis of the receptor protein for N-linked 
glycosylation to determine specificity and the immunoreactivity of this antibody. 
 
The anti-P2Y4 receptor antibody detected strong multiple bands in all the cell types 
including the control 1321N1 cells. The calculated molecular weight of human P2Y4 
receptor is 40.83 kDa (gi: 4505561). Most of the prominent bands observed in all cell 
types including ECV304 and EAhy926 cell extracts are of higher molecular mass, in the 
range of 50-70 kDa. However, unlike in EAhy926 cells RT-PCR studies (Chapter 4) in 
ECV304 cells have shown the presence of P2Y4 mRNA transcripts. The detection of 
P2Y4 mRNA and the subsequent DNA sequence result (Chapter 3) in ECV304 cells, 
however, is inconsistent with previous functional studies, which suggest that the P2Y4 
receptor is not present in ECV304 cells (Brown, 2001). There is no evidence to support 
the expression of P2Y4 receptors by BAE cells (Brown and Brown, 2002) and there is 
no published evidence that BRIN-BD11 cells express P2Y4 receptors. However, the 
immunogenic peptide sequence of this antibody also corresponds to amino acid residues 
(70%) 306-365 of bovine predicted uridine nucleotide receptor (gi:61868522) and 
amino acid residues (68%) of 302-361 of  rat P2Y4 receptor (gi:13928944). 
Nonetheless, the detection of multiple bands in all cells including 1321N1 cells suggests 
that this antibody may not be P2Y4 receptor specific and not useful in P2Y4 receptor 
research. 
 
The anti-P2Y6 receptor antibody stained multiple protein bands in all the cell extracts. 
The calculated molecular weight of human P2Y6 receptor is 36.29 kDa (gi: 29029612) 
and in ECV304 cells this antibody produced a strong band at 39 kDa. Other bands of 
higher molecular range between 50-85 kDa appeared in both ECV304 and EAhy926 
cells. The binding at higher molecular mass is also reported previously with other anti-
P2Y6 antibodies. The anti-P2Y6 antibody (Glaxo Wellcome) stained one band at 45 kDa 
and 75 kDa in human umbilical vein endothelial cells (Wang et al., 2002). RT-PCR 
studies have shown that both ECV304 and EAhy926 cells express P2Y6 mRNA 
transcripts (Chapter 4). However, P2Y6 agonist hexokinase – treated UDP failed to 
elicit accumulation inositol phosphates and cytosolic calcium response in ECV304 cells 
(Brown et al., 2000) and EAhy926 cells have reported to show the lack of functional 
response to P2Y6 receptor agonists (Paul et al., 2000). However, studies have shown the 
dose-dependent accumulation of inositol phosphates in response to UDP (Chapter 3) 
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supporting expression of P2Y6 mRNA in these cells. Even though the RT-PCR studies 
have indicated the presence of P2Y6 mRNA in both ECV304 and EAhy926 cells; the 
contrasting pharmacological results obtained in response to receptor specific agonists 
highlight the difficulty of P2Y receptor pharmacology. Furthermore, anti-P2Y6 antibody 
detects multiple bands in 1321N1 and ECV304 cell extracts in which P2Y6 receptors are 
not expressed. Therefore, taking these results into consideration the next main objective 
is to analyse the immunospecificity of this antibody with antigen control to determine 
whether the strong bands showed by this antibody are P2Y6 receptor specific.  
 
The multiple strong bands produced by this antibody in 1321N1 are probably due to non 
specific binding as these cells do not respond to nucleotides. Furthermore, RT-PCR 
studies showed no sign of P2Y6 mRNA in 1321N1 cells (Chapter 4). This anti- P2Y6 
rabbit polyclonal antibody corresponding to amino acids 1-70 mapping the N-terminus 
of human P2Y6 also corresponds to  amino acid residues (81%) 1-70 of rat P2Y6 
receptor (gi:47938969) and residues 1-89 (39%) of bovine G protein-coupled receptor 8 
(gi:27806597). However, the binding shown in BAE and BRIN-BD11 cells by this 
antibody cannot be accounted for cross species reactivity as there is no published data 
for the expression of P2Y6 receptor by BRIN-BD11 and BAE cells. Therefore, as with 
anti-P2Y4 antibodies, the anti-P2Y6 antibody appears to be of no value in P2Y receptor 
research. 
 
The anti-P2Y11 receptor antibody detected weak bands in both ECV304 (44 kDa and 60 
kDa) and EAhy926 cells (60 kDa, 88 kDa, 114 kDa and 132 kDa). The calculated 
molecular weight of human P2Y11 receptor is 40.21 kDa (gi: 23463303). In human 
umbilical vein endothelial cells, P2Y11 antibody (Glaxo Wellcome) has been reported to 
detect a band at 60 kDa, which disappeared when the antibody was pre-absorbed with 
the immunogenic peptide (Wang et al., 2002). Moreover, the RT-PCR studies have 
shown that ECV304 cells express P2Y11 mRNA transcripts which matched with primer 
specific mRNA sequence with >98% similarity (Chapter 4). Besides, ECV304 cells has 
been shown to dose-dependently accumulate inositol phosphates in these cells in 
response to ADPβS, a P2Y1 and P2Y11 agonist (Brown, 2001). Furthermore, the 
expression of P2Y11 receptor has been supported by studies showing the accumulation 
of cAMP and inositol phosphates and intracellular calcium release in response to 
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ADPβS in ECV304 cells (Brown, 2001). The accumulation of inositol phosphates in 
response to BzATP and ATPγS, the potent agonists of P2Y11 receptors suggest the 
presence of P2Y11 receptors in ECV304 cells. In addition, the dose-dependent 
accumulation of cAMP in ECV304 cells in response to ATPγS further supports the 
presence of functional human P2Y11 receptors coupled to both the phosphoinositide and 
the cyclic AMP pathways (Chapter 3). Therefore, based on pharmacological and RT-
PCR studies it appears that functional P2Y11 receptors are expressed in ECV304 cells. 
 
RT-PCR studies have shown that EAhy926 cells do not express P2Y11 receptors and the 
functional studies with 2MeSATP, and BzATP a potent agonist of P2Y11 did not show 
any significant dose-dependent accumulation of inositol phosphates (Chapter 3 and 
Chapter 4). These results suggest that EAhy926 cells do not express functional P2Y11 
receptors. There are no reports to support the expression of P2Y11 receptors in BAE 
cells. However, similar pattern has been also seen with 1321N1 and BRIN-BD11 cells. 
Therefore, western blot analysis with anti-P2Y11 antibody pre-absorbed with 
immunogenic peptide may prove to be vital in determining the immunospecificity of 
this antibody. Nevertheless, the response is very weak at the highest possible 
concentration used from the available stocks, suggesting that this antibody is not 
sensitive. 
 
The anti-P2Y12 receptor antibody did not show any immunoreactive bands in any of the 
cell extracts used in this study. The calculated molecular weight of the human P2Y12 
receptor is 39.30 kDa (gi: 12232483). RT-PCR studies have shown the presence of 
P2Y12 mRNA transcripts in ECV304 cells (Chapter 4). ADP, an agonist of P2Y12 
receptors has shown weak agonistic potency in ECV304 cells (Brown et al., 2000). 
Likewise ADPβS (agonist at P2Y1, P2Y11, P2Y12) has caused the accumulation of 
inositol phosphates and a rise in intracellular calcium release. However, these responses 
cannot be attributed to the functional expression of P2Y12 receptors because of their 
shared affinity to other P2Y subtypes. Therefore, the absence of pharmacological data 
and the evident western blot results suggest that ECV304 cells do no express P2Y12 
receptors.  
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The anti-P2Y13 receptor antibody detected strong bands in 1321N1, ECV304, EAhy926, 
BAE and BRIN-BD11 cells. All these bands are of higher molecular mass than the 
calculated molecular weight of 38.27 kDa for human P2Y13 receptor (gi: 29171721). 
RT-PCR studies have shown the presence of P2Y13 mRNA transcripts in ECV304 cells 
(Chapter 4). ECV304 cells showed weak agonistic potency whereas EAhy926 cells 
(Chapter 3) did not produce significant stimulation of inositol phosphates in response to 
ADP, a potent agonist of P2Y12 and P2Y13 receptors (Brown et al., 2000). 
Pharmacological data and RT-PCR studies suggest that both ECV304 and EAhy926 
cells do not express P2Y13 receptors. Future studies may include measurement of cAMP 
in response to 2MeSADP and 2MeSATP; and inositol phosphate assays with P2Y12 and 
P2Y13 antagonists to determine whether these cells express receptors that are coupled to 
the inhibition of adenylyl cyclase. Furthermore, without exact sequence of immunising 
peptide (obtained from second extracellular loop of the human P2Y13 receptor) it is 
difficult to ascertain the cross species reactivity in BAE and BRIN-BD11 cells. 
Therefore, western blot analysis of anti-P2Y13 antibody pre-absorbed with 
immunogenic peptide may determine the immunospecificity of this antibody.  However, 
the immunoreactivity of anti-P2Y13 antibody in 1321N1 cell extracts coupled with a 
lack of evidence from RT-PCR studies suggest that this antibody is not suitable to study 
P2Y receptors. 
 
These results suggest that L247 anti-P2Y2 antibody is P2Y2 receptor specific and 
recognises denatured receptors in both ECV304 and EAhy926 cells. Furthermore, this 
antibody also recognises native non-denatured P2Y2 receptors in ECV304 cells as 
shown by immunofluorescence studies. The commercially available anti-P2Y2 
antibodies show dissimilar and non specific reactivity in western blot studies and 
therefore may not be recognising the denatured P2Y2 receptors. A weak band was 
detected in ECV304 cell extracts by anti-P2Y11 antibody. Therefore, based on the 
established pharmacological and RT-PCR data it appears that ECV304 cells co-express 
P2Y2 and P2Y11 receptors. Furthermore, pharmacological and RT-PCR studies also 
confirm that the EAhy926 cells co-express P2Y2 and P2Y6 receptors.  
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CHAPTER 7 
 
GENERAL DISCUSSION 
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7.1 Justification for this research project 
 
Study of P2Y receptors has been compromised by the lack of selective ligands.  
Functional studies using nucleotide agonists provide inconclusive data for the 
expression of P2Y receptors. This is because P2Y receptors can be activated by 
different nucleotides and a single nucleotide activates more than one receptor. 
Moreover, the use of radiolabelled nucleotides has been constrained by their metabolic 
instability and their binding to non-P2 receptor proteins. In addition, anti-P2Y receptor 
antibodies were not available at the beginning of this study. Building on studies of 
peptide receptors, with which P2Y receptors share the sequence homology, peptides 
were designed and synthesised specifically mimicking the extracellular regions of the 
human P2Y2 receptor. Peptide L247 from ECIV (extracellular region IV) and spanning 
amino acid residues 271-284, mimicking the third extra cellular loop of the human P2Y2 
receptor was shown to be a weak agonist of inositol phosphate (IP3) production and 
shown to stimulate nitric oxide synthase activity in both epithelial and endothelial cells. 
In addition, when added simultaneously with ATP, L247 has been shown to have 
synergistic effects on inositol phosphate production and intracellular calcium release in 
epithelial cells suggesting that L247 acted as allosteric modulator of the P2Y2 receptor 
(Brown, 2001). These results appeared to agree with reports that peptides designed to 
mimic the defined regions extracellular loops of peptide receptors act like a functional 
agonist (Van Rhee et al., 1995; Howl and Wheatley, 1996). Furthermore, these results 
were in accord with the suggestion that for peptide receptors the neuropeptide binding 
involves residues on the top of several transmembrane domains and in extracellular 
loops of the receptors (Berthold and Bartfai, 1997). Based on these promising results, 
L247 peptide was used as an immunogen to raise P2Y2 receptor sensitive and selective 
antibody in order to study endogenous P2Y2 receptors in their native environment. 
Moreover, the immunogenic peptide sequence (RSLDLSCHTLNAIN) is unique for the 
P2Y2 receptor as it did not show homology when aligned with other P2Y receptor 
sequences. Thus, peptide-specific antibody strategy was selected to raise the antibody 
and also to minimize or eliminate the cross-reactivity with other closely related P2Y 
receptor subtypes. 
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7.2 Purification of polyclonal antibodies 
 
The rabbit polyclonal antiserum was purified using a PROSEP- Thosorb thiophilic 
affinity adsorbent column and the results suggest that this system can be reliably used 
for the purification of antibodies. The analysis of the purified antibody fractions using 
indirect ELISA suggests that the antibody fractions have a strong and specific 
immunoreactivity with L247 peptide, the immunising antigen (L247 peptide). The two 
antibody fractions that were tested bound to L247 peptide in a dose-related manner 
suggesting the reaction specificity of the antibody to antigenic immunogen, although 
fraction II bound four fold higher than fraction I. Furthermore, the binding observed for 
an unrelated peptide (designed to HERV) was minimal, confirming the specificity of 
antibody to L247 peptide. The minimal binding that occurred with HERV peptide may 
be due to cross reactivity of antibody fractions and the presence of non-specific 
immunoglobulins eluted during the purification process. Synthetic antigen linked to the 
affinity adsorbent column can eliminate the presence of non-specific immunoglobulins 
during the purification process to provide the antibody with desired specificity 
(Muronetz and Korpela, 2003). The results from indirect ELISA suggest the successful 
generation of sequence specific antibody to L247 peptide designed to mimic specific 
region in the extracellular domain of the human P2Y2 receptor. 
 
7.3 Evaluation of P2Y2 receptors in epithelial and endothelial cells  
 
The dose-dependent accumulation of inositol phosphate and intracellular calcium 
release with UTP and ATP, the equipotent agonists at P2Y2 receptors, have already 
established the presence of functional human P2Y2-like receptors in ECV304 cells 
(Brown et al., 2000). Furthermore, receptor desensitisation studies carried out in tandem 
with intracellular calcium release suggests the absence of human P2Y4 receptors in 
these cells (Brown, 2001). The detection of mRNA transcripts for P2Y2 receptors is 
consistent with previous reports suggesting the expression of  P2Y2  receptors in 
ECV304 cells (Brown et al., 2000). 
 
The dose-dependent accumulation of inositol phosphates in response to UTP and ATP 
observed in this study are consistent with previous reports suggesting the expression of 
P2Y2 receptors in EAhy926 cells (Graham et al., 1996a; Graham et al., 1996b; Paul et 
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al., 2000). As both UTP and ATP are full agonists at both P2Y2 and P2Y4 receptors, 
RT-PCR studies were used to determine which receptor is expressed in EAhy926 cells. 
Functional data (Chapter 3) and the presence of mRNA transcripts for P2Y2 and not 
P2Y4 receptors (Chapter 4) suggest that the P2Y2 receptor is functionally expressed in 
EAhy926 cells. 
 
7.4 Characterisation of a novel anti-P2Y2 antibody 
 
Evaluation of rabbit polyclonal anti-P2Y2 antibodies raised to L247 peptide designed to 
mimic the third extracelluar loop of  human P2Y2 receptor, suggests that this antibody is 
not only immunospecific but can also bind to the P2Y2 receptor in its native 
environment. This anti-P2Y2 antibody detected bands in ECV304, EAhy926, BAEC and 
BRIN-BD11 cell extracts. Furthermore, these responses were antigen specific as the 
pre-absorption of the antibody with the immunogenic peptide abolished the response 
seen for ECV304 and EAhy926 cells.  This further confirms the specificity of this 
antibody to the peptide immunogen. These results are consistent with the 
pharmacological data and detection of mRNA transcripts supporting the expression of 
P2Y2 receptors in ECV304 and EAhy926 cells (Graham et al., 1996a; Graham et al., 
1996b; Brown et al., 2000; Paul et al., 2000; Brown, 2001). The bands observed for 
BAE cell extracts, known to express P2Y1 and P2Y2 receptors and BRIN-BD11 cells 
may be of non specific nature as they did not disappear after pre-absorption with 
immunogenic peptide.  
 
The higher observed molecular weight of the P2Y2 receptor in ECV304 and EAhy926 
cells may have been due to post-translational modifications involving glycosylation, 
ubiquitination, and sumoylation that are known to increase mass of a protein (Sage and 
Marcus, 2002; Ahmad et al., 2005). Receptor glycosylation has been shown to be a 
feature of P2Y2 receptors (Flores et al., 2005). The reduced band size of the protein 
post-deglycosylation confirmed this. Further evidence for the glycosylation of P2Y2 
receptor in ECV304 cells was provided by the detection of a short protein sequence 
which was not evident prior to deglycosylation of samples. However, the protein 
sequence did not match with the human P2Y2 receptor. The protein was sequenced from 
the unstained section of PVDF membrane area, which was corresponding to the band 
detected with anti-P2Y2 antibody. Therefore, it is most likely that some other protein 
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that migrates in close proximity to the P2Y2 receptor on the SDS-PAGE gel may have 
been sequenced. Analysis of the sequence obtained suggests that it closely matches with 
the sequence of Transducin-like enhancer protein 3 with the predicted molecular mass 
of 83.41 kDa, which is in the range of the reduced band size of 80 kDa of the protein 
post-deglycosylation. Therefore it is possible to have sequenced transducin protein that 
is of similar molecular size and migrates at the same rate as P2Y2 receptor protein. 
 
On the other hand, P2Y2 receptor protein in ECV304 cells may exist as a homo-
oligomer or hetero-oligomer and may exist in the form of a complex with some 
unknown protein which is resistant to SDS dissociation and heat. However, complex 
formation is not likely to occur between the receptor and transducin, but perhaps may be 
between another, much smaller as yet unidentified protein. Activated P2Y2 receptors 
through RGD motif in the first extracellular loop have been reported to bind αvβ3/β5 
integrins and to stimulate integrin signalling pathways that regulate cytoskeletal 
reorganization and cell motility (Weisman et al., 2005). Interaction of P2Y2 receptors 
with vitronectin receptors has been reported to be essential for P2Y2 mediated signal 
tranduction (Gonzalez et al., 2005). Furthermore, heteromeric association between A1 
adenosine receptor and P2Y1 receptor in heterologously transfected cells and rat brain 
tissues has been shown to alter the pharmacology of A1 adenosine receptor and generate 
P2Y-like agonistic pharmacology (Yoshioka et al., 2001; Yoshioka et al., 2002a; 
Yoshioka et al., 2002b; Nakata et al., 2005). Therefore, it is possible that the close 
association of the unknown protein in P2Y2 receptor complex is essential for P2Y2 
receptor mediated signaling. Furthermore, the detection of a protein band at high 
molecular mass in EAhy926 cells may suggest that the P2Y2 receptor is forming a 
complex in cells that contain a tumour component.  
 
Agonist induced receptor desensitisation studies further confirmed the specificity of 
L247 anti-P2Y2 antibody. The fading or losss of bands after desensitisation suggests that 
the desensitised P2Y2 receptor was not accessible for antibody binding. From these 
studies it appears that the receptor is sequestered (internalised) on agonist stimulation 
for more than 1 hour. Furthermore, the antibody could not detect the internalised 
receptor in the membrane enriched fractions used in this study suggesting that only an 
insignificant number of receptors may have remained on the membrane surface after 
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agonist induced sequestration. The prominent bands observed with L247 anti-P2Y2 
antibody after 24 hours of UTP stimulation suggest that the receptor is resensitised 
possibly as a result of agonist degradation over 24 hours by endogenous 
ectonucleotidases. The resensitisation of the receptor observed in this study after 24 
hour incubation with the agonist is significant. Studies in the past have reported that the 
receptor is resensitised the after 3 hour incubation with the agonist (Garrad et al., 1998). 
Thus, this study support the argument that  the prolonged agonist incubation causes 
internalisation of the receptor, causing the reduction in the surface receptor number (Yu 
et al., 1993). Furthermore, it also appears that prolonged agonist incubation causes its 
degradation resulting in resensitisation of the receptor and that the desensitisation and 
sequestration are reversible (Sromek and Harden, 1998). These results are also 
consistent with the argument that the sequestration is essential to facilitate 
resensitization of the receptors by a process involving dephosphorylation and 
subsequent recycling of the receptor  as reported in β2-adrenergic receptors (Barak et 
al., 1994).  Therefore, agonist induced desensitisation/sequestration of P2Y2 receptors 
seen here may involve an increase in receptor phosphorylation as reported previously 
(Flores et al., 2005). Moreover, pre-incubation with histamine for similar time periods 
did not show any difference on antibody binding. Thus, agonist stimulation for an hour 
causes the desensitisation and sequestration of the P2Y2 receptor, which is resensitised 
and recycled back to the surface after degradation of the agonist caused by prolonged 
incubation. 
 
The commercially available rabbit anti-P2Y2 receptor antibodies detected different 
immunoreactive profiles with multiple bands (of different molecular mass) both in 
ECV304 and EAhy926 cells. These antibodies also showed strong immunoreactivity 
with 1321N1 cells, which are not responsive to nucleotides. Furthermore, the 
desensitisation effect did not manifest when commercial rabbit anti-P2Y2 receptor 
antibody was used to study the effect of receptor desensitisation on antibody binding. 
There was no noticeable difference between the bands in control cells and cells 
challenged with agonist for 1 hour. Immunofluorescence analysis using L247 anti-P2Y2 
antibody in ECV304 cells showed widespread binding including the membrane and the 
nucleus making it difficult to localise P2Y2 receptors. Immunofluorescence results 
obtained using other commercial anti-P2Y2 antibodies showed similar results to L247 
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anti-P2Y2 antibody. However, these studies only suggest immunoreactivity of the 
antibodies with the non-denatured (intact) receptor. The lack of receptor specific 
immunoreactivity with denatured receptor shown by commercial antibodies suggest that 
results obtained from immunofuorescecence studies may be due to the recognition 
epitopes of unrelated protreins. Therefore, even if the commercial antibodies are recepor 
specific their lack of immunoreactivity with denatured receptor in western blot analysis 
limit their usefulness as a diagnostic tool in receptor pharmacology. Therefore, these 
antibodies do not detect denatured P2Y2 receptor and are marketed without full 
characterisation. In conclusion, these results suggest that L247 anti-P2Y2 antibody is a 
highly sensitive and specific antibody to human P2Y2 receptor.  
 
7.5 Evaluation of P2Y1 receptors in epithelial and endothelial cells  
 
RT-PCR studiesd and subsequent DNA sequence results show that the P2Y1 receptors 
are transcribed in ECV304 cells. The pharmacological data in ECV304 is not conclusive 
as potent P2Y1 agonist 2MeSADP was without effect and increase in the intracellular 
calcium release observed in response to 2MeSATP may have been mediated by P2Y11 
receptors and are not due to sub – population or passage specific effect, suggested 
previously (Conant et al., 1998; Brown et al., 2000; Brown, 2001). Similarly, a small 
accumulation of inositol phosphates observed in ECV304 cells in response to ADPβS, 
may have been caused by its agonistic activity at P2Y11 receptor (Communi et al., 
1999b; Brown, 2001). Moreover, adenosine diphosphates have been shown to act as 
partial agonists at P2Y11 receptors (Qi et al., 2001). In EAhy926 cells, P2Y1 agonist 
2MeSATP, did not generate significant dose-dependent accumulation of inositol 
phosphates (Graham et al., 1996a). Furthermore, RT-PCR studies did not detect the 
presence of P2Y1 mRNA transcripts to suggest that these receptors are not expressed in 
EAhy926 cells. Under these circumstances, the strong band detected by anti-P2Y1 
antibody in EAhy926 cells suggests that this antibody is not detecting P2Y1 receptor 
and therefore not suitable for P2Y research.  
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7.6 Evaluation of P2Y4 receptors in epithelial and endothelial cells 
 
Receptor desensitisation studies carried out in ECV304 cells in tandem with 
intracellular calcium release have established that both UTP and ATP are both acting at 
the P2Y2 receptor suggesting that P2Y4 receptors are not expressed in ECV304 cells 
(Brown, 2001). Although RT-PCR studies show the presence of P2Y4 mRNA 
transcripts in ECV304 cells, the lack of functional data suggest that P2Y4 receptors are 
not functionally expressed in ECV304 cells. The dose dependent accumulation of 
inositol phosphates in response to UTP and ATP are consistent with previous reports 
suggesting the expression of P2Y2/4 receptors in EAhy926 cells (Graham et al., 1996a; 
Graham et al., 1996b; Paul et al., 2000). However, RT-PCR and DNA sequence results 
do not show the presence of P2Y4 mRNA transcripts suggesting that these receptors are 
not present in EAhy926 cells. The anti-P2Y4 receptor antibody used in this study 
detected strong multiple bands in all the cell types including 1321N1 cells, which do not 
respond to nucleotides. Given the absence of P2Y4 receptors in ECV304 and EAhy926 
cells, the bands detected by this antibody are not specific to P2Y4 receptors. Therefore, 
these results suggest that this anti-P2Y4 antibody is not useful for P2Y research. 
 
7.7 Evaluation of P2Y6 receptors in epithelial and endothelial cells 
 
Previous studies in ECV304 cells reported the absence of P2Y6 receptors in these cells 
based on the lack of response to P2Y6 agonist in assays to determine the accumulation 
of inositol phosphate and cytosolic calcium response (Brown et al., 2000). Even though 
RT-PCR studies detected the mRNA transcripts for P2Y6 receptors, the lack of P2Y6 
receptor mediated functional response suggests that these receptors are not functionally 
expressed in ECV304 cells. UDP has been shown to dose-dependently accumulate 
inositol phosphates in EAhy926 cells. The presence of P2Y6 mRNA transcripts further 
support the functional responses elicited by P2Y6 receptors in EAhy926 cells. The anti-
P2Y6 receptor antibody used in this study detected multiple bands in all the cell extracts 
including 1321N1 cells which do not express P2Y receptors. Therefore, even if this 
antibody detects the P2Y6 receptor in EAhy926 cells, the strong immunoreactive profile 
of this antibody in cells which do not express P2Y6 receptors makes it unreliable for 
P2Y research. 
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7.8 Evaluation of P2Y11 receptors in epithelial and endothelial cells 
 
Previous studies in ECV304 cells reported the expression of receptors that are coupled 
to adenylyl cyclase in ECV304 cells (Howl et al., 1998; Brown et al., 2000). High 
concentrations of ADPβS, the partial agonist at human P2Y11 receptor has been shown 
to evoke inositol phosphate accumulation and intracellular calcium release (Brown, 
2001). Furthermore, the accumulation of inositol phosphates in response to BzATP and 
ATPγS and the dose-dependent accumulation of cAMP in response to ADPβS and 
ATPγS suggest the expression of P2Y11 receptors in ECV304 cells. RT-PCR studies and 
DNA sequence results showed that P2Y11 mRNA is transcribed in ECV304 cells 
consistent with pharmacological data. Functional studies involving 2MeSATP and 
BzATP did not show any significant dose-dependent accumulation of inositol 
phosphates in EAhy926 cells suggesting that P2Y11 receptors are not expressed in them. 
Furthermore, RT-PCR studies did not show the presence of P2Y11 mRNA transcripts in 
EAhy926 cells. The anti-P2Y11 receptor antibody used in this study detected weak 
bands in all cell types used in this study including ECV304 and EAhy926 cells. Even if 
this antibody detects P2Y11 receptors in ECV304 cells, the response is very weak even 
at the highest possible concentration used from the available source. These results 
suggest that this antibody is not sensitive and may not be useful to study P2Y receptors. 
 
7.9 Evaluation of P2Y12 and P2Y13 receptors in epithelial and endothelial cells 
 
ADP the potent agonist of P2Y12 and P2Y13 receptors has shown mild agonistic potency 
in ECV304 cells (Brown et al., 2000). However, ADP is also an agonist at P2Y1 
receptor and a mild agonist at P2Y11 receptor. Besides, there are no reports to suggest 
that these cells express receptors that are coupled to the inhibition of adenylyl cyclase. 
Furthermore, ADPβS, an agonist at P2Y1 and P2Y13 receptors and a partial agonist at 
P2Y11 receptors, has shown only weak agonistic potency in ECV304 cells (Brown, 
2001). Given the absence of P2Y1 receptors in ECV304 cells, it is possible that these 
weak responses may have been mediated by P2Y11 receptors. Previous studies have 
reported that 2MeSADP, the potent agonist at P2Y12 and P2Y13 receptors, did not induce 
functional response in ECV304 cells (Brown, 2001). Although, RT-PCR studies have 
shown the presence of P2Y12 and P2Y13 mRNA transcripts in ECV304 cells, the lack of 
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functional responses mediated by these receptors suggests that they are not functionally 
expressed in ECV304 cells. Furthermore, RT-PCR studies did not show the presence 
P2Y12 and P2Y13 mRNA transcripts in EAhy926 cells confirming their absence. The 
anti-P2Y12 antibody did not detect bands in any cell types used in this study including 
ECV304 and EAhy926 cells. However, given the absence of P2Y12 receptors in 
ECV304 and EAhy926 cells, the receptor specificity of this antibody cannot be 
determined. The anti-P2Y13 receptor antibody produced strong bands in all cell types 
used in this study including 1321N1, ECV304 and EAhy926 cells. As P2Y13 receptors 
are not functionally expressed in ECV304 and EAhy926 cells, these responses by anti-
P2Y13 antibody seems non-specific. Therefore, these results suggest that this anti-P2Y13 
antibody do not detect P2Y13 receptors and is not useful in P2Y research.  
 
7.10 Antibodies for P2Y research 
 
Metabolic instability and binding to non-P2 receptor proteins has restricted the use of 
radiolabelled nucleotides in P2Y research. Results from this study highlight the well-
known problems associated with studying P2Y receptor pharmacology. It is evident 
from these studies that it is not possible to establish the functional expression of P2Y 
receptors using nucleotides alone, thus emphasising the need for a receptor subtype 
specific agonist or antibody. Highly sensitive and specific antibody is essential to study 
the localization and quantitation of the receptor in different human tissues. Antibodies 
directed to different receptor subtypes have been available recently, which were not 
available when this study was commenced. The commercial polyclonal antibodies used 
in this study appear as if they are not receptor specific. Manufacturers of these 
antibodies claim that they detect non-denatured receptor in immunofluorescence studies. 
However, when used in western blot studies they do not detect denatured receptors. 
These results raise questions about the immunoreactivity shown by these antibodies in 
immunofluorescence studies and whether it was a consequence of binding with 
seemingly unrelated proteins. This assumption is realistic as the immunogenic peptide 
chosen to raise the antibody may have homology with epitopes on other proteins from 
same organism. Therefore, it is necessary to determine if this reactivity is antigen 
specific or the result of non-specific reactivity. However, most of these antibodies are 
marketed without this data making the selection of antibodies extremely tricky.  
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C-terminus of the proteins is often used to generate anti-peptide antibodies as they are 
hydrophilic, exposed and flexible. However, if the C-terminus is part of the 
transmembrane segment, the sequence tends to be hydrophobic (Thornton and Sibanda, 
1983; Van Regenmortel, 1986). Commercial anti-P2Y2 antibodies and anti-P2Y4 
antibodies used in this study were raised against amino acids mapping the C-terminus of 
receptor proteins. Likewise, N-terminus is also frequently used as an ideal candidate for 
antibody generation  as peptides derived from this region have been shown to be 
comparatively diverse between closely related receptors (Gupta and Devi, 2006). The 
third extracellular loop of diverse family A receptors has been shown to regulate 
transition to the active conformation and in ligand recognition (Lawson and Wheatley, 
2004).  
 
In this study, L247 anti-P2Y2 antibody raised against peptide designed to mimic specific 
region in the third extracellular loop has been shown to be a good candidate for receptor 
specific antibody to study endogenously expressed P2Y2 receptors. This highly specific 
and sensitive antibody provides an important tool to study tissue distribution and 
cellular expression levels of P2Y2 receptor, with negligible cross-reactivity from the 
other members of the P2Y family. Therefore, because of its unique selectivity and the 
current state of lack of selective ligands to P2Y2 receptors, L247 anti-P2Y2 antibody can 
be used to distinguish P2Y2 receptors from other P2Y receptor subtypes. Moreover, 
because polyclonal antibody interacts with the target molecule at multiple sites, this 
antibody will be expected to give stronger signals and more effective at 
immunoprecipitation studies. 
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7.11 Future work 
 
These studies have highlighted the problems associated with studying P2Y receptor 
pharmacology because of lack of selective ligands and the generation of receptor 
specific antibody to P2Y2 receptors. It is clear from these studies that carefully selected 
peptide sequence mapping the epitope of the extracellular region of P2Y receptor can be 
used as an immunogen for the generation of antibodies. Furthermore, this antibody 
successfully binds to P2Y2 receptor protein in both native and denatured conditions. 
Nonetheless, this antibody should be further characterised to exploit its full potential. 
 
Future studies will involve confocal microscopy using molecular markers to determine 
localisation and map distribution of P2Y2 receptors in human cells and tissues. 
Furthermore, using an ELISA for cells or membranes coated onto 96 well-plates, a rapid 
screening assay will be generated to reliably measure the levels of P2Y2 receptors in 
human endogenous tissues. This antibody will be used in conjunction with other P2Y2 
agonists in pharmacological assays such as measurement of inositol phosphates, nitric 
oxide synthase studies and intracellular calcium assays to determine the ability of this 
antibody to generate receptor specific activity and inhibit or augment responses of 
natural agonists. These studies will be extended to determine if the binding of the 
antibody changes P2Y2 receptor confirmation affecting its ligand binding. This study 
will involve capturing of extracellular region of P2Y2 receptor and receptor agonists by 
anti-P2Y2 antibody in a P2Y2 receptor - capture ELISA or P2Y2 ligand-capture ELISA 
(Schmidt et al., 2001). Similar studies will be used to generate antibodies using the 
peptide sequences mimicking other extracellular regions of P2Y2 receptors to establish 
the regions important for high affinity ligand binding. 
 
Further studies will include stable homologous or heterologous expression of P2Y2 
receptors to determine binding affinity of the antibody and its effect on signal 
transduction. These studies will help to understand the oligomeric nature of P2Y2 
receptor in ECV304 cells and may lead to the development of superior therapeutic 
agents that target these receptors. Furthermore, these studies will also determine the 
effect of molecular density and/or the cellular environment of the target receptors on 
antibody binding. Finally, RT-PCR studies to establish the molecular identity of P2Y 
receptor subtypes in BAE cells with receptor specific primers will be able to confirm the 
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functional expression of P2Y1 and P2Y2 receptors arrived from the pharmacological 
studies (Gomes et al., 2005).  
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CONCLUDING REMARKS 
 
On the basis of the data outlined in this thesis the following conclusions can be made: 
 
1.  The accumulation of inositol phosphates in response to BzATP and ATPγS, the 
potent agonists of P2Y11 receptors, suggests the presence of P2Y11 receptors in 
ECV304 cells. Furthermore, the dose-dependent accumulation of cAMP in 
ECV304 cells in response to ADPβS and ATPγS further supports the presence 
of functional human P2Y11 receptors in addition to already established P2Y2 
receptors in these cells. 
 
2. The dose-dependent accumulation of inositol phosphates in response to ATP, 
UTP and UDP confirms previously published data in support of P2Y2/P2Y4 and 
P2Y6 like receptors in EAhy926 cells.  
 
3. RT-PCR and DNA sequence results established the presence of mRNA 
transcripts for P2Y1, P2Y2, P2Y4, P2Y6, P2Y11, P2Y12 and P2Y13 in ECV304 
cells. However, this data only support the functional expression of P2Y2 and 
P2Y11 receptors in ECV304 cells. The presence of mRNA transcripts for P2Y1, 
P2Y4, P2Y6, P2Y12 and P2Y13 receptors seems to suggest that these receptors are 
not expressed at functional level to initiate receptor specific signalling pathways. 
This strengthens the concept that RT-PCR studies only indicate the presence or 
absence and not the functional expression of receptors. 
 
4. RT-PCR and DNA sequence studies in EAhy926 cells show the presence of 
mRNA for P2Y2 and P2Y6 receptors thereby confirming the pharmacological 
data for functional expression of P2Y2 and P2Y6 receptors in these cells. P2Y 
receptor transcripts were not detected in 1321N1 cells, which confirm the 
functional absence of P2Y receptors in these cells. 
 
5.  L247 rabbit polyclonal antiserum was successfully affinity purified. The purified 
fractions showed strong immunoreactivity with immobilised immunogenic 
antigen (L247 peptide) in ELISA suggesting successful generation of sequence 
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specific antibody to L247 peptide designed to mimic specific region in the 
extracellular domain of the human P2Y2 receptor. Control experiments using an 
unrelated peptide (designed to HERV) confirmed the specificity of binding to 
L247 peptide.  
 
6.  L247 rabbit polyclonal anti-P2Y2 antibody showed strong bands in ECV304, 
EAhy926 cells and on pre-absorption with the immunogenic peptide these 
responses were abolished suggesting that the antibody is antigen specific. These 
results also confirmed the functional expression of P2Y2 receptors in both 
ECV304 and EAhy926 cells as established by functional studies and RT-PCR 
results. 
 
7.  The deglycosylation studies revealed that the P2Y2 receptors are glycosylated in 
ECV304 cells as shown by the higher molecular mass bands with L247 anti-
P2Y2 antibody prior to deglycosylation. 
 
8.  Post-deglycosylation it appears that the P2Y2 receptor protein in ECV304 cells 
exists as a homo-oligomer or hetero-oligomer resistant to SDS dissociation and 
heat. 
 
9. Agonist induced P2Y2 receptor desentisation in ECV304 cells further confirmed 
the specificity of L247 antibody as the prolonged agonist incubation caused the 
receptors to internalise and they were not available for interaction with the 
antibody. The receptor internalisation was further supported by the fact that this 
study used only membrane fractions and therefore there were not enough 
receptors in the extracted membrane fractions or a very small number of 
receptors remained on the membrane to interact with the antibody. 
 
10. The polyclonal rabbit anti-P2Y2 receptor antibodies from commercial sources 
produced completely different immunoreactive profiles with multiple bands 
even in 1321N1 cells. Furthermore, in comparison to L247 anti-P2Y2 antibody 
the commercial antibody showed no difference between normal and agonist 
incubated cells suggesting that this antibody may not be recognising the P2Y2 
receptors in ECV304 cells.  
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 11.  Immunofluorescence analysis using L247 anti-P2Y2 antibody and commercial 
anti-P2Y2 antibodies in ECV304 cells showed that commercial antibodies bind 
cell membranes in a manner similar to L247 ant-P2Y2 antibody suggesting that 
they may be only recognising non-denatured receptors.  
 
12. Polyclonal rabbit antibodies to P2Y1, P2Y4, P2Y6, P2Y11 and P2Y13 receptors 
either showed no response or showed strong immunoreactive profile with 
multiple bands in all cell types including 1321N1 cells suggesting that these 
antibodies are not receptor specific and may not have been extensively 
characterized. Given the absence of P2Y12 receptors in ECV304 and EAhy926 
cells and the lack of response from anti-P2Y12 antibody, the receptor specificity 
of this antibody cannot be determined. 
 
13. These studies suggest that the L247 anti-P2Y2 antibody raised against peptide   
designed to mimic specific region in the third extracellular loop of human P2Y2 
receptor is highly specific and sensitive and provides an important tool to study 
P2Y2 receptor pharmacology. 
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